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ABSTRACT 
 
REBECCA CLEWELL: Mode of Action Studies with Phthalate Acid Monoesters:  
Pharmacokinetic and Pharmacodynamic  Factors Affecting Steroidogenesis  
(Under the direction of Melvin Andersen and Louise Ball) 
 
 
 
The use of phthalate esters in plastics and resulting human exposure has led to 
concern over potential adverse effects in fetal development.  This project provided data and 
quantitative tools to improve phthalate risk assessments.  In vivo, in vitro and in silico 
experiments evaluated pharmacokinetic and pharmacodynamic factors responsible for anti-
androgenic effects of phthalate esters.  For pharmacokinetics, plasma and tissue metabolite 
levels were measured in maternal and fetal rats following DBP administration.  A 
physiologically based pharmacokinetic (PBPK) model was developed for DBP distribution in 
rat gestation, tested against a variety of data across life-stages, doses and exposure routes, 
and accurately predicted maternal and fetal plasma MBP levels for acute and repeated 
dosing.  The validated model permitted direct correlation of testes phthalate concentrations 
and testosterone.  When extended to DEHP, the model also predicted MEHP kinetics.  For 
pharmacodynamic evaluation, monoester concentrations were measured in the fetal testes 
after repeated doses of BBP, DEP, DBP, DEHP, and DMP. An in vitro assay tested the effect 
of inhibition of steroidogenesis directly in the Leydig cell.  The differential ability of the 
monoesters to cause developmental toxicity was found to result from differences in their 
pharmacodynamic potency.  Finally, we attempted to identify the molecular target for the 
phthalates in the Leydig cell.  The phospholipase A2 (PLA2) inhibitor CQ and MEHP had a 
 ii
similar ability to inhibit testosterone production, steroidogenic gene expression and AA 
release in the LH-stimulated (MA-10) Leydig cell.  Both compounds interfered with 
translocation of fluorescently tagged cPLA2 in human HEK-cells after activation by a 
calcium ionophore, providing at least indirect evidence that inhibition of AA release by 
cPLA2 is likely to be involved in phthalate anti-androgenic effects.  When CQ was 
administered to the pregnant rat, fetal testes testosterone levels were reduced in a dose-
dependent manner.   CQ also down-regulated steroidogenic genes as noted with active 
phthalate administration.  Our results strongly indicate that cPLA2 is a key target of these 
phthalates in relation to decreased testosterone production.  The improved understanding of 
phthalate dose-response and mechanism of action, together with in vitro derived potencies of 
phthalates for testosterone inhibition, should greatly improve cumulative risk assessments for 
the phthalates.  
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CHAPTER 1 
 
 
 
 
INTRODUCTION 
 
A.  PHTHALATE ESTERS 
Commercial Use and Population Exposure 
The phthalic acids are a family of dialkyl esters that are primarily used as softeners in 
plastic products, but may also be found in paint, glue, putty, pharmaceutical products and 
cosmetics [1, 2].  Phthalates are not chemically bound to the plastics and as a result, they may 
leach from the surface over time.  Human exposure primarily occurs via the oral route.  
Phthalates from plastic food and liquid containers may leach into the packaged contents to be 
ingested with the food.  Dermal exposure is also possible, through clothes and beauty care 
products (perfume, cosmetics).  Inhalation of some phthalates, such as di-2,4-ethylhexyl 
phthalate (DEHP), may occur due to association with dust particles.  The presence of DEHP 
in blood storage bags and iv tubing could also result in relatively high exposures to 
transfusion patients.   
Though the relative source contributions have not been characterized in the United 
States, a recent study in Europe found that food sources accounted for 40-90% of the overall 
exposure to di-n-butyl phthalate (DBP) and DEHP; inhalation and dermal exposures are 
dominant sources of diethyl (DEP) and dimethyl phthalate (DMP) [3].  Biomonitoring 
studies have identified the metabolites of DBP and several other phthalates in the urine of the 
US population including adults, children, infants, and pregnant women [4-6]. The most 
recent NHANES study, which tested a cross section of human urine samples obtained from 
children aged six to adults, reported measurable metabolite concentrations for 6 of the 7 
tested phthalates [7].  Estimated exposure to two of the more prevalent phthalates, DEHP and 
DBP, is in the range of 2-6 and 1-4 μg/kg/day, respectively [5, 8].    
 2
 Metabolism, Distribution, and Excretion of Phthalates 
 Phthalates are manufactured as dialkyl esters and typical human exposure is to this 
form.  The diesters are then rapidly and efficiently metabolized to their monoalkyl form, 
regardless of the route of exposure, by a variety of non-specific hydrolases in GI, skin, blood, 
liver, kidney and lung [9].  The parent diester and monoester metabolites for some of the 
more common phthalates are shown in Figure 1.1.  These monoester metabolites are thought 
to be the active species responsible for reported effects in animal toxicity studies.  
Differences in alkyl chain length and degree of branching can have significant effects on the 
metabolism, distribution and excretion of the monoesters [10]. The shorter chain phthalates 
are excreted mainly as the unchanged monoester.  Increased length and branching, however, 
leads to more extensive metabolism.   Monobutyl phthalate (MBP), the monoester metabolite 
of DBP, is excreted primarily as the free monoester or as its glucuronide conjugate.  
Oxidative metabolites make up only a small portion of the total excreted MBP [11].  On the 
other hand, monoethylhexyl phthalate (MEHP; the monoester metabolite of DEHP) 
undergoes extensive oxidative alkyl group metabolism in both the rat and human.  
Unchanged MEHP makes up only a small portion of the excreted dose [12, 13].   
Differences in metabolism can have significant effects on the kinetic behavior of the 
monoesters and ultimately on the target tissue dose.  In general, the in vivo kinetics of the 
various phthalates are poorly characterized.  With the exception of DEHP and DBP, very 
little quantitative information has been collected on metabolism and distribution in the rat or 
human.  Often, the published kinetic information is limited to qualitative analyses of excreted 
metabolites or blood concentrations at a handful of time-points.  
 3
 Hepatic Effects and Enzyme Induction 
 Some of the phthalates (i.e., DEHP) are peroxisome proliferators (PPs), which induce 
liver tumors in rodents through the activation of peroxisome proliferator activated receptors 
(PPAR). PPARs are a nuclear hormone receptor superfamily of ligand-activated transcription 
factors [14].  After forming a heterodimer with retinoid X-receptor (RXR) in the cytoplasm, 
the ligand/PPAR/RXR complex is transported to the nucleus where it binds a particular 
sequence within the promoter region on target genes (PPAR response element; PPRE) and 
initiates gene transcription [14-17].  PPARα appears to be responsible for the majority of 
hepatic effects observed with PP administration in rodents. 
Several key events have been identified in the development of liver tumors following 
sustained PP treatment:  1) PPARα activation;  2) up-regulated transcription of genes 
involved in peroxisome proliferation, lipid metabolism, and cell cycle/apoptosis; 3) increased 
fatty acid β-oxidation and oxidative stress;  4) hepatomegaly (enlarged liver); 5) stimulation 
of non-parenchymal cells and inhibition of gap junction intercellular communication; and 
finally 6)  increased cell proliferation and decreased apoptosis leading to proliferation of 
DNA-damaged cells, hyperplasia and hepatic tumors [14, 18, 19].   
  Many of the genes up-regulated by PPARs are involved in fatty acid metabolism.  
Peroxisomal acyl-coA oxidase, an enzyme associated with β-oxidation of long chain fatty 
acids and very long chain fatty acids, can be increased by as much as 15-fold with PP 
treatment [20]. Similarly, the expression of cytochrome P450 4A (CYP4A) enzymes has 
been shown to increase more than 20-fold after PP treatment [21].  The CYP4A superfamily 
is responsible for ω and ω-1 oxidation of fatty acids.   Induction of these and other enzymes 
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that mediate lipid and cholesterol metabolism leads to reduced serum cholesterol and 
triglyceride levels – an effect which led to the classification of many PPs as hypolipidemic 
drugs [22]. 
 The phthalates differ significantly in their PP activity [23].  DEHP induces 
peroxisome proliferation, acyl-coA oxidase activity and CYP4A expression in rodents [24, 
25].  In vitro, MEHP binds both PPARα and PPARγ, and up-regulates expression of PP 
associated enzymes, including acyl-coA oxidase.  MBP, the monoester metabolite of DBP, 
however, does not bind either PPARα or γ in vitro [26].  While DBP induces CYP4A and 
acyl-coA oxidase in vivo, the doses of DBP required to induce these enzymes are much 
higher than those of DEHP [25].  
The carcinogenicity of PPs varies widely among species.  In contrast to rats and mice, 
where PPAR activation is associated with hepatocarcinogenicity, chronic exposure to PPs has 
not been shown to lead to tumors in humans or non-human primates [19]. Several reasons for 
the different susceptibility of rodents and humans have been suggested, including reduced 
levels of PPARα in the human liver [27, 28] and differences in PPRE activity [29].  Recent 
studies in humanized mouse models (PPARα-/- mice expressing human PPARα) showed 
that activation of human PPARα up-regulates enzymes associated with lipid metabolism, but 
does not lead to tumor development [30, 31].  Based on observed differences in species 
susceptibility, the International Agency for Research on Cancer (IARC) has categorized 
DEHP as a Class 3 carcinogen (no evidence of cancer causing potential in humans).  
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Effects of phthalates on testosterone-mediated sexual development 
Treatment of rats with some of the longer chain alkyl phthalates, including DEHP and 
DBP, has identified these as potential reproductive toxicants in rats [32-34].  High doses 
administered during gestation (> 100 mg/kg/day) leads to reduced anogenital distance 
(AGD), nipple retention, hypospadias (malformed penis), delayed testes descent, and vaginal 
pouch development in the male rat pup.  Many of these effects are associated with reduced in 
fetal testosterone production.  In studies specifically designed to test the effect of phthalates 
on fetal testes development, DBP, DEHP, butylbenzyl phthalate (BBP) and dipentyl 
phthalate caused significant reduction in a large number of genes involved in steroid 
synthesis.  Phthalates also cause cryptorchidism (undescended testes), increased 
multinucleated gonocytes in the fetal testes, increased seminiferous tubule diameter and 
Sertoli-germ cell detachment.  These effects do not appear to be dependent on alterations in 
testosterone production, however [35]. 
The similarity between the steroidogenic pathway in rats (where toxicity has been 
observed) and humans [36] and the widespread exposure to phthalates has led to a high 
degree of public concern regarding perinatal exposure through medical devices and childcare 
products (i.e., iv tubing, bottles, pacifiers, and infant toys).  Recently, several epidemiology 
studies have been performed in an effort to identify effects of phthalate exposure in the 
human.  Studies in adult men reported a negative association between MEHP and serum 
testosterone, estradiol [37] and semen quality [38].  Findings in children, however, have been 
less clear.  Studies comparing maternal urine metabolite concentrations of several phthalates 
to neonatal AGD and several sex hormone markers have had conflicting results.  Swan et al. 
[39] reported a negative correlation between AGD and maternal urine levels of several 
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phthalates, including the known anti-androgen MBP and the DEP metabolite MEP, which is 
not endocrine active in animal studies.  No correlation was found between AGD and MEHP.  
Main et al. [40] measured several markers of sex hormone homeostasis in male infants and 
compared observed changes to phthalate concentrations in maternal breast milk.  The results 
showed no direct correlation between maternal phthalate exposure and serum total 
testosterone.  However, some differences were noted in other indices.  MBP was negatively 
correlated to free testosterone, MEP, a similar inactive phthalate (monomethyl phthalate; 
MMP), and MBP were positively correlated to LH:free testosterone ratio.  MEHP was not 
significantly correlated to any of the measured indices.  More recently, a study found a 
negative correlation between urine MBP levels and AGD in female, but not male, infants 
[38].  While the authors interpreted these results as evidence of phthalate effects on human 
sexual development, the conclusions have been met with a fair amount of controversy in the 
scientific community.  Primary concerns about the interpretation of these studies include the 
inability to account for confounders and the findings of significant associations between 
phthalates that do not affect sexual development or testosterone production in laboratory 
animals [41]. 
 
Phthalate kinetics in gestation and dose-response for fetal effects 
Despite the number of in vivo effects studies, little information is available regarding 
phthalate disposition during gestation.  In fact, with the exception of DBP, no data has been 
published on fetal phthalate concentrations.  A few studies are available that examined DBP 
kinetics during gestation. Fennell [42] obtained time-course data for MBP and MBP-
glucuronide (MBP-G) in maternal and fetal plasma and amniotic fluid after a single dose of 
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50, 100, or 250 mg DBP/kg on gestation day (GD) 20. Saillenfait [43] also measured MBP 
and MBP-G kinetics in maternal plasma, placenta, fetal plasma, and amniotic fluid in rats 
given single oral dose of 500 or 1500 mg 14C-DBP/kg on GD 14.  Calafat [44] identified 
MBP as well as MBP-G in the amniotic fluid and urine of rats after repeated DBP exposures.   
DEHP kinetic data have been published for the blood and excreta of the pregnant dam, but 
not the fetus itself [44, 45].  
While developmental effects have been associated with multiple day phthalate 
exposures [46, 47], most of the published kinetic studies in gestation have focused on acute 
metabolite kinetics [42, 48, 49].  Repeated DEHP and DBP administration to adult male rats 
induces hepatic expression and activity of CYP4A isozymes, which catalyze 
ω−hydroxylation of fatty acids [24, 25, 50, 51].   Exposure to DBP at 500 mg/kg/day from 
GD 12-19 has also been shown to induce CYP2B1, 3A1 and 4A1 mRNA and protein 
expression in the liver of the pregnant rat and fetus and uridine 5'-diphospho-
glucuronosyltransferase (UDPGT) mRNA in the dams [52].  The effect of the up-regulation 
of CYP enzyme and UDPGT expression on DBP and/or MBP kinetics has not been 
previously examined.  Studies on the effect of P450 enzyme induction on body burden of the 
MEHP have had variable results: some showed slightly greater clearance after repeated 
dosing [45, 53] while others showed no difference [54].  
There is currently very little data regarding the fetal phthalate concentrations 
associated with developmental effects.  Prior to the current work, the available studies related 
fetal/pup effects to the maternal administered dose.  Because of non-linearities expected in 
metabolism and its induction and limited data on placental transfer, it was not previously 
possible to relate the developmental effects to the phthalate concentration in the fetus.   
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 Testosterone synthesis and potential mechanisms for phthalate disruption 
Testosterone (T) synthesis is stimulated by the release of luteinizing hormone (LH) 
from the pituitary, which binds to a G-protein coupled receptor (GCPR) on the surface of the 
Leydig cell.  Release of the G-protein increases intracellular levels of cyclic AMP (c-AMP), 
activating protein kinase A (PKA) and several transcription factors, including those 
regulating steroid acute regulatory (StAR) protein expression.  StAR protein plays an 
important role in steroidogenesis by facilitating cholesterol transport into the mitochondria.  
GCPR binding also leads to activation of cytosolic phospholipase A2 (cPLA2) and the release 
of arachidonic acid (AA), which also stimulates transcription of genes required for 
steroidogenesis, including StAR.  The c-AMP pathway appears to be dominant in the adult 
Leydig cell, though both the c-AMP and AA pathways are necessary for the maintenance of 
normal T levels [55].  The interdependence of these two pathways is not well characterized, 
though a few studies have shown that AA release occurs either downstream or independently 
from c-AMP [55-57].   
While phthalate inhibition of steroid synthesis has been shown to occur through direct 
interaction in the Leydig cell, the molecular target for these anions has not yet been 
identified.  Because of the known PP activity of some phthalates, and presence of PPARα 
and δ in the testes, PPAR activation has been identified as a potential mechanism of testicular 
toxicity [26, 58].  Studies in knockout mice show that PPARα is involved in DEHP-
dependent testicular toxicity, though PPARα alone cannot account for the full range of 
effects seen in testes of male mice [58].  Furthermore, the trend seen when comparing the 
potency of different phthalates is not consistent with PPAR as a regulator of testicular 
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toxicity.  While DEHP and DBP cause similar effects on fetal sexual development and 
testosterone production, they have different abilities to activate PPAR [25]. In transfected 
COS cells [59], MEHP was a potent activator of mouse PPARα (IC50 = 0.6 μM), but MBP 
showed no significant activation at concentrations up to 300 μM.   
 A second potential target, PLA2, was identified based on the studies recognizing its 
metabolic product AA as a necessary signaling molecule in Leydig cell steroidogenesis 
together with the historical data on MEHP’s ability to inhibit AA release in platelets [60].  
While the AA pathway appears to be secondary to the c-AMP/PKA pathway, AA inhibition 
does cause decreased steroidogenesis in vitro [55, 61] and negatively effects male sexual 
development in vivo [62]. As opposed to PPAR [59], preliminary studies in our laboratory 
showed that MEHP and MBP have a similar ability to inhibit AA cPLA2 activity (see 
Chapter 5).  Additionally, in vivo studies have shown decreased cPLA2 activity in the testes 
of male fetal rats exposed to DEHP during gestation [63]. 
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 B.  PHTHALATE RISK ASSESSMENT AND LEGISLATION 
 Despite the lack of clear evidence for developmental effects in humans, the consistent 
findings in animals have led to several legislative acts aimed at reducing children’s risk of 
endocrine disruption.  In 2005, the European Union banned the use of six phthalate esters in 
plastics manufactured for use in children’s toys and childcare products.   California state 
legislature followed suit in 2007 and in 2008, the United States Senate banned the use of 
three phthalates in toys and childcare products, BBP, DEHP and DBP.  They also placed a 
temporary ban on three additional phthalates pending further study.  US public health 
agencies have yet to recommend standards for the plasticizers based on potential 
developmental effects.  Both the Environmental Protection Agency (EPA) and the Food and 
Drug Administration are currently evaluating the available data.  Previous recommendations 
by the EPA predate the developmental toxicity studies and are based on effects in adult rats, 
such as increased liver weight (BBP, DEHP) and mortality (DBP), which occur after long-
term dosing at 470, 19 and 600 mg/kg/day, respectively.  Development of a quantitative 
estimate of human risk to phthalate-induced developmental effects, however, is severely 
limited by insufficient relevant data.  To determine the relevance of rodent toxicity studies to 
the human population, a better understanding is needed of the fetal dose required to cause the 
adverse effects and of molecular targets by which the phthalates exert their effect. 
 
 
 
 11
C.  STUDY OBJECTIVE  
The purpose of this project was to improve the current understanding of the 
pharmacokinetic and pharmacodynamic factors governing the testosterone-dependent effects 
in the fetal rat upon administration of certain phthalates, such as DEHP and DBP.  In order to 
better define both the chemical kinetics and the mechanism of action of the phthalates, a 
variety of in vivo, in vitro and in silico approaches were employed.  Ultimately, the goal of 
this work was to provide both data and predictive tools (PBPK models) that could be used to 
improve accuracy of current and future risk assessment efforts.  This thesis describes a series 
of experiments designed to answer specific questions regarding the pharmacokinetic and 
pharmacokinetic determinants of phthalate developmental toxicity: 
a) Pharmacokinetic evaluations 
 The in vivo kinetic studies in Chapter 2 examine the distribution of DBP and its major 
metabolites (MBP and MBP-glucuronide; MBP-G) in the pregnant and fetal rat after a 
single dose of 500 mg/kg on gestation day (GD) 19 or repeated doses of 50, 100, or 500 
mg/kg/day from GD 12-19.  The dose regimens used in this study are designed specifically 
to correlate fetal testosterone reduction to internal measures of dose, including maternal 
plasma, fetal plasma and fetal testes MBP concentrations.  Because these studies are also 
intended to support the development of a PBPK model for DBP in the pregnant and fetal 
rat, time-course data were collected for MBP and MBP-G in maternal plasma, placenta, 
fetal plasma, testes and amniotic fluid at each dose. 
 Development of a quantitative physiological pharmacokinetic model which relates 
external dose to maternal, fetal, and target tissue (fetal testes) concentrations of MBP and 
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MEHP, the active metabolites of DBP and DEHP, respectively, is described in Chapter 3.  
PBPK models are useful tools for describing the relationship between external dose and 
time-dependent tissue concentrations quantitatively.  The models described in Chapter 3 
are based on a variety of in vitro and in vivo data taken from the published literature and 
from the studies described in Chapter 2. 
 
b) Pharmacodynamic Evaluations 
 Chapter 4 describes a series of studies designed to determine whether the difference 
in potency among phthalates is a result of PK or PD differences.  The monoester 
metabolites of several phthalates (both endocrine active and inactive) are reported for the 
fetal testes following maternal dosing to determine differences in fetal exposure.  
Additionally,  an in vitro assay was developed to evaluate the effect of several phthalates 
directly in the Leydig cell, the steroidogenic cell in the testes. 
 The use of the in vitro assay to determine the molecular target for the phthalates is 
presented in Chapter 5.  These experiments evaluate the potential role of arachidonic acid 
release by cPLA2 in phthalate inhibition of steroidogenesis.  Additionally, the effect of 
phthalate exposure on cPLA2 activation and translocation using confocal microscopy and 
fluorescently tagged protein is described. 
   Finally, an in vivo experiment designed to test the role of arachidonic acid on fetal 
sexual development is reported in Chapter 6.  Administration of chloroquine (CQ), a 
known inhibitor of AA release, and resulting changes in several markers of fetal testes 
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development are described.  The design of this experiment is based on the premise that 
the AA inhibitor should have similar effects on fetal steroidogenesis as the phthalates, if 
AA does mediate phthalate anti-androgen activity.  Taken together, our studies indicate a 
key role of cPLA2 as a target for the phthalate monoesters developmental toxicity. 
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Figure 1.1. Chemical structure of common phthalate esters. 
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Kinetics of selected di-n-butyl phthalate metabolites and fetal testosterone following 
repeated and single administration in pregnant rats 
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A.  ABSTRACT 
Human exposure to phthalic acid diesters occurs through a variety of pathways as a 
result of their widespread use in consumer products and plastics.  Repeated doses of di-n-
butyl phthalate (DBP) from gestation day (GD) 12-19 disrupt testosterone synthesis and male 
sexual development in the fetal rat.  Currently little is known about the disposition of DBP 
metabolites, such as monobutyl phthalate (MBP) and its glucuronide conjugate (MBP-G), 
during gestation after repeated exposure to DBP.   In order to gain a better understanding of 
the effect of repeated dosing on maternal and fetal metabolism and distribution, pregnant 
Sprague-Dawley rats were given a single dose of 500 mg/kg DBP on GD 19 or daily doses of 
50, 100, and 500 mg/kg/day from GD 12-19 via corn oil gavage.  Dose-response evaluation 
revealed a non-linear increase in maternal and fetal plasma concentrations of MBP.   
Maternal and fetal MBP levels were slightly lower in animals after eight days of dosing at 
500 mg/kg/day.  Fetal plasma MBP levels closely followed maternal plasma, while the 
appearance and elimination of MBP-G in fetal plasma were significantly delayed.  MBP-G 
accumulated over time in the amniotic fluid.  Inhibition of testosterone was rapid in fetal 
testes when exposed to DBP (500 mg/kg/day) on GD 19.  Within 24 hrs, the level of 
inhibition in the fetus was similar between animals exposed to a single or multiple daily 
doses of 500 mg/kg/day.  Examination of testosterone time-course data indicates a rapid 
recovery to normal levels within 24 hrs post-dosing at DBP doses of 50 and 100 mg/kg/day, 
with a rebound to higher than normal concentrations at later time-points.  MBP kinetics in 
fetal testes allows direct comparison of active metabolite concentrations and testosterone 
response in the fetal testes. 
 17
 B.  INTRODUCTION 
Phthalate esters are found in drinking water, food, and personal care products and are 
used in the coating of some medications [1, 3, 64].  Though relative source contributions 
have not been characterized in the United States, a recent study in Europe found that food 
sources accounted for 40-90% of the overall di-n-butyl phthalate (DBP) exposure [3].  
Biomonitoring studies have identified the metabolites of DBP and several other phthalates in 
the urine of the US population including adults, children, infants, and pregnant women [4-6].  
Some of these phthalates, including (DBP), are developmental toxicants in rats and mice [32-
34, 65-68].  Exposure to DBP between gestation days (GD) 12 and 19 disrupts male rat 
sexual development, as evidenced by reduced anogenital distance, nipple retention, 
hypospadias, delayed testes descent, and vaginal pouch development in male pups [69].  The 
anti-androgenic effects of DBP are thought to result from inhibition of fetal testosterone 
synthesis by the monoester metabolite, monobutyl phthalate (MBP) [33, 70-72]. Repeated 
doses of DBP cause reduced testosterone levels in the blood of adult male rats [70, 72, 73] 
and in the testes of male fetuses from rats exposed to doses as low as 50 mg/kg-day from GD 
12 – 19 [46].   To date, studies have not been performed to determine target tissue phthalate 
concentrations associated with these observed effects.   
MBP, the active metabolite of DBP, is formed by intestinal hydrolases upon ingestion 
and is quickly absorbed in the gut [11].  MBP can be excreted unchanged in the urine, 
undergo oxidative metabolism (primarily ω and ω-1-hydroxylation), or be conjugated to 
glucuronic acid by uridine 5'-diphospho-glucuronosyltransferase (UDPGT) [74].  
Glucuronide conjugation is a major route of clearance for MBP in the rat, particularly at 
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higher doses where developmental effects have been found.  Urinary MBP-glucuronide 
(MBP-G) was shown to account for 17% of the dose 24 hrs after 10 mg/kg iv or 36% of the 
dose after a single 2000 mg/kg oral administration [49, 75].  
 A few studies are available which examined DBP kinetics during gestation.  Fennell  
[42] fetal plasma and amniotic fluid after a single dose of 50, 100, or 250 mg DBP/kg on GD 
20.  Saillenfait [43] also measured MBP and MBP-G kinetics in maternal plasma, placenta, 
fetal plasma, and amniotic fluid in rats given single oral dose of 500 or 1500 mg 14C-DBP/kg 
on GD 14.  Both studies showed similar kinetics to that of the male rat, with more than 77% 
of the dose excreted in the urine in 24 hrs.  Both free MBP and MBP-G were found in the 
fetal rat plasma and amniotic fluid after maternal DBP exposure.  Calafat [44] also identified 
MBP as well as MBP-G in the amniotic fluid and urine of rats after repeated DBP exposures.  
Despite the fact that the developmental effects of DBP have been associated with 
multiple day exposures (with the exception of testosterone reduction) [46, 47], previous 
studies in gestation have focused on acute metabolite kinetics [42, 48, 49].  As is true with 
the related phthalate ester diethylhexyl phthalate (DEHP), DBP administration to adult male 
rats induces expression and activity of CYP4A isozymes, which catalyze ω−hydroxylation of 
fatty acids [24, 25, 50]. Exposure to DBP at 500 mg/kg/day from GD 12-19 also induces 
CYP2B1, 3A1 and 4A1 mRNA and protein expression in the liver of pregnant rats and in the 
fetal liver.  UGT mRNA was also up-regulated in these dams [52].  The effect of the up-
regulation of P450 and UGT expression on DBP and/or MBP kinetics has not been 
previously examined.  Studies on the effect of P450 induction on body burden of the DEHP 
monoester, monoethylhexyl phthalate, have had variable results: some showed slightly 
greater clearance after repeated dosing [45, 53] and while others showed no difference [54].   
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The purpose of this study was (1) to develop a better understanding of maternal and 
fetal DBP kinetics under exposure conditions where developmental effects have been 
observed and (2) to directly relate fetal concentrations of the active metabolite (MBP) with 
changes in testes testosterone concentration.   Thus, pregnant rats were given daily doses of 
DBP at 50, 100, and 500 mg/kg/day on GD 12 -19 MBP and MBP-G kinetics were measured 
in maternal and fetal plasma, placenta, and amniotic fluid for two days post-dose.  To test 
whether MBP metabolism is significantly altered after multiple high dose exposures, a study 
was also performed in which maternal and fetal kinetics were examined after a single dose of 
500 mg/kg on GD 19.  The fetal testes were collected and measured for both MBP and 
testosterone.  These were quantified in order to evaluate the dose-response relationship 
between the MBP and testosterone, a sensitive marker for disruption of sexual development 
in the target tissue.     
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C. METHODS 
Animals 
 Pregnant Sprague-Dawley (Crl:CD(SD)) rats (sperm plug positive GD 0) were 
obtained from Charles River Laboratories (Raleigh, NC) and housed in the Animal Care 
Facility of the The Hamner Institutes for Health Sciences, which is accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care International. Rats 
were acclimated in a temperature- and humidity-controlled, HEPA-filtered environment on a 
12 hr light-dark cycle.  NIH rodent diet (NIH-07, Zeigler Bros., Gardner, PA) and reverse-
osmosis water were provided ad libitum. This study was approved by The Hamner Institute’s 
Animal Care and Use Committee.  
 
Dosing Solutions and Treatment  
 Dosing solutions of DBP at concentrations of 50, 100 and 500 mg/mL were prepared 
in corn oil (Sigma-Aldrich, St. Louis, MO) and administered to rats at a volume of 1 mL/kg.   
The actual concentrations of DBP in the dosing solutions were 48 + 0.4, 89 ± 10, and 502 ± 9 
mg/mL (mean ± SE) by gas chromatography using a method described by Fennell et al. 
(2004) [42]. Time points of tissue collection were selected based on the rapid 
pharmacokinetics of MBP and the pharmacodynamics of testosterone changes in fetal testes 
following administration of DBP.  In the repeated dose study, pregnant rats (n=4/dose 
group/time point) were administered a daily dose of DBP (0, 50, 100 or 500 mg/kg) from GD 
12-19.  At 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 24, and 48 hrs after the final dose, rats were 
euthanized by CO2 asphyxiation and exsanguination.  In the single dose study, pregnant 
Sprague-Dawley rats (n=4/dose group/time point) were administered 1.0 mL/kg of corn oil 
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on GD 12 – 18 and corn oil (0 mg/kg) or DBP (500 mg/kg) on GD 19.  Maternal rats were 
euthanized with CO2 followed by exsanguination at 0.5, 1, 2, 24 and 48 hrs post-dosing.  
Litter sizes varied from 12 -17 fetuses per dam. Fetuses were delivered by caesarean section 
and amniotic fluid was collected from 4 fetuses, selected randomly.  Amniotic fluid that was 
visibly clear of blood or other contaminants was pooled by litter, snap frozen in an 
ethanol/dry ice bath, and stored at -80oC.  Fetal blood was collected from the jugular vein 
using heparinized capillary tubes and pooled by litter in glass centrifuge tubes. Placentas 
were pooled by litter, snap frozen an ethanol/dry ice bath and stored at -80oC.  Testes from 
each male fetus were stored separately.  Maternal livers taken from the 500 mg/kg dose 
groups were snap frozen in an ethanol/dry ice bath and stored at -80oC.  Maternal blood was 
obtained at the time of sacrifice by cardiac puncture.  Plasma was separated from maternal 
and fetal whole blood by centrifugation and stored at -80oC.   
 
MBP and MBP-G Sample Preparation 
MBP and MBP-G were extracted from plasma, amniotic fluid, and tissues prior to 
analysis based on previously described methods Saillenfait [42, 48]. Aliquots (25 μl) of 
plasma or amniotic fluid (pooled by litter) were thawed, vortexed, and added to a solution 
containing internal standard 13C4-MBP (25 µL, Cambridge Isotope Laboratories, Andover, 
MA), HPLC-grade water (25 µL, Burdick and Jackson), and 0.1% (v/v) formic acid in 
acetonitrile (425 µL, EMD Chemicals Inc., Gibbstown, NJ). Samples were shaken for 6 min 
at 4oC, vortexed, and centrifuged at 1900 x g at 4oC. The supernatant was transferred to a 
glass vial with a deactivated siliconized glass insert.  
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Fetal testes were pooled by litter and homogenized in 1% PBS (500 µL per testes 
pair) with a Mixer Mill 300 for 5 minutes at 30 Hz.  The homogenate was divided into two 
200 μl fractions; the first fraction was prepared for analysis of MBP and MBP-G, the second 
was prepared for testosterone analysis.  The fraction designated for MBP/MBP-G analysis 
(200 µL) was transferred to a 2.0 mL microcentrifuge tube and 200 µL of 1% formic 
acid/water and 25 μL of 13C-MBP (6 mg/mL) were added to the tube. The sample was 
vortexed and then centrifuged at 1900 x g for 6 min at 4oC.  The supernatant was loaded onto 
an LC-18 SPE column (Honeywell Burdick and Jackson, Morristown, NJ) that had been 
rinsed twice with 0.1% formic acid in methanol (1 mL/rinse) followed by two rinses with 
0.1%  formic acid in water (1 mL/rinse).  After loading the sample, the column was washed 
with a 3:1 mixture of 0.1% formic acid in water and 0.1% formic acid in methanol.  MBP 
and MBP-G were then eluted with 2 mL of 0.1% formic acid in methanol added in 2 
increments of 1 mL. Eluted samples were evaporated to dryness under nitrogen and 
reconstituted in 200 µL of 0.1% formic acid in ACN/H2O (90%/10%) for injection on the 
LC-MS/MS. 
 
Testosterone Sample Preparation 
The second fraction of the testes homogenate (200 µL) was added to 13C2-testosterone 
(Cambridge Isotope Labs, 10 µL), diluted with 4 M urea (Sigma-Aldrich, 200 µL), and 
heated to 60oC for 30 min [76].  Samples were cooled to room temperature, transferred to 
LC-18 SPE columns previously conditioned with methanol and water, and rinsed with 25% 
methanol.  Methanol (100%) was used to elute the testosterone. Samples were dried under 
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nitrogen, reconstituted in 25 μL chloroform and testosterone was derivatized with n-
heptafluorobutyrylimidazole (HFBI, Indofine, Hillsborough, NJ) for 4 hrs at 60oC. 
 
Calibration and quality control standards 
MBP (TCI America, Portland, OR) was dissolved in acetonitrile/water (1:1, v/v) at 2 
mg/mL.  MBP-G was purified from urine from rats dosed with 50 mg/kg MBP as described 
previously [48]. Calibration standards consisted of the stock solution, control plasma, and 
extraction buffer, and were prepared daily. Preliminary studies indicated that control plasma 
could be used as the biological matrix in preparation of the calibration curves for maternal 
plasma, fetal plasma, amniotic fluid, and fetal testes. Calibration curves for MBP and MBP-
G consisted of 12 serial dilutions of MBP (0.1-200 µg/mL) and MBP-G (0.04-90 µg/mL).  
Testosterone (Steraloids, Newport, RI) was dissolved in chloroform and standards were 
prepared individually (no serial dilution) with concentrations ranging from 0 to 20 ng/mL. 
 
MBP/ MBP-G Analysis with Liquid Chromatography/Mass Spectrometry (LC-MS/MS) 
LC-MS/MS (Applied Biosystems, Foster City, CA) was used to quantify MBP and 
MBP-G in plasma, amniotic fluid, and tissues. The LC was a Series 200 from Perkin Elmer 
(Norwalk, CT) and consisted of 2 MicroPumps, autosampler, and on-line Vacuum Degasser. 
Chromatography was performed on a Luna® phenyl-hexyl column (50 mm*2 mm*3 µm) 
with a SecurityGuard™ phenyl(phenylpropyl) guard column (Phenomenex, Torrence, CA). 
The mobile phase consisted of 0.1% formic acid in HPLC-grade water and acetonitrile. The 
acetonitrile gradient was increased from 30 to 95% over 3 min, with a 5-min post-run 
equilibration time.   
 24
MS analysis (Applied Biosystems API 3000) was conducted in negative ion mode 
with a turbo ionspray interface. Curtain, nebulizing, and collision gases were set in the PE 
Sciex Analyst 1.1 software at 11 (nitrogen), 7 (air), and 3 (nitrogen), respectively. 
Turbospray gas was nitrogen at 7 L/min at 375oC. The nebulizing, declustering, and focusing 
potentials were -4000 V, -25 V and -90 V. Quantitation was performed using selected 
reaction monitoring of precursor-product ion transitions at m/z 221.1 to 77.1 for MBP, m/z 
225.1 to 79.1 for 13C4-MBP, and m/z 397.1 to 221.1 for MBP-G. Collision energy was 
optimized to -25 eV for MBP and 13C4-MBP and -22 eV for MBP-G. Data acquisition and 
initial analysis used PE Sciex Analyst 1.1 software.  
Background levels of MBP and MBP-G were calculated by averaging daily plasma 
from control animals. Peak area counts were calculated by subtracting blanks and comparing 
to calibration standards, both averaged by analysis date. Samples were randomly placed into 
queue. Visually outlying results and random samples were verified by reextraction and/or 
reanalysis.  
 Limits of detection (LOD) for MBP and MBP-G were determined to be 6 and 1 
ng/mL, respectively, using standard solutions.  However, in control plasma samples both 
MBP and MBP-G levels were above the LOD (control levels: MBP = 0.26 ± 0.30 mg/L; 
MBP-G = 0.003 ± 0.003 mg/L). The method limit of quantitation (LOQ) was therefore 
determined from standards prepared in control plasma, yielding values of 0.26 and 0.003 
mg/L (or 0.0024 and 0.0011 mg/L minus background from controls) for MBP and MBP-G, 
respectively. The LOQs for placenta, amniotic fluid and testes were calculated from the 
lowest point in the linear portion of the standard curve and adjusted for dilution during 
sample preparation.  The resulting values for the LOQ for MBP and MBP-G were 2.4 and 1.1 
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mg/L in the fetal testes, and 0.0024 and 0.0011 mg/L in the placenta and amniotic fluid when 
adjusted for background levels.  The potential source of the MBP background has not been 
determined, though internal studies have shown little to no detectable contamination from 
laboratory supplies. For example, there were no significant differences in MBP background 
following extraction and analysis using glass as compared to plastic lab supplies.  Control 
animals were used to normalize MBP levels and to negate any phthalate contamination from 
laboratory supplies. 
 
Testosterone Analysis with Gas Chromatography/Mass Spectrometry (GC-MS) 
Testosterone was quantified using an Agilent 6890 gas chromatograph (GC) coupled 
to an Agilent 5973 inert mass spectrometer (MS). GC separations were carried out by 
injecting 1 μl onto a DB-5 column (30 m * 0.25 mm, 0.25 μm) (J&W Scientific, Folsom, 
CA) with an injector temperature of 280oC (split-less mode) and a carrier gas (helium) flow 
of 0.9 mL/min. The GC temperature program was 150oC for 0.5 min, ramped to 300oC at 
10oC/min, and held at 300oC for 1.5 min before returning to 150oC. The mass selective 
detector was run in negative chemical ionization mode with methane as the reagent gas. 
Quantitation was conducted using selective ion monitoring of the 464 and 466 atomic mass 
unit ions for testosterone and 13C2-testosterone, respectively. Data were collected and 
integrated using Agilent Chemstation software.  
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Bicinchoninic Acid (BCA) Protein Assay 
Protein concentration in fetal testes homogenate (10 µL) was quantified using a 
commercially-available Bicinchoninic acid (BCA) method (Pierce, Rockford, IL). 
 
Pharmacokinetic Analysis 
Pharmacokinetic parameters for MBP and MBP-G in the maternal and fetal plasma 
from the repeated dosing study were calculated in WinNonlin® version 4.5 (Pharsight, 
Mountain View, CA). Data were averaged by time point and dose group and modeled using 
noncompartmental analysis with extravascular administration and no weighting.  The data 
from the single dose study did not contain a sufficient number of time points to carry out a 
comparable analysis. 
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D.  RESULTS 
MBP Pharmacokinetics after Repeated Dosing: 
 The dosing regimen of repeated dosing study was carried out in the same manner as 
[46], which showed a dose-dependent decrease in fetal testes testosterone concentrations.   
MBP and MBP-G were quantified in maternal plasma, maternal liver, placenta, amniotic 
fluid, and fetal plasma and testes using LC-MS/MS. Elution times for MBP-G, 13C4-MBP, 
and MBP were comparable to previous LC-MS/MS results [46].  Concentration time courses 
were collected for MBP in maternal and fetal tissues after daily exposure to DBP from GD 
12 to 19 (Figure 2.1).   MBP in maternal plasma, placenta, and fetal plasma was mostly 
eliminated after 24 hrs.  In the 50 mg/kg/day group, tissue distribution of free MBP occurred 
rapidly.  Both placenta and fetal serum kinetics closely followed the maternal plasma, though 
the fetal plasma showed a slight delay in the time to reach peak concentration (Tmax = 1 vs. 
0.75 hr).  Fetal plasma levels were consistently lower (~60%) than maternal plasma.  
Placental tissue concentrations also remained lower than the plasma; peak MBP 
concentrations in the placenta were 15% of peak plasma levels in the 50 mg/kg/day dams.  
 Plasma and placenta MBP kinetics were qualitatively similar in the 100 and 500 
mg/kg/day groups when compared to the 50 mg/kg/day group (Figure 2.1), with nearly 
complete clearance within 24 hrs and rapid, but limited, distribution into the placenta and 
fetal plasma. The half-life for MBP in maternal and fetal plasma was also similar across 
doses (Table 2.1).  However, some pharmacokinetic parameters calculated from a 
noncompartmental model for maternal and fetal plasma (Table 2.1) did indicate the existence 
of dose-dependent differences.     
 28
 The dose normalized area under the curve (AUC/D) was nearly 2-fold higher in the 
plasma of the 100 and 500 mg/kg/day dams than 50 mg/kg/day.  In contrast, the dose 
normalized maximum concentration (Cmax/D), time of peak concentration (Tmax), and mean 
residence time (MRT) were similar between the 50 and 100 groups, but differed in the 500 
mg/kg/day group. The Cmax/D was reduced nearly 3-fold at 500 mg/kg/day, while Tmax and 
MRT were increased more than 2-fold in the 500 mg/kg/day group.   Fetal MBP parameters 
showed the same trends as the dam, with increased values for AUC/D (2-fold) and Tmax (4-
fold) at 500 mg/kg/day. However, dose-dependent changes in Cmax/D and MRT in the fetus 
were minor (<20%).   
Amniotic fluid MBP levels were not linearly correlated with either the maternal or 
fetal plasma when examined across doses (Figure 2.1).  As opposed to the fetal plasma, 
where the AUC/D remained constant at the lower doses (50 – 100 mg/kg/day), amniotic fluid 
AUC/D increased 2-fold between the 50 and 100 mg/kg/day groups and another 3.4-fold 
between 100 and 500 mg/kg/day.  Furthermore, while the half-life for MBP in the plasma did 
not change, the T1/2 in the amniotic fluid decreased with increasing dose (11.7 – 4.1 hr).   
 
MBP-G Pharmacokinetics after Repeated Dosing: 
Concentrations of MBP-G in the maternal plasma, placenta, fetal plasma and 
amniotic fluid were also measured (Figure 2.2).  The nearly complete elimination of MBP-G 
from maternal plasma within 24 hrs, and the low MBP-G concentrations at the 15 min time 
point, indicated that MBP-G was not accumulated with repeated dosing.  In the 50 mg/kg/day 
dose group, MBP-G appeared rapidly in the maternal blood and placenta, with Tmax values 
similar to MBP (Table 2.1).  However, appearance of MBP-G in the fetal plasma was slower 
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than free MBP (Figure 2.2), with peak concentrations occurring between 4 and 12 hrs post-
dosing (as opposed to 1-2 hrs for MBP).  Clearance of MBP-G from the fetal blood was 
somewhat slower than free MBP with a calculated T1/2 of 8.2 hrs (versus 5.2 hrs for free 
MBP). 
When compared across dose groups, the trends seen in MBP-G kinetics were similar 
for maternal plasma, fetal plasma and placenta, i.e., rapid appearance in maternal blood and 
placenta, delayed appearance in fetal plasma and amniotic fluid, no indication of 
accumulation in maternal or fetal plasma.  However, as noted with free MBP, examination of 
the kinetic parameters (Table 2.1) revealed some dose-dependent differences in the chemical 
distribution and clearance.  Trends seen in many of the MBP-G parameters were similar to 
those described above for MBP in the maternal plasma: Tmax, AUC/D and MRTinf increased 
at doses above 50 mg/kg/day and T1/2 did not change with dose.   Notably, the difference in 
AUC/D in fetal plasma was more pronounced than was seen with either metabolite in the 
dam or with fetal MBP. The AUC/D increased nearly 6-fold between the plasma from the 50 
and 500 mg/kg/day dose groups.  
Amniotic fluid MBP-G levels were non-linear with respect to both external dose and 
fetal plasma MBP-G (Figure 2.2).  MBP-G concentrations in the amniotic fluid were similar 
to the fetal plasma at 50 and 100 mg/kg/day.  However, the AUC was approximately 2-fold 
greater in amniotic fluid than fetal plasma at 500 mg/kg/day.   
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Single versus Repeated Dosing 
Previous studies in pregnant rats showed induction of P450 expression in the liver of 
dams and fetuses exposed to 500, but not 50 mg/kg/day DBP from GD 12-19.  UDPGT 
expression was also increased in the maternal liver [52].  To test whether these changes in 
enzyme expression translate to altered metabolite kinetics, maternal and fetal plasma and 
amniotic fluid were collected after a single DBP dose (500 mg/kg) and the MBP and MBP-G 
concentrations at 0.5, 1, 2, and 24 hrs post-dosing were compared to repeated dosing results.  
Use of the single dose study for comparison is based on the assumption that there would be 
insufficient time to induce these enzymes in the absence of pre-exposure. Livers were also 
collected from dams in the single and repeated (500 mg/kg/day) dose study in order to 
directly measure the effect of repeated dosing on liver metabolite concentrations.   
Maternal and fetal plasma MBP levels were consistently lower with repeated doses 
compared to a single dose (Figure 2.3A-B), suggesting that metabolism of MBP was induced 
with multiple exposures.  Peak maternal and fetal plasma MBP concentrations from animals 
exposed from GD 12-19 were 67% and 55% compared to those given a single dose.  
Maternal liver MBP levels were also reduced after multiple exposures; the Cmax for MBP 
after multiple doses was 72% of the single dose (Figure 2.3C).  Maternal liver MBP-G 
concentrations were not significantly different in the single and repeated dose groups (Figure 
2.3C).  MBP concentrations in the amniotic fluid were also reduced with repeated doses of 
500 mg/kg DBP (Figure 2.3D).  MBP-G, however, was not decreased (Figure 2.3D). In fact, 
the amniotic fluid MBP-G concentrations were consistently higher in the repeated dosing 
study than the single dose.   
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Testosterone Response in Fetal Testes 
In order to directly compare target tissue dose of MBP and testosterone concentration 
for DBP administration that results in developmental effects, fetal testes were collected from 
rats from both the repeated and single dose studies.  Testes were pooled by litter, 
homogenized and split into two aliquots.  One aliquot was analyzed for MBP and MBP-G 
and the other was analyzed for testosterone (Figures 2.4 – 2.6).  Fetal testosterone levels were 
not expected to undergo the same diurnal cycling seen in the adult; plasma levels increase 
during gestation to peak levels at GD 18, followed by a slight decrease until birth [77].  In 
order to account for changes in testosterone levels with prenatal age, controls were taken on 
the day of sacrifice (0.5 hr) and on each subsequent day (24 and 48 hr post-dosing).  A 12 hr 
control was also collected in the 50 mg/kg/day study (Figure 2.4A).   The small tissue 
volume and the amount of dilution necessary to run the same sample through both the 
phthalate and testosterone analysis resulted in many of the samples being below the LOQ for 
MBP and MBP-G.   
All testes samples in the lowest dose (50 mg/kg/day) were below LOQ for MBP and 
MBP-G and testosterone levels were significantly lower than controls only at the 12 hr time 
point (Figure 2.4A).  At 100 mg/kg/day (Figure 2.4B), MBP was measurable for the first 4 
hrs following the final administration of DBP and the testes showed significant decrease 
(43%) in testosterone at 0.5 hr post-dosing (GD 19).  Testosterone levels recovered to control 
levels by 24 hrs post-dosing (GD 20) and at 48 hrs (GD 21) fetal testosterone levels for the 
100 mg/kg/day group exceeded control levels (p < 0.05).  At the highest DBP dose (500 
mg/kg/day), MBP was measurable up to 12 hrs after the final dose and testosterone was 
significantly decreased, with testosterone levels at 25 and 19% of controls on GD 19 and 20 
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(Figure 2.4C).  Mean testosterone concentrations in testes of this high dose group remained 
low on GD 21 (48 hrs post-dosing), but were not statistically different from control values (p 
> 0.05).   More time points were taken for DBP treated animals than controls, as described in 
the Methods section.  Figure 2.5 shows relative changes in testosterone at all time-points 
collected in DBP treated rats versus estimated control values calculated by linear 
interpolation of the available time-points.  Because control values were not available for 
every time point, the statistical significance could not be determined for time points other 
than those shown in Figure 2.4.  Nonetheless, the time courses for the 50, 100 and 500 
mg/kg/day dose groups clearly show a pattern of testosterone reduction followed by recovery 
after cessation of dosing.  In lower doses, 24 hrs is sufficient for complete recovery of normal 
testosterone levels, while the highest dose would require more time to reach control levels. 
Testes MBP levels did not differ significantly (p > 0.05) between animals given a 
single 500 mg/kg dose and those dosed daily from GD 12-19 (Figure 2.6A).  Testosterone 
levels were significantly reduced on GD 20 (24 hrs post-dosing) but not GD 19 or 21 (0.5 
and 48 hrs post-dosing) in the fetal testes of dams given a single dose of 500 mg/kg (Figure 
2.6B).  Mean changes in testosterone levels were less pronounced after a single dose as 
compared to repeated dosing.  The testes testosterone concentrations after a single or 
repeated dose of 500 mg/kg day were 40 vs. 19% of control at 24 hrs and 76 vs. 55% of 
control at 48 hrs post-dosing. 
In order to directly relate the internal dose for the active phthalate metabolite 
concentration to measured changes in testosterone, the average testosterone concentration 
(0.5 – 24 hr) was calculated for GD 19 using WinNonlin® and plotted against the calculated 
AUCinf for MBP in the plasma of the same fetuses.  Fetal plasma MBP was used instead of 
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testes levels as they were above LOQ for all time-points on GD 19.   Figure 2.7 illustrates the 
fetal plasma MBP concentration-dependent decrease in fetal testosterone.   
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E.  DISCUSSION 
DBP causes a variety of developmental effects in the male fetuses of rats exposed 
during the critical window for testosterone-dependent sexual development (GD 12-19).  It is 
thought to exert its effect through inhibition of testosterone synthesis by the free monoester 
metabolite MBP.  Thus, it is important to understand both 1) metabolite disposition with 
repeated DBP exposures during the critical period of gestation; and 2) how target tissue MBP 
concentrations relate to changes in fetal testes testosterone levels.  In this study, MBP and its 
primary metabolite, MBP-G, were measured in maternal and fetal plasma, placenta and 
amniotic fluid after DBP doses where developmental effects have been found.   
Analysis of the dose-response data from the repeated dosing study indicated dose-
dependence in several pharmacokinetic parameters in maternal and fetal plasma, including 
AUC/D, Tmax, MRT and Cmax/D.  While these differences were generally subtle (~ 2-fold), 
they are supported by their reproducibility across studies in both the pregnant [42] and non-
pregnant rat (NIEHS, 1994).  Fennell et al. [42] reported an increase in AUC/D in pregnant 
rats given a single dose of 250 mg/kg DBP versus those dosed with 50 or 100 mg/kg [42].  
Evaluation of published data in male rats [78] using WinNonlin® revealed increases in 
AUC/D (3.7-fold), Tmax (2-fold), and MRT (1.8-fold) and a decrease (3-fold) in Cmax/D  after 
administration of 43 or 857 mg DBP/kg via oral gavage.  The reproducible increase in Tmax 
and corresponding decrease in Cmax/D seen at the higher doses, suggests that uptake of the 
monoester is dose limited.  This is likely due to saturation of the intestinal lipases, which 
convert the poorly absorbed diester to the rapidly absorbed monoester phthalate [9].    
Despite this reduced uptake, AUC/D and MRT are increased at higher doses, suggesting that 
metabolite clearance is also saturated.   
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Amniotic fluid showed notably different dose-response trends compared to either 
maternal or fetal plasma.  The calculated AUC/D for MBP and MBP-G for amniotic fluid 
showed greater increases across doses than would be expected from fetal plasma levels.  
Both metabolites also exhibited a decrease in T1/2 that is not recapitulated in the plasma.   
The reason for the different dose-response in the amniotic fluid and the fetal plasma are not 
known, though the existence of these differences suggest that amniotic fluid kinetics are 
governed by more complex processes than simple passive exchange with either the maternal 
or fetal plasma.  Both trends are reiterated in the data of Fennell et al. [42], who noted 
decreasing T1/2 (11 – 6.2 hr) and increasing AUC/D (1.54 – 2.56) in the amniotic fluid after a 
single dose of 50, 100, or 250 mg/kg DBP.  Similar increases (nearly 10-fold) to the current 
study were also seen in AUC/D for amniotic fluid MBP-G between the 50 and 250 mg/kg 
dose.  However, Fennell et al. [42] also noted a much longer T1/2 than was observed in 
present study.  The data in Fennell et al. [42] was taken on GD 20 rather than GD 19.  It is 
not clear whether the timing of gestation and development of UDPGT activity would account 
for this difference between the studies.  The relatively high concentrations of MBP-G in 
amniotic fluid at 15 min and 24 hrs post-dosing indicate that MBP-G may be accumulating in 
the amniotic fluid.      
The results from the repeated dosing study indicate there is no bioaccumulation of 
MBP or MBP-G in the dam or fetus, with the possible exception of MBP-G in the amniotic 
fluid.  This conclusion is supported by previous radiolabeled studies in male rats showing 
little to no residual activity 24 hrs after a single DBP dose [11].  The fact that MBP-G, but 
not MBP, accumulates in the amniotic fluid suggests that MBP-G may require hydrolysis 
before re-entering fetal circulation.  Fennell et al. [42] showed amniotic fluid MBP-G 
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underwent pH-dependent rearrangement, which was not present in the plasma.  These 
rearranged glucuronides are more resistant to hydrolysis via β-glucuronidase than the 
original congeners.  Resistance of MBP-G toward hydrolysis may account for the anomalous 
kinetics of the amniotic fluid. 
The reduced MBP and MBP-G concentrations in the tissues of animals dosed 
repeatedly with 500 mg/kg DBP from GD 12-19 versus those administered a single dose on 
GD 19 indicates that there is some induction of oxidative metabolism with repeated high 
dose administration.  Peak MBP concentrations in the maternal and fetal plasma were 
reduced by nearly 50% after eight days of dosing.   Despite the increase in UGT expression 
in the maternal liver at 500 mg/kg/day [52], the current results do not indicate a 
corresponding increase in glucuronide conjugation.  Peak MBP-G levels were not elevated in 
either the maternal or fetal plasma, or in the liver of the maternal rat.  In fact, like MBP, 
MBP-G plasma levels were reduced in animals given several, rather than one, 500 mg/kg 
dose.  
The difference between the single and repeated 500 mg/kg/day dose studies may be 
explained by increased oxidative metabolism, which was not directly measured in this study.  
Wyde et al. [52] demonstrated increased mRNA and protein expression of more than one 
family of the P450 enzymes, including CYP4A, after repeated exposures to DBP at these 
levels.  CYP4A is the primary P450 involved in ω−hydroxylation of fatty acids and is 
thought to play a role in metabolism of MEHP, a phthalate that is similar in structure to MBP 
[24]. The current study, together with studies of repeated DEHP exposures [45, 53, 54] 
indicates that oxidative metabolism is likely to be induced with repeated high doses of some 
phthalates, but the effect on overall kinetics is small.  In the current study, the difference in 
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peak plasma levels was less than a factor of two between repeated and a single 500 mg/kg 
DBP dose.  While the half-lives could not be compared, MBP levels at the 24 hr time-points 
were not statistically different between the single and repeated dose studies.  
Fetal MBP-G may arise either from delivery via maternal blood or through fetal 
metabolism.  The presence of MBP-G in plasma of the GD 19 fetus could, but does not 
necessarily, indicate placental transfer of the glucuronide conjugate.  UGTs become active in 
the fetal liver as early as GD 16 in the rat [79].  The slow appearance of MBP-G in the fetus 
versus the dam may indicate that fetal MBP-G is derived from conjugation in the fetus rather 
than placental transfer, especially since clearance of MBP-G is not slowed to the same extent 
as its appearance in the fetus.  However, without additional data it is not possible to 
definitively state if fetal MBP-G levels are a product of maternal or fetal conjugation.   
Decreases in testosterone levels after repeated dosing was similar to previous studies.  
Lehmann et al. [46] reported a mean decrease of 24, 33, and 94% in fetal testes testosterone 
levels 2 hr after the final dose of 50, 100, and 500 mg/kg/day, respectively, administered 
from  GD 12-19.  In the current study, the closest comparable time-point with corresponding 
controls was 0.5 hr.  The testes testosterone concentration was reduced by 17, 33, and 75% in 
the 50, 100, and 500 mg/kg/day groups with respect to the control animals.  Changes in 
testosterone concentration were rapid in fetal testes after a single DBP dose of 500 mg/kg.  
Within 24 hrs, the decrease in testosterone was equal to that seen in the repeated dose study.  
Recovery time was also similar in the single and repeated dose groups.   Evaluation of the 
testosterone time-course data showed a return to control levels within 24 hrs for doses < 100 
mg/kg/day.  The 100 mg/kg/day group returned to levels that were significantly greater than 
the pretreatment controls, indicating a tendency of the system to over-compensate for 
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temporary decreases in the hormone.   This trend may have also been true for animals given 
500 mg/kg/day.  However, because animals at the highest dose took longer to recover, it 
would have been necessary to measure testosterone at time-points greater than 48 hr after 
dosing to see this response.  
Repeated DBP exposures during the period of sexual development can interfere with 
normal testosterone-dependent development, with the following effects occurring at doses at 
100 – 500 mg/kg/day:  hypospadias (cleft penis), nipple retention, reduced anogenital 
distance (AGD), cryptorchidism, seminiferous tubule degeneration, testis interstitial cell 
proliferation, and malformed epididymis, seminal vesicle, vas deferens and ventral prostate 
[47].  The current study correlates testosterone inhibition at these exposures to target tissue 
levels of MBP and MBP-G   At exposures where effects are seen (100 and 500 mg/kg/day) 
peak fetal testes MBP concentrations were 72 and 152 μM.  Although method sensitivity 
prohibits the calculation of testes MBP AUCs using traditional noncompartmental analyses, 
they can be correlated to maternal plasma average daily MBP concentrations of 5, 11, and 60 
mg/L.   
This study provides the first description of DBP disposition after repeated dosing in 
gestation that directly correspond to exposures associated with reduced testosterone in the 
fetal rat, which has been repeatedly shown to cause delayed sexual development of the male 
rat both in our laboratory [34, 46, 47, 68, 80] and others [32, 33, 63].  Examination of the 50, 
100 and 500 mg/kg/day groups confirms the dose-dependent differences in plasma 
pharmacokinetics noted in previous acute studies [42].  A comparison of the pharmacokinetic 
and testosterone response in animals given single or multiple doses of 500 mg/kg DBP shows 
little difference between the two groups, though the statistically significant decreases in MBP 
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tissue concentrations at early time-points indicated that there may be some up-regulation of 
oxidative metabolism at repeated high doses.   This study further supports the direct 
correlation of fetal testosterone response to fetal metabolite levels.   
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Table 2.1. Calculated Pharmacokinetic Parameters for MBP and MBP-G in Maternal 
Plasma, Fetal Plasma, and Amniotic Fluid after Repeated Doses of 50, 100, and 500 
mg/kg/day from GD 12 to GD 19 calculated with WinNonlin®. 
 50 mg/kg/day 100 mg/kg/day 500 mg/kg/day   
 MBP MBP-G MBP MBP-G MBP MBP-G      
Maternal Plasma       
Tmax (hr) 0.75 1.0 1.0 1.0 2.0 4.0 
Cmax (mg/L) 169 27 502 80 959 131 
Cmax/D  
(μmol/L-mg/kg dosed) 0.94 0.15 1.39 0.22 0.53 0.07 
T1/2 (hr) 3.3 3.5 4.5 2.4 3.0 3.5 
AUCinf  
(μmol-hr/L) 591 107 1839 405 12271 2110 
AUCinf/D 
(μmol-hr/L-mg/kg dosed) 3.3 0.6 5.1 1.1 6.8 1.2 
MRTinf (h) 3.5 4.2 3.8 4.1 7.7 8.7 
Fetal Plasma       
Tmax (hr) 1.0 4.0 1.0 4.0 4.0 12.0 
Cmax (mg/L) 48 3 142 29 386 169 
Cmax/D  
(μmol/L-mg/kg dosed) 0.27 0.02 0.39 0.08 0.21 0.09 
T1/2 (hr) 5.2 8.2 5.9 3.7 4.8 5.5 
AUCinf  
(μmol-hr/L) 241 41 833 235 5082 2564 
AUCinf/D 
(μmol-hr/L-mg/kg dosed) 1.3 0.2 2.3 0.7 2.8 1.4 
MRTinf (h) 7.4 12.2 6.4 7.2 8.9 11.8 
Amniotic Fluid       
Tmax (hr) 4.0 8.0 4.0 8.0 4.0 12.0 
Cmax (mg/L) 9 1 38 13 810 321 
Cmax/D  
(μmol/L-mg/kg dosed) 0.05 0.01 0.10 0.04 0.45 0.18 
T1/2 (hr) 11.7 17.4 9.4 7.8 4.1 13.5 
AUCinf  
(μmol-hr/L) 151 37 581 210 9930 7943 
AUCinf/D 
(μmol-hr/L-mg/kg dosed) 0.8 0.2 1.6 0.6 5.5 4.4 
MRTinf (h) 18.2 27.3 14.4 14.6 9.3 22.7 
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Figure 2.1.  Concentration of MBP after the last dose of DBP administered  
from GD 12-19.   
Values represent mean + SE of four dams given (▼) 50, (O) 100, or (■) 500 mg/kg/day.  
Placenta, amniotic fluid and fetal plasma samples were pooled by litter before analysis. 
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 Figure 2.2.  Concentration of MBP-G after the last dose of DBP administered  
from GD 12-19.   
Values represent mean + SE of four dams given (▼) 50, (O) 100, or (■) 500 mg/kg/day.  
Placenta, amniotic fluid and fetal plasma samples were pooled by litter before analysis. 
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Figure 2.3.  MBP and MBP-G concentrations after single (GD 19) or repeated doses 
(GD 12-19) of 500 mg/kg DBP.  
Values represent mean + SE for four dams. *p < 0.05, two-tailed student’s t test.  Placenta, 
amniotic fluid and fetal plasma samples were pooled by litter before analysis. 
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Figure 2.4  MBP and testosterone in fetal testes from dams exposed to (A) 50, (B) 100, 
or (C) 500 mg DBP/kg/day from GD 12-19.   
Circles represent mean measured MBP concentration in the fetal testes.  White bars represent 
testosterone from control animals.  Grey bars represent testosterone from DBP treated 
animals expressed as percent control.  Values represent mean + SE for the fetal testes (pooled 
by litter) from 3-4 dams.  *p < 0.05, two-tailed student’s t test.  MBP concentrations are 
shown only for the (B) 100 and (C) 500 mg/kg/day dose groups.  Sample concentrations were 
below the LOQ for all time-points in the 50 mg/kg/day dose group. 
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Figure 2.5.  Testosterone recovery (A) 4 and (B) 24 hours after the last dose of DBP at 
50, 100, or 500 mg/kg/day from GD 12-19.   
For time-points where direct controls were not available, control testosterone values were 
estimated from linear interpolation between measured points.  Values represent mean + SE 
for the fetal testes (pooled by litter) from 3-4 dams. Statistical differences were calculated 
only for samples with comparable controls and are shown in Figure 4. 
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Figure 2.6.  MBP and testosterone in fetal testes from dams exposed to a single dose of 
500 mg DBP/kg/day on GD 19.  
Circles represent mean measured MBP concentration in the fetal testes.  Bars represent 
testosterone from control (white) and DBP treated (grey) animals expressed as percent 
control.  Values represent mean + SE for the fetal testes (pooled by litter) from 3-4 dams.  *p 
< 0.05, two-tailed student’s t test. 
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Figure 2.7.  Dose-response for testes testosterone in the GD 19 fetus after 
administration of 50, 100, or 500 mg DBP/kg/day to the pregnant dam.   
Circles and cross-bars represent the mean + SD of the percentage of control testosterone with 
respect to fetal plasma MBP.   
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Tissue exposures to free and glucuronidated monobutylyphthalate in the pregnant and 
fetal rat following exposure to di-n-butylphthalate: Evaluation with a PBPK model 
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A.  ABSTRACT 
 Human exposure to phthalic acid diesters occurs through a variety of pathways as a 
result of their widespread use in plastics.  Repeated doses of di-n-butyl phthalate (DBP) from 
GD 12-19 disrupt testosterone synthesis and male sexual development in the fetal rat.  To 
gain a better understanding of the relationship of the target tissue (testes) dose to observed 
developmental effects, the pharmacokinetics of monobutyl phthalate (MBP) and its 
glucuronide (MBP-G) were examined in pregnant and fetal rats following single and repeated 
administration of DBP from GD 12-19.   These data, together with results from previously 
published studies, were used to develop a physiologically based pharmacokinetic (PBPK) 
model for DBP and its metabolites in the male, pregnant and fetal rat.   The model structure 
accounts for the major metabolic (hydrolysis, glucuronidation, oxidative metabolism) and 
transport processes (enterohepatic recirculation, urinary and fecal excretion, placental 
transfer).  Extrapolation of the validated adult male rat model to gestation successfully 
predicts MBP and MBP-G levels in maternal plasma, placenta and urine, as well as the fetal 
plasma and testes.  Sensitivity analysis indicates that plasma MBP kinetics are particularly 
sensitive to glucuronidation and enterohepatic recirculation: a decrease in the UDPGT 
capacity during gestation results in an increased MBP residence time, and saturation of 
UDPGT  at the highest doses (> 100 mg/kg/day) causes a flattening out of the plasma time-
course data.  Oxidative metabolism plays a significant role in elimination only at low doses 
(<50 mg/kg DBP).  Insights gained from modeling of the rat data will be used to support 
development of a human PBPK model for DBP.   
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B.  INTRODUCTION 
 Phthalate esters are found in drinking water, food, personal care products and are 
used in the coating of some medications [1, 3, 64].  Although the relative source 
contributions have not been well characterized in the United States, a recent study in 
Europeans found that oral exposure through food sources accounted for 40-90% of the 
overall DBP exposure [3].  Metabolites of several phthalates have been found in the urine of 
the US population, including adults, children, infants, and pregnant women [4-6, 81, 82], 
with the highest levels in women of child-bearing age.  Some of these phthalates, including 
di-n-butylphthalate (DBP), are developmental toxicants in rats and mice [32-34, 65, 66, 68].  
Exposure of pregnant rats to DBP impairs development of male reproductive tissues, as 
evidenced by reduced anogenital distance, nipple retention, hypospadias, delayed testes 
descent, and vaginal pouch development in male pups [47, 83].  While the mechanism of 
action of DBP has not been fully elucidated, these anti-androgenic effects result, at least in 
part, from the ability of the monoester metabolite (MBP) to inhibit testosterone production in 
the fetal rat testes [33, 70-72]. Repeated doses of DBP have been shown to reduce 
testosterone levels in the blood of adult male rats [63, 70, 72, 84] in the testes of male fetuses 
from pregnant rats exposed to doses as low as 50 mg/kg/day from gestation day (GD) 12 – 19 
[46].    
 In the environment, phthalates exist primarily as their dialkyl esters [1].  After 
ingestion, they are rapidly hydrolyzed to the monoester and released into systemic circulation 
[9, 85].  Monobutyl phthalate (MBP) is the most prevalent metabolite of DBP in rat and is 
thought to be the principal biologically active species [11, 69].  MBP can be excreted 
unchanged in the urine, further metabolized via oxidation, or conjugated to glucuronic acid 
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by uridine 5'-diphospho-glucuronosyltransferase (UDPGT).  Oxidation of MBP occurs 
primarily through ω and ω-1 sidechain cleavage [74].  The resulting oxidative metabolites 
may be further oxidized (with a terminal product of phthalic acid), conjugated by UDPGT, or 
excreted in urine [74].  Glucuronidation appears to be a major route of clearance for MBP in 
the rat:  MBP-glucuronide (MBP-G) accounted for greater than 20% of the total urinary 
metabolites and approximately 17% of the administered dose in rats after 1 – 10 mg/kg DBP 
iv [49].  Both free MBP and MBP-G have been identified in the fetal rat plasma after 
maternal exposure to DBP [42, 43, 48], though the processes driving fetal MBP kinetics 
(placental transport, glucuronide conjugation) are not well-characterized.  While placental 
transfer of glucuronidated xenobiotics is typically inefficient [86-88], the presence of MBP-G 
in the rat fetus suggests that it may be important to understanding fetal MBP exposure. 
 The combination of multiple non-linear metabolic processes leads to rather complex 
behavior of DBP and its metabolites in vivo, making it difficult to predict a priori the 
pharmacokinetics of these chemicals at different doses.  Inherent changes in physiology and 
biochemistry during pregnancy further compound this issue.  Yet, in order to evaluate the 
risk associated with exposure to DBP, it is necessary to have a quantitative understanding of 
the dose-response of the active compound (MBP) at the target organ (fetal testis).  The 
purpose of this research was two-fold:  1) to gain a quantitative understanding of the 
relationship of fetal plasma and testes metabolite concentrations to external DBP doses, and 
2) to identify the biochemical processes that are the major determinants of metabolite 
kinetics.  In order to accomplish these goals, two in vivo studies were performed in which the 
distribution of MBP and MBP-G in the pregnant rat and fetus was measured after single or 
repeated doses of DBP.  These data were then used to inform the development of a 
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physiologically based pharmacokinetic (PBPK) model for DBP and its metabolites during 
gestation.   
The structure of the PBPK model was determined based on three primary 
considerations: 1) its intended use, 2) the available data, and 3) previous investigations into 
DBP kinetics using PBPK models.  The ultimate goal of our work was to develop a single 
model description that could be used with confidence to predict DBP, MBP, and MBP-G 
distribution and elimination in the pregnant and fetal rat under a variety of dosing scenarios, 
particularly those associated with observed developmental effects (repeated oral dosing).  
While a few studies were available in the literature with information on DBP disposition 
during gestation [42-44, 48], some significant data gaps still existed.  In particular, urinary, 
fecal, and biliary excretion and the potential differences in kinetics after multiple exposures 
had not been characterized in the pregnant rat.  Since more complete information on 
metabolite kinetics (including bile, urine and feces) was available in the adult male than the 
pregnant rat, the model was initially parameterized for the adult male and then extended to 
gestation using the published and newly obtained kinetic data.    
 A previous PBPK model for DBP was also available in the literature [89] and was 
used to inform the current model structure.  Keys et al. [89] evaluated the ability of four 
different models (flow-limited, diffusion-limited, pH-trapping, and enterohepatic 
recirculation) to recapitulate blood levels of MBP after iv and oral dosing.   The data 
available to Keys et al. [89] and the goal of their work required that the models be kept 
relatively simple in structure (few adjustable parameters), precluding any description of the 
MBP metabolism or characterization of excreted products.  In order to describe not only DBP 
and MBP, but also the glucuronide conjugate and oxidative metabolites of MBP in the 
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plasma, urine, feces and developing fetus, a more comprehensive model is needed.  By 
including all major metabolic (hydrolysis, oxidation, glucuronidation) and transport (biliary 
excretion, tissue partitioning, urinary and fecal excretion) processes, the current model 
provides both a means for investigating the processes driving kinetics and a platform for 
future use in risk assessment applications including extrapolation across doses, exposure 
routes and eventually species.   
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C.  METHODS 
Pharmacokinetic Studies In Vivo 
 Pregnant Sprague-Dawley (Crl:CD(SD)) rats (Charles River Laboratories, Raleigh, 
NC) were housed in a temperature- and humidity-controlled, HEPA-filtered environment on 
a 12 hr light-dark cycle. Rats were provided NIH rodent diet (NIH-07, Zeigler Bros., 
Gardner, PA) and reverse-osmosis water ad libitum.  Dosing solutions were prepared by 
mixing DBP and corn oil (Sigma-Aldrich, St. Louis, MO). DBP concentrations in the dosing 
solutions were verified to be 48 + 0.4, 89 ± 10, and 502 ± 9 mg/mL (mean ± SE) by gas 
chromatography with the method of Fennell et al. [42].  
 In the single dose study, GD 19 pregnant Sprague-Dawley rats (sperm positive on GD 
0) were administered a single oral dose of DBP (0 or 500 mg/kg) in corn oil (1.0 mL/kg).  
Rats were euthanized with CO2 at 0.5, 1, 2, and 24 hrs post-dosing.  In the repeated dose 
study, pregnant rats were given a daily dose of DBP (0, 50, 100 or 500 mg/kg) dissolved in 
corn oil (1.0 mL/kg) from GD 12 through 19.  At 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 24, and 48 hrs 
after the final dose, rats were euthanized by CO2.  Maternal blood was drawn by cardiac 
puncture.  Fetal blood was collected using heparinized capillary tubes and pooled by litter in 
glass centrifuge tubes. Plasma was separated from whole blood by centrifugation at 1900 x g 
at 4oC and stored at -80oC.  Placenta samples and amniotic fluid that was visibly clear of 
blood or other contaminants were pooled by litter.  Testes from each male fetus were stored 
separately.  All amniotic fluid and tissue samples were snap frozen in liquid nitrogen and 
stored at -80oC.  Tissues were prepared and analyzed for MBP and MBP-G as described in 
the Supplemental Materials (SM-1).   
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 Area under the curve (AUCt-inf), half-life (T1/2), and mean residence time (MRTt-inf) 
for MBP and MBP-G in the maternal and fetal plasma data from the repeated dosing study 
were calculated in WinNonlin (Pharsight, Mountain View, CA). Data were averaged by time 
point and dose group and modeled using a noncompartmental analysis with extravascular 
administration and no weighting.  The data from the single dose study did not contain a 
sufficient number of time-points to carry out a comparable analysis. 
 
PBPK Model Structure 
 Keys et al. [89] showed that a simple flow-limited model was sufficient for the 
description of DBP in the blood, while transport-limited tissue distribution and enterohepatic 
recirculation were important determinants of short-term MBP kinetics.  These insights were 
used to inform the initial model structure.  However, as the current model was intended to 
describe several aspects of DBP metabolite kinetics that were not addressed in the Keys 
model (MBP-G in plasma, fecal and urinary excretion products, and most importantly, fetal 
exposure), decisions regarding the current model structure were ultimately based on available 
disposition data.  Defining the structure of the model was an iterative process, wherein the 
behavior of the data was used to develop an initial model, which was then tested by 
simulating additional data sets. Failure to recapitulate data led to revisions of the mechanistic 
hypotheses and model restructuring.  For example, in the most preliminary version, only 
DBP, MBP and MBP-G were specified in the model. However, when simulations were 
performed for the data of Payan et al. [49], it was clear that urinary clearance and total 
plasma radioactivity could not be accurately described without including a description of the 
oxidative metabolites.  Thus, the model was extended to include a simple description of the 
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combined oxidative metabolites in the plasma and urine, which allowed the whole data set to 
be reproduced.   
 The final model (Figure 3.1) contains four inter-connected sub-models, each with the 
necessary amount of detail to adequately describe its chemical species: DBP, MBP, MBP-G, 
and the combined oxidative metabolites (MBP-O). The individual sub-models interact at sites 
of metabolism (hydrolysis of the diester, glucuronidation, hydrolysis of the glucuronide, and 
oxidation).  The models for each chemical species in the adult rat are described below, 
followed by the modifications made to describe gestation.  PBPK model simulations were 
performed using ACSL 11.0 (Advanced Continuous Simulation Language, AEgis 
Technologies Group, Inc., Huntsville, AL).  Examples of model equations are shown in the 
Supplemental Materials (SM-2). 
 
Adult Male Rat Model 
Intact DBP   
 Enzymes responsible for the hydrolysis of DBP are present in the intestinal mucosa, 
plasma and liver [11, 85].  Hydrolysis of DBP in the plasma (kbc) and liver (kc) is described 
as a first order rate as none of the tested doses were sufficient to overwhelm hydrolysis.  
Hydrolysis of the DBP in the upper GI (stomach + small intestine; GC1), on the other hand, 
is described as a saturable process based on the in vitro data of Rowland et al. [85] and the 
apparent saturation of oral uptake at the highest doses (~500 mg/kg) [78].  In vitro studies 
suggest that DBP is poorly absorbed in the gut, though a small amount may enter circulation 
intact, particularly at doses where hydrolysis is overwhelmed [9].  Unabsorbed DBP may 
also be passed in to the lower intestine (GC2) and cleared in the feces.  Oral absorption is 
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described as a first order process (kad).  Transport between the upper intestine (G1) and 
lower intestine (G2) compartments (kgic) is a first order rate.  Fecal excretion (kfc) is 
described using a clearance rate (L/hr).  DBP that is taken up into the gut wall is passed to the 
liver via the portal blood where it is hydrolyzed, released into systemic circulation with the 
plasma or excreted into the bile [11].  Biliary transfer of DBP into the duodenum is modeled 
as a clearance rate (kbdc) from the liver to the upper intestine (GC1).  Efficient hydrolysis 
ensures that essentially 100% of the DBP is de-esterified before it can be taken up into the 
bile.  However, competition between these processes (particularly after saturation of 
intestinal lipases at > 500 mg/kg doses) is included in the model in order to describe the wide 
range of published data.   Transport of DBP into the tissues is assumed to be flow limited. 
 
Free MBP 
 Oral absorption is described as a first order process (kam).  Movement through the GI 
and fecal excretion are clearance rates.  Unlike DBP, MBP is readily absorbed in the gut wall 
and passed to liver via the portal blood.  Glucuronidation and oxidation of free MBP in the 
liver are described using saturable kinetics.  Free MBP may also be excreted into the bile or 
released into systemic circulation.  Transfer of MBP in the bile is described in the same 
manner as DBP, using a clearance rate (kbmc) from the liver to the upper intestine (GC1).  
The MBP may then be reabsorbed or transported (kgic) into the lower intestine (GC2).  
Absorption may occur in both the upper and lower intestine compartments.  Free MBP that is 
not absorbed in the intestine is cleared via the feces (kfc).  Transport of MBP into the tissues 
from the plasma is modeled using diffusion-limitation.  Secretion of free MBP into the urine 
is a saturable process, based on non-linear behavior of excretion data at low doses [49].   
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 MBP-glucuronide   
 MBP-G formed in the liver (VmaxLc, KmL) may be excreted into the bile or released 
into systemic circulation.  Biliary transfer of MBP-G is modeled as described for free MBP 
above.  MBP-G then travels through the intestine (kgic) and is either hydrolyzed to MBP via 
β-glucuronidase (khydrc) in the lower intestine (GC2) or passed in the feces using first order 
clearance rates.  In the model, the hydrolysis of MBP-G is the rate limiting step for 
reabsorption of conjugated MBP from the bile.  Distribution of MBP-G into the tissues is 
modeled using flow-limitation, assuming distribution with body water. Urinary excretion of 
MBP-G is modeled as a first order clearance rate from the plasma compartment.    
 
Oxidative Metabolites of MBP.   
 MBP-O formed by P450 metabolism (VmaxOc, KmO) in the liver is released into the 
body via the venous blood.  A one-compartment volume of distribution model is used to 
describe the combined oxidative metabolites.  Distribution is assumed to be the body water 
compartment.  Urinary excretion is modeled as a first order clearance rate from the central 
compartment. 
 
Modifications for Gestation 
  During gestation, both MBP and MBP-G are allowed to move freely between the 
arterial and placental plasma.  Transfer of MBP between the placental plasma and the fetal 
plasma is described as diffusion-limited [90].  Versions of the model were tested which did 
or did not allow MBP-G to cross the placenta (described below).  Based on the fit of the 
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model simulations to available data, the final model does not include placental transfer of 
MBP-G.  Based on fetal MBP kinetic data, as well as published data on UDPGT and β-
glucuronidase activities in fetal tissues [79, 91, 92], glucuronidation of MBP and hydrolysis 
of MBP-G are included in both dam and fetus. Transfer of MBP and MBP-G between the 
fetus and amniotic fluid are described as first-order processes.   Transfer between the fetal 
plasma and testes tissue is described using diffusion-limited transport. 
  
Parameterization in the Adult Male Rat PBPK Model 
Physiological Parameters   
 Physiological parameters were obtained from measured values in the literature (Table 
3.1).  Adult male rat, body weight, cardiac output, and fractional tissue volumes and blood 
flows were available from Brown et al. [93].  Fractional tissue volumes were scaled by BW 
and blood flows were scaled by BW0.75.   
 
Kinetic Parameters 
 Final values for the kinetic parameters are given in Table 3.2.  The majority of the 
data presented in this paper was obtained from Sprague-Dawley rats.  However two of the 
studies in the adult male rat were performed in Wistar-Furth rats [7, 78].  While some 
variability may exist for parameters between these strains, it was not possible to tease out 
differences in biochemical parameters between rat strains based on the limited data currently 
available.  Therefore kinetic parameters were kept the same for both strains and scaled 
allometrically as is typical for intra- and inter-species extrapolation [94].  PA, Vmax, and 
clearance constants were scaled by BW0.75.  With the exception of metabolism parameters, 
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fetal parameters were scaled in a similar manner to the maternal parameters; PA’s were 
scaled by vfet0.75 and then multiplied by the total number of fetuses (n=8) to obtain the value 
for the litter.  Metabolism parameters (glucuronide conjugation and hydrolysis; VmaxLf and 
khydrfc) were scaled by adjusting the adult value by the ratio of the fetal:adult liver weight, 
since the fetal liver weight is not linearly correlated with body weight.  The value for the total 
litter was then calculated by multiplying by the number of fetuses (n=8).  Whenever possible 
parameters were taken from published values or calculated from in vitro studies.  
Nonetheless, the lack of specific tissue and metabolism data required that many of the model 
parameters be fitted to in vivo kinetic data.  
 
Measured Parameters   
 Tissue:plasma partition coefficients were obtained from radiolabeled DBP studies 
[95], and as such, represent total phthalate rather than a specific compound.  However, since 
free MBP is expected to be the primary chemical form in the tissues, the total radioactivity 
should be a reasonable predictor of MBP partitioning.   Tissue:plasma ratios obtained from 
early time-points (4 hrs post-dosing) of radiolabeled studies were generally similar to the 
values obtained from vial equilibration studies performed by Keys et al. [89] (PMR = 1.3 v. 
1.2), with the exception of the partition coefficient for the slowly perfused tissue (muscle).  
Since their vial equilibration studies yielded questionable results for the muscle, Keys et al. 
[89] used their published values for MEHP as a surrogate for MBP partitioning in the slowly 
perfused tissue (PMS).  While muscle was not measured in Williams & Blanchfield [95], 
another study indicated that muscle:blood ratios were similar to the other richly perfused 
tissues 24 hrs post-dosing [11].  Both the in vitro value for MEHP and the value described 
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above for MBP in the richly perfused tissue at 4 hr post-dosing were tried as surrogates for 
the PMS by running the model against iv plasma data [78] and slowly perfused tissue data 
(not shown) [11].  The value for PMR (1.3) provided a better visual fit to the data and was 
therefore used in the model. 
 The affinity constant (Km) for hydrolysis in the gut was calculated from the data of 
Rowland et al. [85].   Rowland and coauthors spiked 1 mL aliquots of rat stomach contents 
with various concentrations of DBP and measured remaining DBP after 16 hrs.  The Km for 
hydrolyzing enzymes (KmG = 350 mg/L) in the intestine was calculated by fitting a one-
compartment model to the data in Berkeley Madonna (University of California, Berkeley, 
CA).  
 
Fitted and Calculated Parameters   
 For parameters that were not measured experimentally, the values were estimated by 
adjusting the parameters to obtain the best visual fit of the model to time-course data.  At this 
stage of model development and evaluation, a statistical program was not used to estimate 
model parameters, although such an exercise would be particularly useful in conjunction with 
further applications (e.g., extrapolation to the human). For the duration of this paper, fitting 
of parameters refers to the manual process of determining one set of parameters that could 
consistently recapitulate a large base of diverse data. In order to minimize uncertainty in 
parameters, a sequential approach was followed so that the most pertinent data sets were used 
for each parameter. This approach to model parameterization is illustrated in Figure 3.2 and 
is described below. 
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 Time-course data on plasma MBP levels after a single iv dose (8 mg/kg) of the 
monoester [78] were used to develop initial estimates of values for the parameters governing 
liver metabolism and diffusion-limitation in the richly and slowly perfused tissues (PARc and 
PASc).  First approximations of these parameters were based on this iv data set because it 
represented the simplest possible dosing scenario, and was therefore dependent upon the least 
number of adjustable parameters.  However, as this study measured only plasma MBP 
concentrations, additional data were needed to refine the parameters driving elimination and 
enterohepatic recirculation. 
 Payan et al. [49] provided a more comprehensive data set, which was ideal for 
estimating elimination and metabolism parameters.  Both iv and dermal exposure data were 
presented.  However, as the dermal data could not be used in the model without significant 
changes to the structure that were not pertinent to the current work, only the iv data were 
used.   The iv study included plasma DBP, MBP, MBP-G and total 14C levels after a single iv 
dose of either 1 or 10 mg/kg 14C-DBP to adult male rats.  Elimination of MBP, MBP-G and 
total 14C was measured over 72 hrs in the urine.  Bile cannulation or a sham operation 
(controls) was performed on a subset of rats dosed with 1 mg/kg 14C-DBP and the total 
amount of 14C excreted in the bile and/or feces and urine was measured at 30 hr.  Metabolism 
parameters (glucuronide conjugation, oxidation), and urinary clearance rates were adjusted to 
fit DBP, MBP, MBP-G and total 14C in the plasma and urine at the 1 mg/kg dose. Based on 
the increased water solubility of glucuronide conjugates, it was assumed for the sake of 
simplicity that MBP-G would be distributed with the water (VD = 0.65).  The partition 
coefficient for MBP-G in the tissue (PGT) was then calculated from the VD, blood volume 
(VB) and combined tissue volume (VT) to be 0.3 (PGT = (VD-VB)/VT).   Bile cannula 
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studies were simulated by turning off transfer of DBP, MBP and MBP-G from the liver to the 
upper intestine and biliary transport parameters (kbg, kbm, kbd) were fit to the bile excretion 
data.  The rates of MBP-G hydrolysis in the gut (Khydrc) and fecal excretion (kfgc, kfdc, 
kfmc) and movement in the gut (kgic) were then adjusted to reproduce fecal excretion and 
plasma data in sham-operated rats.  
 With the above parameters constrained, the first order rate of MBP oral absorption 
(kam) was determined.  Kam was fit to plasma MBP data obtained from adult male rats after 
a single oral bolus of 34 mg/kg MBP [78].  Absorption of unchanged DBP was then 
calculated based on in vitro data using everted gut preparations [9].  The measured rate for 
DBP absorption was 67-fold less than MBP.  Using this measured ratio and the previously 
determined value for MBP absorption (20 hr-1), a value of 0.3 hr-1 was calculated for kad.  
 
PBPK Model Validation in the Adult Male Rat 
 Validation of the model structure and the final parameters was performed using 
separate data sets from those used for parameterization [49, 78]. No parameters were 
changed to improve model fits to the “validation” data.   
 
Application of Adult Male Rat DBP PBPK Model to Gestation   
Physiological Parameters:  
 During gestation, mammary gland (VM) and fat (VF) tissue growth were described as 
a linear processes based on the data of [96-99], as described in Clewell et al. [99].  Placental 
volume (VPl) was described as the sum of the yolk sac and chorioallantoic placenta based on 
the model of O’Flaherty et al. [100].  Growth equations were available in the cited papers.  
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The total body weight of the dam was made equal to the initial body weight plus the change 
in volume of the uterus, fat, mammary gland, placenta, and fetus.  Fetal volume (Vfet) was 
described using the equations of O’Flaherty et al. [100].  Growth of fetal testes is 
proportional to the total body weight, accounting for approximately 0.1% of the total fetal 
volume from GD16 through the end of gestation [72, 101, 102].  Changes in amniotic fluid 
volume were described using a TABLE function in ACSL, with linear interpolation between 
data points [103, 104].   
 Maternal cardiac output was described as the sum of initial cardiac output [93] and 
the change in blood flow to the placenta, mammary and fat tissues, per the approach of 
O’Flaherty et al. [100].   Changes in the fractional cardiac output to the mammary gland, fat 
and yolk sac were assumed to be proportional to changes in tissue volumes, with the 
exception of the chorioallantoic placenta which increased more rapidly than the tissue 
volume.  Chemical transport within the fetus was modeled using diffusion, rather than blood-
flow limitation.  Thus, no assumptions were made as to proportional blood flows to fetal 
tissues. 
 
Kinetic Parameters 
 Two kinetic parameters were adjusted before using the model in the pregnant dam 
based on published in vitro studies: VmaxGc and VmaxLc.  VmaxGc, the maximum capacity 
for DBP hydrolysis in the intestine, was decreased based on in vitro metabolism studies.  
Rowland et al. [85] measured the disappearance of DBP in 1 mL aliquots of small intestine 
contents from adult male and female rats (33 – 40 days old).  Their studies showed a sex 
difference in the ability to hydrolyze DBP, with the females metabolizing only 60% as much 
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as the males.  This sex difference was accounted for in the model by reducing the unscaled 
value for VmaxGc (90 vs. 150 mg/hr/kg) for all simulations of female rats.  The parameter 
was then scaled by BW0.75 to account for differences in body weight. 
 VmaxLc, the maximum capacity for glucuronide conjugation in the liver, was also 
reduced in simulations of pregnant rats.  In vitro studies in livers of non-pregnant female and 
pregnant rats showed that UDPGT activity for a variety of substrates (steroidal and non-
steroidal) was decreased by approximately 50% during gestation (GD 19-20) [91, 105].  This 
difference in activity was included in the model by reducing the unscaled value of VmaxLc 
by 50% (150 vs. 300 mg/hr/kg) during gestation, which was scaled by BW0.75 to account for 
changes in body weight.  All other maternal parameters were scaled allometrically from the 
adult male rat.     
 Parameters describing transfer between the dam and fetus, and the fetus and amniotic 
fluid were fit to published placenta, fetal plasma, and amniotic fluid time-course data [42].  
Because no previous data were available for MBP concentrations in the placenta tissue or 
fetal testes, the partition coefficients (Pmpl, Pmft) for these tissues were fit to the data from 
the single dose data from the current studies (500 mg/kg).    
 Two possible explanations were considered for the presence of MBP-G in the fetus 
[42]: (1) MBP-G is not significantly transported in the placenta and fetal MBP-G must be 
formed in the fetus itself, or 2) maternally formed MBP-G is able to cross the placenta.  
Alternative versions of the model were developed and tested with the MBP-G time course 
data to determine which one described the data more accurately.  In the first version, 
glucuronide conjugation and hydrolysis of MBP-G was described in the central compartment 
of the fetus (plasma).  Fetal metabolism parameters were estimated from in vitro data 
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described below.  In the second version of the model, placental transfer of MBP-G was 
described in the same manner as free MBP, in addition to fetal UGT and β-glucuronidase 
activity.  The partition coefficient and permeability area cross product were adjusted to 
achieve the best visual fit to the fetal plasma MBP-G time course data.      
 During fetal development, rat UDPGTs are classified into two distinct classes based 
on the preferred substrates.  Steroidal UDPGTs are characterized by a low activity in the fetal 
liver, with a rapid increase to adult levels after birth.  Non-steroidal UDPGTs show a peak in 
activity on GD 19 at nearly adult levels, followed by a drop in activity at birth and a 
subsequent increase in adolescent rats [79, 92].  Although studies haven’t been performed 
specifically on glucuronidation of MBP in fetal livers, studies with a similar chemical, 
monoethylhexyl phthalate, showed that it is metabolized by steroidal UDPGTs [106].   
Therefore, the fetal UDPGT activity in the model was estimated from the ratio of measured 
fetal:adult UDPGT activities towards several steroidal substrates from measured in vitro 
values.  The in vitro activity averaged for the measured steroidal substrates was 0.6, 1.3, 2.5, 
11.8, and 11.4% of the adult male rat value per mg microsomal protein on GD 17, 18, 19, 20 
and 21 [79, 92].  These relative activities were used to calculate the value for maximum 
capacity of fetal UDPGT according to Equation 1.  The amount of microsomal protein in the 
liver of the Sprague-Dawley fetus (~7.3 mg/g liver) was obtained from Alcorn et al. [107], as 
it was not reported in the Lucier and McDaniel [92] or Wishart [79, 92] studies.  The final 
values for VmaxLf (0.05, 0.12, 0.6, 3.0, and 4.4 mg/hr) were coded into the model using a 
TABLE function, which employs linear interpolation to estimate parameter values between 
defined points.  Fetal β-glucuronidase activity (khydrfc) was found to be 20% of the adult 
value based on measured activities per mg microsomal protein in vitro for various substrates 
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[91, 108].  Khydrf was estimated from the adult male rat value in the same manner as 
VmaxLf.   
 VmaxLf = VmaxL x RAfL x MPC x LW x numfet    
where VmaxL is the maximum capacity for glucuronide in the adult male rat (after scaling 
for BW), RAfL is the in vitro relative activity expressed as the ratio of fetal to maternal 
activity per mg microsomal protein), MPC is the ratio of microsomal protein content of the 
fetal to maternal liver (mg/g liver), LW is the ratio of the fetal:maternal liver weight (g), and 
numfet is the number of fetuses per litter.  
 After setting the parameters, testing the model against the data of Fennell et al. [42] 
and deciding on a final model for the fetal MBP-G, the gestation model was then tested with 
additional data sets from single dose studies on different days of gestation and alternate dose 
routes:  current studies (GD 19, po); Saillenfait et al., 1998 (GD14, po) [43], and Kremer et 
al., 2005 (GD 19, iv) [48].  Saillenfait et al.  [43] treated GD 14 Sprague-Dawley rats with a 
single oral dose of 500 or 1500 mg/kg 14C-DBP in mineral oil.  Total radioactivity, 14C-
MBP and 14C-MBP-G were measured in the maternal plasma, placenta, amniotic fluid and 
whole fetus at 0.5, 1, 2, 4, 6, 8, 24, and 48 hrs post-dosing.  Total radioactivity in the 
maternal urine and feces was also measured at 24 and 48 hrs post-dosing.   Kremer et al. [48] 
performed a time-course study in GD 19 Sprague-Dawley rats after a single iv dose of 10, 30, 
or 50 mg/kg MBP.  Serial samples were collected from cannulated rats, and MBP and MBP-
G plasma concentrations were measured at 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 8 hrs post-
dosing.   
 
 68
Extrapolation of Acute DBP Gestation PBPK Model to Multiple Day Exposures 
 The ability to describe repeated dosing scenarios was tested by running the model 
against the repeated dosing data from the current studies without adjusting any of the model 
parameters determined from the single dose data.  The model was also tested with the data of 
Calafat et al. [44], who measured free MBP in the amniotic fluid of GD 18 Sprague-Dawley 
rats.  Dams received an oral dose of 0, 100, or 250 mg/kg DBP once daily from GD 12- 17.  
Amniotic fluid was pooled by litter and collected at the time of sacrifice (GD 18).  Urine 
catch samples were also collected on GD 17 (approximately 6 hrs post-dosing).  However, 
since the urine samples were presented as concentrations and volumes were not included, 
they could not be used straightforwardly in the model. 
 
Sensitivity Analysis of Model Parameters 
 A normalized sensitivity analysis was run on the gestation model to examine the 
relative influence of each of the parameters on model output.  The model was run to 
determine the change in the average plasma MBP concentrations (24 hr AUC: area under the 
curve) resulting from a 1% change in the value of each kinetic parameter.  In an effort to 
determine the effect of metabolic saturation on relative parameter importance, the sensitivity 
analysis was performed at two nominal doses of DBP, representing unsaturated and saturated 
states (10 and 500 mg-kg, respectively).  The following equation shows the calculation of the 
sensitivity coefficient. 
 Sensitivity Coefficient = ((A - B)/B)/((C - D)/D) 
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Where A is the plasma AUC with 1% increased parameter value, B is the plasma AUC at the 
starting parameter value, C is the parameter value after 1% increase and D is the original 
parameter value. 
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D.  RESULTS 
 In order to relate tissue concentration of DBP metabolites to observed effects during 
fetal development, the distribution of MBP and MBP-G in the pregnant rat and fetus were 
determined after a single dose of 500 mg/kg DBP and repeated doses of DBP at a low (50 
mg/kg), medium (100 mg/kg) and high (500 mg/kg) doses.  In addition to allowing direct 
comparison of external and tissue dose, these data also supported the development of a PBPK 
model that was used to evaluate the relative importance of transport and metabolic processes 
in the pharmacokinetic behavior of DBP across doses, providing a robust platform for future 
risk assessment applications.   
 
Pharmacokinetic Studies In Vivo 
 The repeated dosing study was designed to reproduce the experimental conditions of 
the published DBP effects studies in order to gain a better understanding of internal dose 
associated with observed effects.  In this case, maternal and fetal plasma, placenta and 
amniotic fluid MBP levels may be used as surrogates for fetal dose.  Concentration time-
course data collected in this present study appear in the Supplemental Materials (SM-3, 
Tables S1-S4).  Some key aspects of disposition of DBP and its metabolites were noted from 
the initial PK analysis of the data (SM-3, Table S5).   
 Dose-dependent differences in AUC/D, Cmax, T1/2, and MRT illustrate the non-linear 
behavior of MBP in the repeated dosing study (SM-3), leading to some preliminary 
hypotheses about dose-dependent kinetics.  For example, the fact that the apparent parameter 
differences in maternal plasma MBP do not take place at the same dose may suggest that 
more that more than one saturable process is driving MBP dose-response.  Differences (~2-
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fold) in Cmax/D, T1/2 and MRT between the 100 and 500 mg/kg/day groups, may be 
explained by saturation of DBP intestinal hydrolysis and prolonged absorption of MBP.  
AUC/D, on the other hand, increases from 2.6 to 4.8 between the 50 and 100 mg/kg/day 
groups, suggesting that a second saturable process (possibly clearance) may be involved.  
Nonetheless, the parameters are certainly affected by a combination of many factors and 
these simple PK models do not lend themselves to in-depth analysis of the processes driving 
dose-dependent kinetics.  PBPK models that incorporate the various biochemical pathways 
into their description are better suited to mechanistic investigations.  The model described in 
this paper was specifically designed for this purpose.  The PBPK model also allows 
comparison of studies with fewer data points (i.e., the single dose study, testes data), where 
classical PK analysis cannot be performed.  
 
PBPK Model Validation in the Adult Male Rat 
 The results of model development and parameterization in the adult male rate are 
provided in the Supplemental Materials (SM-4).  The final model differed significantly in 
structure from the previous model of Keys et al. [89], primarily as a result of the current need 
to describe additional metabolites in tissues and urine and to facilitate extension to gestation.  
Differences between the two models are summarized in the Supplemental Materials (SM-4; 
Table S6).  Before extending the model to gestation, the final model structure and parameter 
values were tested by simulating data in the male rat that were not used for parameterization.  
No parameters were altered to fit the validation data.  Plasma and urine metabolite kinetics 
were well-described by the model for iv doses of 10 mg/kg 14C-DBP (Figure 3.3).  Predicted 
fecal and urinary excretion were 9 and 89% of the total dose compared to the measured 
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values of 10.9 + 1.1 and 85.8 + 2.4 %, respectively [49].   The model also reproduced plasma 
MBP kinetics after a single iv dose of 20 mg/kg DBP or an oral dose of 50 or 200 mg/kg 
DBP [7] (Figure 3.4).   
 
Application of Adult Male Rat DBP PBPK Model to Gestation   
 The reduced value for VmaxLc based on in vitro data improved the fit of the model to 
maternal plasma simulations of the data of Fennell et al. [42] (Figure 3.5).   Increasing the 
value for khydrc would provide similar benefits to model fit.  However, literature suggests 
that β-glucuronidase activity is not increased in the maternal liver during gestation [109].  
Therefore, the value for khydrc was not changed in the gestation model.   The reduced 
capacity for diester hydrolysis in the female versus the male (90 vs. 150 mg/hr/kg) did not 
affect plasma appreciably at these dose levels (50 – 250 mg/kg DBP).  No additional 
parameters were changed to obtain the fits shown in Figure 3.6A.   
 Fetal plasma MBP data from this same study [42] were used to fit the permeability 
area cross product and partition coefficient for placental-fetal transfer of MBP (PAFetc, 
PMFet), and first order transfer rates between the fetal plasma and amniotic fluid (ktransm1c, 
ktransm2c) (Figure 3.6B-C).   
 Two descriptions of fetal MBP-G kinetics were tested with the model.  The first 
version assumed fetal MBP-G is formed and hydrolyzed in situ.  Using this description, 
together with the literature-derived parameters for glucuronide conjugation and hydrolysis, 
the model successfully described the slower appearance of MBP-G in the fetal plasma as 
compared to MBP (Figure 3.6B).   The second version of the model included the possibility 
of diffusion-limited transfer of MBP-G between the mother and fetus.  Addition of placental 
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transfer did not improve the fit of the model to the published data over that which assumes all 
MBP-G is formed in the fetus.  In fact, any attempt to include transfer to or from the fetus 
caused the model to over-predict MBP-G uptake or clearance in fetal plasma, respectively 
(not shown).  Thus, the placental transfer was not included in the final version of the model.  
This description is supported by the ability of the model to reproduce the non-linear behavior 
of fetal MBP-G across doses, as well as the changes in fetal MBP-G levels across different 
days of fetal development.  Nonetheless, additional studies (i.e., ex vivo placenta perfusion) 
are needed to definitively rule out placental transport of the glucuronide. 
 The utility of the gestation model for extrapolation across doses, routes and 
gestational age was tested against a combination of data from our laboratory and published 
studies: single oral DBP dose on GD 19 (current study; Figure 3.7) single oral DBP dose on 
GD14 (Figure 3.8), and single iv MBP dose on GD 19 (Figure 3.9).  Model simulations were 
consistent with single dose kinetics in the maternal and fetal plasma, and placenta across 
dose routes (iv vs. po) and dose levels (10 mg/kg MBP – 500 mg/kg DBP) without changing 
any of the previously determined parameters.  The success in simulating the trend of the data 
from GD 14 to 20 supports the approach used to estimate parameters that are changing 
throughout gestation.   In particular, maternal glucuronide levels in gestation (reduced versus 
predictions in male rat) and the increase in fetal glucuronidation capacity with gestational age 
are reproduced using the Vmax values calculated from the in vitro activity measured for 
steroidal substrates.    
 The model adequately captures the kinetic behavior of MBP and MBP-G in the 
amniotic fluid at the lower doses (50 – 250 mg/kg) 19 – 20.  However, they were not as 
concordant for GD 14 (not shown).  The data of Saillenfait et al. [43] suggested that 
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clearance of both MBP and MBP-G is much faster in the GD 14 fetus.   It was not possible to 
fit that particular data set without making large changes (>10-fold) in the fetal/amniotic fluid 
transport parameters.  Without additional support for a time-dependent difference in amniotic 
fluid transfer, this change was not made to the model.  In contrast, amniotic fluid MBP and 
MBP-G levels from the current single dose studies indicated reduced clearance at the 500 
mg/kg dose on GD 19 (Figure 3.7C).   The model is able to predict amniotic fluid after doses 
of 50 – 250 mg/kg DBP, but under-predicts amniotic fluid levels at 500 mg/kg.  The reason 
for this non-linear relationship between the fetal plasma and amniotic fluid is not currently 
known. 
 Fetal testes parameters were fitted to the data from the current single dose study 
(Figure 3.7D), as no previous data were available for this tissue.  Both MBP and MBP-G 
appear to be distributed with body water.  Partition coefficients were 0.3 and permeability 
area cross products were 1 L/hr/kg, suggesting rapid equilibration with the plasma.   
 Model predictions for 24 hr urinary (77% of dose) and fecal (15% of dose) excretion 
in the GD 20 rat were similar to the measured values in the naïve female rat (77 + 8  and 7 + 
3.5% of dose, respectively) after a 100 mg/kg oral DBP dose [42].   Model predicted 
excretion did not differ between the non-pregnant and GD 20 rat.   
 
Extrapolation of Acute DBP Gestation PBPK Model to Multiple Day Exposures 
 In general, the model was able to predict maternal and fetal plasma and placenta 
kinetic behavior at the 50, 100, and 500 mg/kg/day doses from the current repeated dose 
studies (Figures 3.10-3.11) without changing any kinetic parameters.   While the model falls 
outside of the standard deviations for some time points, it consistently captures the kinetic 
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behavior of MBP and MBP-G, including the slowed uptake and clearance of MBP at high 
doses (Figure 3.10A) and the apparent accumulation of MBP-G in the fetal plasma and 
amniotic fluid over time (Figure 3.11). The majority of the fetal testes samples had MBP and 
MBP-G concentrations that were below the method limit of quantitation, with the exception 
of the 0.5 - 2 hr time points in the 100 mg/kg/day group and the 0.5 - 12 hr time points in the 
500 mg/kg/day groups.  Model simulations based on flow-limited transfer of MBP and MBP-
G between the fetal plasma and testes are shown versus the data in Figure 3.11B.  The lack of 
analytical sensitivity precludes testing of the model at lower doses.  However, the ability to 
predict uptake and peak concentrations within a factor of two from the mean at 100 and 500 
mg/kg/day, suggests that fetal testes concentrations are linearly correlated with fetal plasma 
levels.  Additionally, the ability of the flow-limited model to describe single and repeated 
dose data (Figures 3.7B and 3.11B) suggests that MBP does not accumulate in the fetal testes 
over time.  In fact, the testes concentrations are consistently lower than fetal plasma levels 
(Pmft = 0.3), which are linearly correlated with maternal plasma MBP concentrations. 
 The repeated dosing data clearly exhibits dose-dependent kinetics (Figures 3.10-3.11; 
Table S5).  This behavior was seen consistently across data sets [43, 78].  The model 
successfully simulated the dose-response trend in the plasma, indicating that the model 
structure has components consistent with the biological determinants of metabolite kinetics.  
Visual examination of the model fit with varying parameter values showed that saturation of 
glucuronidation in the maternal liver is primarily responsible for the reduced clearance at 
DBP doses > 500 mg/kg.  Intestinal DBP hydrolysis is also saturated at the high dose, 
leading to slower absorption and a prolonged period of uptake, evidenced by the increased 
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Tmax.  Reduced absorption also leads to increased pre-systemic loss through fecal excretion 
in the model, which has a negative effect on plasma AUC.   
 The model prediction of both MBP and MBP-G is within a factor of two of most of 
the measured amniotic fluid concentrations at the 50 and 100 mg/kg/day doses (Figure 
3.11C).  However, as was noted in the single dose simulations, amniotic fluid concentrations 
are severely under-predicted by the model at the 500 mg/kg/day dose.  Measured MBP and 
MBP-G in the amniotic fluid of the 500 mg/kg/day dose group are approximately 5 times 
higher than would be expected based on the lower dose groups assuming a linear dose-
response.  It is possible that a dose-dependent biokinetic difference (saturable 
transport/hydrolysis within the amniotic fluid, transporter mediated uptake in the fetus, etc.) 
could be responsible for this observed behavior.  Additional studies are needed to better 
define the mechanisms of chemical transport between fetus and amniotic fluid in order to 
better understand observed kinetics across doses.  
 The data of Calafat et al. [44] were simulated (not shown here) by providing a daily 
maternal oral dose of 100 or 250 mg/kg DBP from GD 12 – 17.  The simulation was allowed 
to run to the reported day of sacrifice (GD 18).  The model-predicted amniotic fluid MBP 
concentrations (1.6 and 6.5 mg/L) were within the range of the measured values for both the 
100 (0.3 – 2.4 mg/L) and the 250 mg/kg/day (3.8 – 22.3 mg/L) dose groups.  
 
Sensitivity Analysis   
 Sensitivity analysis performed at 10 and 500 mg/kg DBP revealed a dose-dependent 
difference in model sensitivity to some of the chemical specific parameters (Figure 3.12).  At 
10 mg/kg, the plasma MBP concentrations are more sensitive to parameters governing 
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oxidative metabolism (KmO, VmaxOc) of MBP.  At the higher dose (500 mg/kg), where 
oxidative metabolism is saturated, the model predictions of plasma MBP levels are more 
sensitive to parameters describing elimination and recirculation of the glucuronide conjugate.  
Oral absorption also becomes important at 500 mg/kg/day; VmaxGc and kad are positively 
correlated to plasma levels and kgic is negatively correlated.  This suggests that upon 
saturation of hydrolysis (VmaxGc), inefficient absorption of the diester and clearance via 
fecal excretion increases presystemic loss, and reduces maternal exposure.  As expected, fetal 
plasma MBP levels are influenced by the same parameters governing maternal plasma 
concentrations.  Pmfet, the parameter governing partitioning between maternal and fetal 
plasma, had the largest effect on fetal AUC, with a sensitivity coefficient of 0.9.  The AUC 
for MBP in the fetal testes showed the same dependence on maternal parameters as 
illustrated in Figure 3.12, in addition to Pmfet and the testes:plasma partition coefficient 
(Pmft).  Maternal plasma levels are not affected by changes in Pmfet or Pmft.   
 
Using the Multiple Exposure Model to Interpret Effects Data 
 Several studies have shown that exposure to DBP during the period of sexual 
development in the fetal rat may lead to delayed development of the male reproductive tract.  
Dose response examinations showed several overt effects in the male offspring from dams 
exposed to >500 mg/kg/day from GD 12-21, including hypospadias (cleft penis), nipple 
retention, reduced anogenital distance (AGD), cryptorchidism, seminiferous tubule 
degeneration, testis interstitial cell proliferation, and malformed epididymis, seminal vesicle, 
vas deferens and ventral prostate [47].  Of these effects, only nipple retention and reduced 
AGD have been found lower doses (100 and 250 mg/kg/day, respectively).  Delayed 
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preputial separation has been noted in some studies at doses > 100 mg/kg/day, but not in 
others at doses up to 500 mg/kg/day [34, 47].  All of these adverse effects occur in concert 
with decreased testes testosterone concentration, which may provide a more sensitive marker 
for disruption of androgen-dependent development [33, 46, 83].   
 Although these effects have been well-studied with regard to external DBP dose, 
there is currently no information on the internal (fetal) dose expected from these exposures.  
In order to illustrate how this PBPK model may be used to relate external DBP to internal 
MBP dose in multiple day studies, the model was run with the repeated exposure parameters 
at 16 different dose levels, ranging from 1 to 550 mg/kg/day.  The AUC for the last day of 
dosing was then used to calculate the average concentration in the maternal and fetal plasma, 
and fetal testes (daily AUC/24 hrs).  The predicted dose response is illustrated in Figure 3.13, 
together with reported lowest observed adverse effect levels (LOAELs) for several 
landmarks of male sexual development.  Model predictions suggest that the average daily 
MBP concentration in the fetal rat testes must reach levels of approximately 1, 2 and 18 
mg/L in order to cause noticeable changes in testosterone production, nipple retention or 
more overt effects (i.e., reduced AGD), respectively.  Using the model, these testes 
concentrations may also be correlated to fetal and maternal plasma, which are often used as 
surrogates for fetal dose in the human.  Maternal plasma MBP concentrations associated with 
reduced testosterone, nipple retention and reproductive tract malformations in the rat fetus 
are 5, 11, and 60 mg/L.   
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E.  DISCUSSION 
 Few data are available in which controlled doses of phthalates have been 
administered to human subjects [110].  In order to interpret such data and develop realistic 
estimates of fetus and/or fetal testes exposure, models such as the one provided here must be 
able to relate external dose to plasma, tissue and urine kinetics.  PBPK models use animal 
and in vitro data to build a platform that can be used to predict human kinetics by accounting 
for differences in physiology and, where necessary, biochemistry (i.e., enzyme activities).  In 
order to maximize the utility of this model in future applications to humans, this model 
included descriptions of MBP, MBP-G, and oxidative metabolites in the plasma and tissues 
of interest as well as the urine, feces and bile.   Detailed radiolabeled studies allowed 
parameterization to be performed against specific data. The resulting model described 
metabolite distribution and excretion in adult male rats over doses spanning more than three 
orders of magnitude (1 mg/kg to > 500 mg/kg), regardless of the form of the chemical used 
(MBP, DBP) or the route of exposure (iv, po).    
 Successful extrapolation of the male rat model to describe kinetics in the pregnant rat 
suggests that - with the exception of glucuronidation and intestinal hydrolysis - the metabolic 
and chemical transport processes do not change significantly as a result of pregnancy.  
Reduced hydrolysis of the diester in the intestine of the female rat had little effect on 
maternal kinetics other than the initial uptake at the highest dose (500 mg/kg).  The reduced 
capacity for glucuronide conjugation does affect plasma kinetics, causing a notable increase 
in free MBP residence time in both maternal and fetal plasma.  This dose-dependent behavior 
could have important implications for perinatal toxicity.  As glucuronidation plays a major 
role in the elimination of many xenobiotics, a decrease in capacity during gestation could 
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result in increased fetal exposure to a variety of chemicals.  This finding emphasizes that 
understanding the determinants of chemical kinetics in the adult male will not be sufficient 
for assessing exposure to the pregnant female or fetus.  
 The comprehensive nature of this model allows a thorough investigation into the 
transport and metabolic processes that are responsible for the overall observed kinetics.  
Because all of the major metabolic (hydrolysis, oxidation, glucuronidation) and transport 
(biliary excretion, tissue partitioning, urinary and fecal excretion) processes are included in 
the model, it is possible to examine the effect of these individual processes on chemical 
behavior.  This was accomplished both through a quantitative sensitivity analysis and 
through manual manipulation of model parameters coupled with observation of the effect on 
fits to the data.  Model analysis indicates that saturation of diester hydrolysis is responsible 
for the prolonged absorption observed at doses > 100 mg/kg, and reduced phthalate exposure 
due to the poor absorption and subsequent presystemic loss of DBP.  In fact, saturation of 
diester hydrolysis may mitigate the effect of reduced clearance on the plasma AUC to some 
extent.  Saturation of glucuronidation appears to be responsible for reduced clearance of 
MBP the higher doses (100 -500 mg DBP/kg/day).  This conclusion is particularly interesting 
in light of the available toxicity data, as many of the more serious developmental effects have 
been seen only at doses at or above 500 mg/kg.  Reduced anogenital distance, for example, 
which is a source of concern due to its indication of impaired sexual development in both the 
rat and human [67] is only seen at doses >250 mg/kg/day.  This effect may in fact be a result 
of reduced clearance of MBP due to saturation of glucuronidation.  Saturation of the 
oxidation pathway and renal uptake of MBP occur at much lower doses than saturation of 
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glucuronide conjugation (< 50 mg/kg).  Thus, these pathways do not appear to be responsible 
for slowed clearance at high doses.   
 In the attempt to describe plasma kinetics at low doses (1 mg/kg DBP), it became 
clear that the oxidative metabolites are more important to overall kinetics than has previously 
been assumed based on high dose toxicity studies.  In fact, these metabolites are predicted to 
make up approximately 40% of the excreted metabolites at the 1 mg/kg dose.  The oxidative 
metabolites of monophthalates may still be active and could play a significant role in human 
toxicity, as they have been shown to constitute the largest fraction of the urinary metabolites 
after human exposure to DEHP, a phthalic acid diester with a similar toxicological profile to 
DBP [81].  While the current model attempts to account for these metabolites by including a 
generic compartment and urinary clearance of “other” metabolites, the description could only 
be tested by comparing MBP, MBP-G, and total radioactivity measurements simultaneously. 
The lack of data for validation of oxidative metabolites remains an important gap in the pool 
of information available for phthalate risk assessment efforts.  
 In addition to saturable metabolism and renal uptake, enterohepatic recirculation has a 
significant effect on the retention of MBP and MBP-G in the plasma.  Greater than 40% of a 
given dose is transferred into the bile, and nearly 90% of those bile metabolites are then 
reabsorbed in the intestine and re-released into circulation.  When re-uptake is absent in the 
model, clearance of both MBP and MBP-G from the plasma is increased and the free MBP 
and oxidative metabolites make up only a small fraction of urinary excretion.  Thus, 
extensive enterohepatic recirculation in the rat increases internal exposure to the active 
metabolite (free MBP).   
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 Insights provided by the model into the processes driving MBP kinetics 
(enterohepatic recirculation, glucuronidation) are not only helpful to understanding DBP 
dose-response, but may also help to improve accuracy of model extrapolation to other 
chemicals and other species through the design of targeted experiments.  The successful 
description of UDPGT-dependent MBP kinetics across life-stages based on in vitro data 
bodes well for further applications of this model.  A similar approach may be useful with 
other phthalates (i.e., DEHP) in rats and, more importantly, in other species.  In vitro 
metabolism studies require less time, money, and animals than traditional in vivo studies and 
are much more feasible in the human than in vivo dosing. 
 Inclusion of several possible biomarkers (plasma, urine, amniotic fluid MBP) in the 
model allows evaluation of their usefulness as fetal dose surrogates.  Failure of the model to 
describe amniotic fluid metabolites across doses suggests that more complex processes are 
involved in uptake and clearance of MBP and MBP-G in the amniotic fluid and fetus than 
simple passive diffusion.  In fact, the tendency to concentrate MBP-G speaks to potentially 
limited clearance.  A better understanding of amniotic transport and/or metabolism is needed 
before it could be used with confidence as a surrogate for fetal dose.  With the current model, 
however, it is possible to determine fetal MBP exposure from a variety of surrogates, 
including external dose, and maternal plasma and urine.  Thus, this model provides a means 
of estimating fetal dose from easily obtained biological samples.   
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F.  CONCLUSION 
 This paper illustrates the extension of a model for DBP in the adult male rat to 
describe gestation through the inclusion of maternal and fetal growth and a simple 
description of placental transport, made possible by newly generated data.  By incorporating 
important biochemical processes, it was possible to test how the changes in metabolism 
during pregnancy may affect fetal exposure.   The use of realistic, data-validated kinetic and 
physiological parameters also reduces uncertainty in use of the model to predict target tissue 
exposure across doses, routes, developmental stages and even species.  This validated model 
can now serve as a basis for extrapolation across species, life-stages, and exposure scenarios 
(acute v. repeated dosing) to provide quantitative measures of target tissue dosimetry in the 
population of interest. 
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G.  ADDITIONAL RESEARCH 
Extrapolation of the Published PBPK Model to Describe DEHP Kinetics 
Changes to the Model Structure 
The initial structure was taken from published models for di-n-butyl phthalate (DBP) 
in the non-pregnant, pregnant and fetal rat.  In applying this model to DEHP, very few 
changes had to be made to the original model structure.  In particular, a slightly more detailed 
kinetic description of the combined oxidative metabolism of the monoester was required to 
fit the metabolite excretion data for DEHP. The revised model structure used to describe 
disposition of DEHP in the pregnant and fetal rat is shown in Figure 3.14.   
 In the original DBP model, a one-compartment volume of distribution model was 
used to describe the combined oxidative metabolites.  This description was sufficient for 
DBP, due the fact that the majority of the dose exists as free MBP or MBP-G in the rat.  
However, in the case of DEHP, the metabolite profile is substantially different.  The majority 
of the dose (>90%) undergoes oxidation, free MEHP is only a minor metabolite, and the 
glucuronide conjugate does not exist at detectable levels.  The description of the oxidative 
metabolites was expanded to better describe these kinetic data.   
Oxidative metabolism is described in the liver using a saturable Michealis-Menten 
equation.  The oxidized monoesters are then excreted into the bile or released into systemic 
circulation.  Biliary metabolites are released into the upper intestine (GC1), where they may 
be reabsorbed (described as a first order rate) or passed in the feces (described as a first order 
clearance rate).  A three compartment model was used to describe the oxidative metabolites 
in the blood, liver and other tissues.  Distribution of MEHP-O into the tissues was modeled 
using flow-limitation, assuming distribution with body water. Urinary excretion was modeled 
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using first order clearance from the plasma compartment.   Because the oxidative metabolites 
play only a small role in DBP kinetics, these changes to the model structure had little effect 
on DBP model fits. 
 
DEHP Model Parameterization 
 The physiological parameters were not altered for the DEHP model.  However, it was 
necessary to adjust some of the chemical-specific parameters to fit the available kinetic data 
for DEHP.  In fact, when the DBP model was run “as is” against the MEHP iv and DEHP po 
data, the model over-predicted serum MEHP levels by an order of magnitude (not shown).  
Several observations can be made about the kinetic differences in the two phthalates based on 
available in vitro and in vivo data.  (1) DEHP is not hydrolyzed as efficiently as DBP in the 
gut [85], which leads to a greater loss of unmetabolized diester in the feces and measurable 
concentrations of the diester in the blood. (2) Both DEHP and MEHP are more poorly 
absorbed from the gut than DBP and MBP.  (3) The high lipophilicity of DEHP and the 
reduced hydrolysis in the blood (compared to DBP) results in reduced clearance of the diester 
from blood after iv dosing.  (4) Metabolism of the monoester is also quite different for the 
two phthalates.  A large portion of MBP is removed via glucuronidation; oxidation is 
important at low doses only [49]. In contrast, oxidation, not glucuronidation, is the dominant 
metabolic pathway for MEHP.  Oxidative metabolites make up >90% of the total urinary 
metabolites, while glucuronide conjugates of MEHP have not been detected  in the urine or 
plasma of rats after DEHP dosing [111].   
 Based on these observations, UGT activity (VmaxLc) was turned off in the DEHP 
model.  The Vmax for oxidative metabolism (VmaxOc = 28 mg/hr-kg BW) was adjusted by 
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visually fitting the model simulations to MEHP iv data in the adult male rat [53].  The rate of 
oral absorption of MEHP (kam = 0.4 hr-1) was adjusted based on the fit of the model to 
MEHP oral gavage studies [54]. The maximum capacity for hydrolysis in the gut (VmaxGc = 
80 mg/hr-kg BW), oral absorption of DEHP (kad = 0.015 hr-1), and intestinal clearance of 
DEHP (kgic1 = 0.1L /hr) and the other metabolites (kgic2 = 0.05 L/hr), and the urinary 
excretion rate of MEHP (VmxUc = 1 mg/hr-kg BW, KmU = 450 mg/L) were fit to DEHP oral 
gavage data (blood, feces, urine) in the non-pregnant female rat [45].  All other parameters 
were kept the same as DBP.  
Like DBP, only one kinetic parameter was adjusted before using the adult rat model 
for the pregnant dam: VmaxOc.  Because glucuronidation is set to zero in the DEHP model, it 
was not necessary to adjust that parameter for the reduced capacity for glucuronide 
conjugation during gestation [91, 105].  However, similar studies with hepatic microsomes 
obtained from  pregnant and non-pregnant rats showed approximately 40% reduction in the 
capacity of oxidative metabolism in the pregnant rat liver regardless of the substrate used 
[112].  Therefore, the  maximum capacity for oxidative metabolism of MEHP (VmaxOc) was 
reduced by 40% when applied to the pregnant rat.  All other maternal parameters were scaled 
allometrically from the adult male rat.  Since MEHP is not significantly glucuronidated and 
oxidative metabolism is negligible in the rat fetus, both VmaxGcf and VmaxOcf were set to 
zero.  Transfer of MEHP between the maternal and fetal blood, and between the fetal blood 
and amniotic fluid were assumed to be the same as MBP.   
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DEHP Model Validation 
 There is a much larger database of kinetic studies with DEHP than DBP in the adult 
male rat, primarily due to the fact that DEHP has long been investigated for its ability to 
induce liver tumors through peroxisome proliferation.   In order to test adequacy of the 
revised model structure for predictive use, the model was tested against several data sets 
from the literature.  Final model simulations are shown versus various data sets after iv and 
oral doses of MEHP or DEHP in the non-pregnant rat in Figures 3.15-3.17.   Like DBP, the 
DEHP oral dosing data displays non-linear kinetics, with reduced uptake of the 400 mg/kg 
dose.  
 The model is able to reproduce the oral dose data by incorporating saturable 
hydrolysis of the diester in the gut, and the lower absorption rate of the diester versus the 
monoester seen in vitro [9].  The model appears to under-predict clearance of MEHP from 
the blood after iv dosing of DEHP in early time points (Figure 3.17A), despite its ability to 
predict peak concentrations and later time-points.  It is likely that this rapid disappearance 
from the blood represents a fast redistribution of the diester into the tissues, followed by a 
slow release, which would account for the slow clearance at later time-points.  Including a 
description of DEHP binding in the tissues would improve the fit to the iv blood data.  
However, since there is no tissue data available with which to validate the assumption of 
binding or the chosen parameters, this additional complexity was not added to the model.  
Nonetheless, the model is able to reproduce both peak concentrations and the delayed 
clearance from the blood at later time points.  More importantly, the model adequately 
predicts the dose-dependent kinetics from oral dosing, which is the primary route of exposure 
in the human.    
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Studies of DEHP kinetics during gestation are less abundant than those in the male 
rat.  In fact, to date only one published study provides information on DEHP metabolites in 
the pregnant rat [45].  This study provides time-course information on DEHP and MEHP in 
the maternal blood, feces and urine.  Data were also collected for a single time-point (2 hr 
post-dosing) in the fetal blood, carcass and testes (J. Filser, personal communication).  The 
fetal data allows testing of the assumption that placental MEHP transfer would be similar to 
MBP.  Model predictions are shown with data from the pregnant and fetal rat in Figure 3.18.  
 
Comparing Internal Dose Associated with DEHP and DBP Disruption of Sexual 
Development in Rats 
 
Because there are significant differences in DEHP and DBP kinetics, external dose is 
clearly a poor indicator of relative potency among the phthalates.  The differences in 
metabolism and clearance can affect fetal dose in ways that cannot be accounted for with a 
qualitative approach.  With the use of quantitative biological models, however, it is possible 
to predict the levels of the active metabolites in the tissues of interest, enabling the 
determination of more relevant dose metrics than external dose.   
The DEHP and DBP models were run using the dosing scenarios that correspond to 
published inhibition data in order to predict fetal serum MEHP and MBP concentrations 
associated with testosterone reduction.  The external dose required to cause 50% inhibition 
(ED50) of fetal testosterone was estimated from published dose-response studies to be 35 and 
63 mg/kg/day for DBP and DEHP, respectively (Chapter 2) [46, 72, 113].  Based only on the 
administered dose, DBP appears to be more potent than DEHP with regard to testosterone 
inhibition.   
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These phthalate PBPK models were used to convert the ED50s to internal 
concentrations (IC50) by determining the area under the curve (AUC) for the monophthalates 
in the fetal blood (μmol-hr/kg BW) and dividing by time.  When the phthalate models were 
run at these doses for the amount of time used in the studies (4 – 7 days), the IC50s for MEHP 
and MBP were very similar, despite the difference in the external dose.  Calculated IC50 
values were 1.9 and 1.4 μM for MBP and MEHP, respectively, indicating that the active 
metabolites of DBP and DEHP have a similar potency for testosterone inhibition. 
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Table 3.1. Physiological Parameters 
Physiological Parameter  Source 
Tissue Volumes  
(%BW) 
Adult 
Male 
Gestation  
Body Weight  BW (kg) 0.280 0.280 - 0.361 [100] 
Slowly Perfused  VSc (%BWI) 60.4 57.4 – 52.7 [93] 
Richly Perfused  VRc  (%BWI) 4 2.9 – 2.4 [93] 
Fat  VFc  (%BW) 7 10.0 - 11.0 [93, 98] 
Liver  VLc  (%BWI) 3.4 3.4 [93] 
GI Tract  VGIc  (%BW) 3.6 3.60 [93] 
Upper GI Contents VGC1c (%BW) 3.9 3.9 [114] 
Lower GI Contents VGC2c (%BW) 3.2 3.2 [114] 
Mammary Gland VMc  (%BW) --- 1.0 - 5.5 [97] 
Plasma  VPlasc  (%BW) 4.7 4.7 [93, 115] 
 
Placenta  VPlc  (%BW) --- 0.0 -2.57 [100] 
Fetal Volume Vfet (kg) --- 0.0 – 0.0045 [100] (individual fetus) 
Volume of Distribution in Fetus 
VDc_f  (%Vfet) 
--- 0.65 [93] 
Fetal testes volume (%Vfet) --- 0.1 [72, 101, 102] 
Amniotic Fluid  VAFc  (mL/fetus) --- 0 – 0.56 [103, 104] 
Placenta  VPlc  (%BW) --- 0.0 -2.57 [100] 
Body VBc (%BW) 85-89 85-89 Sum of fat, rich, slow perfused + GI 
  
Blood Flows (%QC) 
  
  
Cardiac Output QCc (L/hr/kg) 14 14 [100, 116] 
Slowly Perfused  QSc  (%QC) 17.0 17 – 15.9 [93] 
Richly Perfused  QRc  (%QC) 56 55.8 – 53.5 [93] 
Fat  QFc  (%QC) 7 7 - 8.1 [93] 
Liver  QLc  (%QC) 4 4 [93] 
GI  QGc  (%QC) 16 16 [93] 
Mammary  QMc   (%QC) --- 0.2 - 1.2 [96] 
Placenta  QPlc  (%QC) --- 0.0 - 12.3 [100] 
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Table 3.2. Kinetic Parameters 
Parameter Value Source 
Partition Coefficients (unitless)     
DBP Liver:Plasma PL 21.8 [89]; personal communication 
DBP Body (Tissues):Plasma  PT 1.0 [89]Keys et al., 2000;  
MBP Gut Tissue:Plasma PMG 1.0 [95]Williams & Blanchfield, 1975 
MBP Liver:Plasma PML 1.3 [95]Williams & Blanchfield, 1975 
MBP Richly Perfused Tissues:Plasma PMR 1.3 same as liver 
MBP Slowly Perfused Tissues:Plasma PMS 1.2 [11, 95] 
MBP Maternal Placenta Tissue:Plasma PMPl 0.3 Fitted - Current Data 
MBP Fetus:Maternal Plasma PMFet  0.7 Fitted-[42] 
MBP Testes:Fetal Central Compartment PMFT  0.3 Fitted - Current Data 
MBP-G Liver:Plasma PGL 0.3 Vol of distribution = 0.65 
MBP-G Body Tissue:Plasma PGT 0.3 Vol of distribution = 0.65 
MBP-G Placenta Tissue:Plasma PGPl 0.3 Vol of distribution = 0.65 
MBP-G Fetus:Maternal Plasma PGFet  --- Fitted - [42] 
MBP-G Testess:Fetal Central Compartment PGFT  0.3 same as maternal tissue:plasma 
Max Capacity, Vmaxc (mg/hr/kg)     
Hydrolysis of DBP in GI Lumen VmaxGc  150 (♂), 90 (♀) Fitted (♂) - [78], (♀)- [9] 
Glucuronidation of MBP in Liver VmaxLc  300 (N); 150 (P) *Fitted (N)- [49] (P)-[92] 
Glucuronidation of MBP in Fetal Liver (/fetus) 
VmaxLFc  0 - 44 [79, 92] 
Oxidation of MBP in Maternal Liver VmaxOc  1 Fitted -[49] 
Uptake of MBP in Urine VmaxUc  5 Fitted - [49] 
Affinity Constants, Km (mg/L)     
Hydrolysis of DBP in GI Lumen KmG  350 [85] 
Glucuronidation of MBP in Liver KmL 300 Fitted - [49] 
Glucuronidation of MBP in Fetal Liver KmLF  300 Same as adult value 
Oxidation of MBP in Maternal Liver KmO  5 Fitted - [49] 
Uptake of MBP into Urine KmU 45 Fitted - [49] 
Permeability Area Cross Products,  (L/hr/kg)     
MBP Liver PALc 1 Fitted - [78] 
MBP Richly Perfused Tissue PARc 1 Fitted - [78] 
MBP Slowly Perfused Tissue PASc 0.15 Fitted - [78] 
MBP Fetus:Maternal Plasma (/fetus) PAFetc  0.05 Fitted –[42] 
MBP Testes:Fetal Central Compartment (/fetus) 
PAFTc 1 Fitted – Current Data 
MBP-G Maternal Tissues (/fetus)  (PAGSc, PAGLc, 
PAGPlc) 1 Fitted – [42] 
MBP-G Fetus:Maternal Plasma (/fetus) PAGFTc --- Fitted – [42]  
MBP-G Testes:Fetal Central Compartment (/fetus) 
PAGFTc 1 Fitted – Current Data 
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Metabolism Rates (/hr)     
Hydrolysis of DBP in Blood  kbc 16 Fitted -[49]  
Hydrolysis of DBP in Liver  kc 16 Fitted - [49] 
Fetal-Amniotic Fluid Transport (L/hr/kg/fetus)   
MBP Transfer from Fetus (Central Compartment) to 
Amniotic Fluid KtransM1c 0.005 Fitted – [42] 
MBP Transfer from Amniotic Fluid to Fetus (Central 
Compartment) KtransM2c 0.01 Fitted – [42] 
MBP-G Transfer from Fetus (Central Compartment) to 
Amniotic Fluid KtransGc 0.003 Fitted – [42] 
Hydrolysis of MBP-G in Amniotic Fluid KhydrAc 0.0025 Fitted – [42] 
Clearance Rates (L/hr/kg)     
MBP-G Urinary Excretion ClGc 0.35 Fitted - [49] 
MBP-O Urinary Excretion ClOc 0.1 Fitted - [49] 
DBP, MBP, MBP-G Fecal Excretion  kfc 0.012 Fitted - [49] 
Enterohepatic Recirculation     
Liver DBP Passed to Bile kbdc (L/hr/kg) 0.1 Fitted - [49] 
Liver MBP Passed to Bile kbmc (L/hr/kg) 0.1 Fitted - [49] 
Liver MBP-G Passed to Bile kbgc (L/hr/kg) 0.76 Fitted - [49] 
Movement in GI Contents kgic  (/hr) 0.01 Fitted – [49, 78] 
Hydrolysis of MBP-G in Maternal GI  khydrc  
(L/hr/kg) 0.3 Fitted - [9, 49] 
Hydrolysis of MBP-G in Fetus khydrfc (L/hr/kg) 0.13 [91, 108] 
Oral Uptake (/hr)     
DBP Absorption in Stomach and Intestine kad 0.75 
Calculated:  kam and White et al. 
[9] 
MBP Absorption in Stomach and Intestine kam 20 Fitted – [78] 
* N = Non-pregnant rat, P = Pregnant rat
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Figure 3.1.  Model structure for DBP kinetics in the pregnant rat.   
Adult male rat model is identical with the exception of the placenta/fetus compartments.  
Dashed arrows indicate first order processes and clearance rates.  Bold dashed arrows 
represent saturable processes.  Solid arrows represent blood flows to the tissue 
compartments.  The solid arrows represent flow-limited (DBP) and diffusion-limited (MBP, 
MBP-G) transport into the tissues.   
 
GI Wall
Liver
Placenta
Fetus
Liver
Body
Urine
Body
Amniotic 
Fluid
Placenta
Fetus
MBP-G MBPMBP-O
GC1
GI Wall
Liver
Plasma
Body
DBP
Feces
Feces
Testes Amniotic 
Fluid
Testes
Plasma
GC2
GC2
Feces
GC1
Plasma
Slowly Perfused
Richly Perfused
GC1 GC2
 
 94
Figure 3.2. Model Development and Validation for the Adult Male,  
Pregnant and Fetal Rat 
Fitted parameters:
Metabolism, elimination, enterohepatic recirculation
8 mg/kg MBP iv (NIEHS, 1994)
1 mg/kg DBP iv (Payan et al., 2001)
Oral absorption of MBP (kad)
34 mg/kg MBP po (NIEHS, 1994)
Intestinal hydrolysis of DBP (VmaxGc)
43, 857 mg/kg DBP po (NIEHS, 1994)
Oral absorption of DBP (kad)
Calculated from DBP:MBP ratio (White et al., 1980)
Measured parameters:
Partition coefficients, DBP hydrolysis
Keys et al., 2000; Rowland et al., 1977;
Tanaka et al., 1978; Williams & Blanchfield, 1975
Literature Search
Decision on Basic Model Structure
Validation of Model Predictions
10 mg/kg DBP iv (Payan et al., 2001)
20 mg/kg DBP iv (NIEHS, 1995)
50, 100, 200 mg/kg DBP po (NIEHS, 1995)
Add fetal/gestation physiology
O’Flaherty et al., 1997
Test Maternal Model Simulations
Fennell et al., 2004
Adjust glucuronidation, 
hydrolysis
Lucier et al., 1975
Rowland et al., 1977
Fitted fetal parameters:
placental transfer, amniotic fluid transfer
50, 100, 250 mg/kg DBP po GD20 (Fennell et al., 2004)
fetal testes (500 mg/kg DBP po; current data)
Calculated fetal parameters:
Glucuronidation, β-glucuronidase
Lucier & McDaniel, 1977
Validation of Gestation Model – Single Dose
10, 30 ,50 mg/kg MBP iv GD19 (Kremer  et al., 2005)
500 mg/kg DBP po GD14 (Saillenfait et al., 1998)
500 mg/kg DBP po GD19 (NIEHS, 1994)
In vivo studies – Single vs. Repeated Dosing in Gestation
500 mg/kg DBP GD19
50, 100, 500 mg/kg-day DBP GD 12-19
Validation of Gestation Model – Repeated Dose
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Figure 3.3.  Total radioactivity, DBP and metabolites in (A) plasma and (B) urine of the 
male rat after a 10 mg/kg iv dose of 14C-DBP.   
Lines represent model simulation, points represent mean measured values [49].  Figure 
illustrates total radioactivity (dashed line, □), unchanged DBP (thin solid line, ♦), MBP (bold 
line, ●), and MBP-G (dotted line, Δ).  For visual clarity, only the means of the data are 
shown. 
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Figure 3.4.  Free MBP in the blood of the adult male rat after exposure to DBP via (A) 
intravenous injection or (B) oral gavage.   
Lines indicate model predictions, points and cross-bars represent the mean + SD of the 
measured data (n=3) [7].  Where available, standard deviations of data are indicated by cross 
bars.  (A) Plasma MBP after 20 mg/kg DBP iv dose.  (B) Plasma MBP after a single oral 
gavage of 50 (dashed line) or 200 (solid line) mg/kg DBP. 
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Figure 3.5.  Maternal Plasma (A) free MBP and (B) MBP-G after a single 100mg/kg 
DBP oral dose on GD 20.   
Solid line indicates model prediction using lower value for VmaxLc based on in vitro UGT 
activity data from pregnant rats.  Dashed line illustrates model prediction using the same 
VmaxLc value as the male rat.  Circles and cross-bars represent the mean + SD of measured 
values [42]. 
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Figure 3.6.  MBP (left) and MBP-G (right) in (A) maternal plasma (B) fetal plasma, and 
(C) amniotic fluid after a single dose of 50, 100, or 250 mg/kg DBP on GD 20.   
Crossbars show the standard deviation of the measured data of Fennell et al. [42].  Lines 
indicate model predictions at 50 (small dashed), 100 (large dashed) and 250 (solid) mg/kg 
DBP. 
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Figure 3.7.  Free MBP and MBP-G in the (A) maternal and (B) fetal plasma (C) 
amniotic fluid, and (D) fetal testes after a single oral dose of 500 mg/kg DBP on GD19.  
Solid lines and circles represent free MBP. Dashed lines and triangles represent MBP-G.   
Cross bars represent the mean + SD from the current studies.  Fetal plasma and amniotic 
fluid were pooled by litter. 
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Figure 3.8.  Model predicted (A) MBP and (B) MBP-G in maternal blood, whole fetus, 
and placenta on GD 14.  
Data is shown for the mean MBP and MBP-G concentrations in maternal blood (x, solid 
line), whole fetus (□, dashed line), or placenta (●, dotted line) after a single oral dose of 500 
mg/kg 14C-DBP to the dam[43].  Only the mean values could be determined from the 
published graphs and are indicated by points.  Lines represent model predictions.   
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Figure 3.9.  Maternal plasma concentrations of (A) free MBP and (B) MBP-G after a 
single iv dose of MBP on GD 19.   
Solid lines indicate model predictions.  Mean MBP and MBP-G concentrations were 
measured after single iv dose of 10 (▲), 30 (●), or 50 (■) mg/kg MBP [48].  For visual 
clarity, only the means of the data are shown. 
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Figure 3.10.  MBP (left) and MBP-G (right) in (A) maternal plasma and (B) placenta 
tissue after the last daily dose of 50 (▲), 100 (o), or 500 (■) mg/kg-day administered 
from GD 12-19.    
Lines represent model predictions.  Cross bars represent the mean + SD from the current 
studies.  Placenta tissue was pooled for each dam. 
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Figure 3.11.  MBP (left) and MBP-G (right) in (A) fetal plasma and (B) fetal testes, and 
(C) amniotic fluid after the last dose of 50 (▲), 100 (o), or 500 (■) mg/kg-day 
administered from GD 12-19.   
Lines represent model simulations. Cross bars represent the mean + SD from the current 
studies.   Fetal plasma and amniotic fluid were taken from each fetus and pooled for the 
entire litter.  Fetal testes were pooled for all the males in a litter.   
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Figure 3.12.  Calculated sensitivity coefficient for model parameters with respect to 
maternal Plasma MBP AUC 24 hrs after a single oral dose of 10 (white bars) or 500 
mg/kg DBP (black bars) on GD 20.   
Only those parameters with absolute values greater than 0.1 are shown.  Coefficients for fetal 
parameters are not shown, with the exception of Pmfet (sensitivity coefficient = 0.9 in fetus), 
predicted fetal plasma levels show the same trends in parameter sensitivity coefficients as are 
seen in the dam.  
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Figure 3.13.  DBP dose response: Predicted average daily concentration of MBP in 
maternal and fetal plasma and fetal testes at external doses ranging from 1 to 550 mg 
DBP/kg-day from GD12.   
Lines represent the average MBP concentrations in the maternal plasma (solid), fetal plasma 
(dashed) and fetal testes (dash-dotted) predicted by the model across doses.  Points and drop 
bars represent the published LOAELs for the identified effects from the studies of Lehmann 
et al. [46] and Mylchreest et al. [34, 47, 68].    
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Figure 3.14. Revised PBPK model structure to describe both DEHP and DBP kinetics in 
the pregnant rat.  Adult male rat model is identical with the exception of the placenta/fetus 
compartments.  Dashed arrows indicate first order processes.  Bold dashed arrows represent 
saturable processes.  Solid arrows represent blood flows to the tissue compartments and are 
diffusion limited.  
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Figure 3.15.  Free MEHP in the blood of the adult male rat after an iv dose of 20 or 50 
mg/kg  MEHP.  Lines indicate model simulations.  Points represent measurements from 
individual animals administered (●) 20 mg/kg MEHP [117], (▼) 50 mg/kg MEHP [53], or 
(Δ) 50 mg/kg MEHP [45]. 
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Figure 3.16.  Free MEHP in the (A) blood of adult male rat after an oral dose of 70, 100, 
or 400 mg/kg MEHP or (B) excreta of adult mat rat after an oral dose of 70 mg/kg 
MEHP .  (A) Lines indicate model simulations.  Points represent measurements from 
individual animals administered (o) 70 mg/kg MEHP [118], (■) 100 mg/kg MEHP [53], or 
(●) 400 mg/kg MEHP [54]. (B) Bars represent model simulations (gray) or mean + SD of 
measured (black) MEHP in the urine and feces rats administered 70 mg/kg MEHP [118]. 
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Figure 3.17.  Free MEHP in the blood of adult rats after an (A) iv dose of 100 mg/kg 
DEHP, or (B) oral dose of 30, 300, or 500 mg/kg DEHP.  Line indicates model simulation.  
Points represent measurements from individual animals administered (A) 100 mg/kg DEHP 
iv [45] or (B) (o) 30 mg/kg, (Δ) 300 mg/kg, or (●) 500 mg/kg DEHP po [45]. 
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Figure 3.18.  Free MEHP in the (A) maternal blood or (B) placenta and fetal tissues 
after the last oral dose of 30 or 500 mg/kg/day administered from GD 14 - 19.  (A) Lines 
indicate model simulations.  Points represent measurements from individual animals 
administered (●) 30 mg/kg/day or (o) 500 mg/kg/day DEHP po [45]. (B) Bars represent 
model simulations (black) or mean + SD of measured concentrations (gray) in the placenta 
and fetal tissues 2 hrs after the last daily dose of 500 mg/kg/day (J. Filser, personal 
communication). 
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CHAPTER 4 
 
 
 
 
 
 
 
 
 
Phthalate Esters: Pharmacokinetic and Pharmacodynamic Factors Affecting 
Potency for Testosterone-Mediated Developmental Effects 
 
 
 
 
 
 
 
 
 
 
 
This chapter is expected to be submitted for publication in Toxicology In Vitro in May 2009.
A.  ABSTRACT 
 Human exposure to phthalates occurs as mixtures of diesters with varying activity 
towards testosterone-dependent development. Dibutyl (DBP), diethylhexyl (DEHP), and 
butylbenzyl (BBP) phthalate disrupt sexual development in the fetal rat.  Dimethyl (DMP) 
and diethyl (DEP) phthalate do not.  This difference in potency may result from 
pharmacokinetic (PK) or pharmacodynamic (PD) differences.   These five phthalates were 
administered to pregnant rats (500 mg/kg-d, GD12-19) and the fetal testes were analyzed for 
the corresponding monoester (MMP, MEP, MBP, MEHP, MBeP). Fetal testes MMP and 
MEP levels were 2 - 40-fold higher than MBP and MEHP. BBP exposure led to very low 
concentrations of MBeP, but similar MBP levels as seen with DBP dosing.  An in vitro assay 
in MA-10 cells was developed to determine the direct effect of monophthalates on Leydig 
cell function.  The MA-10 cell, a tumor line thought previously to have a functioning 
steroidogenic pathway that ended at progesterone, produced testosterone after stimulation 
with luteinizing hormone (LH).  LH stimulated testosterone production was inhibited by 
MEHP at concentrations as low as 1 μM.   When evaluated by RT-PCR, expression of genes 
associated with cholesterol transport and steroid synthesis at steps in the pathway both before 
and after progesterone were significantly decreased at MEHP concentrations of 100 μM.  
Five additional phthalates were tested with the in vitro assay.   MBP and mono-n-octyl 
phthalate showed similar inhibition to MEHP, while MMP, MEP and MBeP did not affect 
testosterone.  These studies indicate that phthalates activity in vivo is dependent upon 
pharmacodynamic, not kinetic, differences in phthalates of varying alkyl chain length.  
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B.  INTRODUCTION 
Exposure to phthalate esters occurs through drinking water, food, personal care 
products.  Some of these esters are also used as a coating for medications [64].  Metabolites 
of several phthalates are found in the urine of the US population at all age ranges from 
infants to adults, and in pregnant women [6].  Some phthalates, such as di-(2,4)-ethylhexyl 
phthalate (DEHP), di-n-buytl phthalate (DBP), and butylbenzyl phthalate (BBP) disrupt male 
sexual development in the rat.  Administration of DBP, DEHP, or BBP to pregnant rats 
causes reduced anogenital distance (AGD), nipple retention, hypospadias, delayed testes 
descent, and vaginal pouch development in the male offspring [33, 47].  Several other 
phthalate esters, however, including diethyl phthalate (DMP), dimethyl phthalate (DEP), and 
dioctyl terephthalate [33] do not affect sexual development of the male rat.  Neither DEP nor 
DMP caused down-regulation of steroidogenic genes or inhibition of testosterone production 
in the fetal rat testes.   
The monoester metabolites are the biologically active forms of the phthalate diesters.  
DBP and DEHP and their monoesters, MBP and MEHP, have been studied extensively in 
vivo in an effort to elucidate their mechanism of action.   While the molecular target(s) has 
not been identified, the monoester metabolites of the endocrine active phthalates have been 
shown to inhibit testosterone synthesis by direct interaction with the testes, reducing the 
steroidogenic response to luteinizing hormone (LH) stimulation [72, 119].   Inactive 
phthalates, such as DEP and DMP, do not reduce fetal testosterone.  It is not clear why some 
phthalates disrupt testosterone-dependent development and others do not.   The difference in 
potency may result from the length and extent of branching in the alkyl chains [33].  The 
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structural differences in the monoalkylesters could affect metabolite kinetics, as well as their 
ability to interfere with steroidogenesis.    
The purpose of this study was to determine whether differences in phthalate potency 
in vivo result from pharmacokinetic (PK) or pharmacodynamic (PD) factors.   Two studies 
were performed with representative endocrine active and inactive phthalates: 1) phthalate 
monoester concentrations were measured in the testes of male fetuses from exposed pregnant 
rats, and 2) an in vitro assay was developed and used to measure directly the effect of the 
various phthalates on Leydig cell steroidogenesis.  
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C.  METHODS 
Six different phthalates were chosen to represent compounds with different potencies 
for steroidogenic effects.  Two of the tested phthalates are known inhibitors of male rat 
sexual development: DEHP (MEHP), DBP (MBP).  Two of the tested phthalates do not 
disrupt reproductive tract development in vivo: DEP (MEP) and DMP (MMP).  Effects of 
butylbenzyl phthalate (BBP) exposure are similar to those of DEHP and DBP [33, 80].  
However, it is not known which metabolite is responsible for the anti-androgenic effects, as 
BBP may be metabolized to MBP or MBeP.  The in vivo activity of two of the phthalates: di-
n-octyl (DnOP) and dibenzyl phthalate (DBeP) has not been tested. 
 
Examination of Pharmacokinetic Differences among Phthalates 
Animals 
 Pregnant Sprague-Dawley (Crl:CD(SD)) rats (sperm plug positive GD 0) were 
obtained from Charles River Laboratories (Raleigh, NC) and housed in the Animal Care 
Facility of the The Hamner Institutes for Health Sciences, which is accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care International. Rats 
were acclimated in a temperature- and humidity-controlled, HEPA-filtered environment on a 
12 hr light-dark cycle.  NIH rodent diet (NIH-07, Zeigler Bros., Gardner, PA) and reverse-
osmosis water were provided ad libitum. This study was approved by The Hamner Institute’s 
Animal Care and Use Committee.  
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Treatment   
 Animal exposures, sacrifice and tissue collection has been described previously [80].  
Briefly, dosing solutions (500 mg/mL) were prepared by mixing DEHP, DBP, BBP, DEP or 
DMP and corn oil (Sigma-Aldrich, St. Louis, MO).   Pregnant rats were given corn oil (1.0 
mL/kg/day) or one of the phthalates (500 mg/kg/day) dissolved in corn oil (1.0 mL/kg) from 
GD 12 through 19.  The dams were euthanized by CO2 asphyxiation and exsanguination 2 
hrs after the final dose.  Fetuses were delivered by caesarean section and sex was determined 
by internal inspection of gonads.  Testes from each male fetus were collected, snap frozen in 
liquid nitrogen, and stored individually at -80oC.  Testes samples that were not used for gene 
expression data provided in Liu et al. [80] were generously provided to us for measurement 
of phthalate concentrations. 
 
Phthalate Analysis 
The monoester phthalates (MEHP, MBP, MBeP, MEP, and MMP) were extracted 
from testes prior to analysis using a previously described method for MBP (Chapter 2).  Each 
testes pair was homogenized in 1% PBS (500 µL) with a Mixer Mill 300 for 5 minutes at 30 
Hz/s.  The homogenate was transferred to a 2.0 mL microcentrifuge tube and 200 µL of 1% 
formic acid/water and 25 μl of [13C]-MBP (6 mg/mL) were added to the tube. The sample 
was vortexed for 5 seconds and then centrifuged at 1900 x g for 6 min at 4oC.  The 
supernatant was loaded onto an LC-18 SPE column (Honeywell Burdick and Jackson, 
Morristown, NJ) that had been pre-activated with a water solution of 2 mL of 0.1 formic 
acid,, added in two 1 mL increments.  After passing 2 mL of a 0.1% formic acid in water/0.1 
formic acid in methanol (75%/25%) in 1 mL increments, the monoester was eluted with a 
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methanol solution of 0.1% formic acid (2 mL) in 1 mL increments. The samples were 
evaporated to dryness under nitrogen and reconstituted in 200 µL of 0.1% formic acid in 
ACN/H2O (90%/10%) for analysis by LC-MS/MS, performed according to previously 
published methods [42]. 
 
Development of an In Vitro assay for Phthalate Inhibition of Steroidogenesis   
Cell Culture 
Mouse Leydig tumor (MA-10) cells were obtained from Dr. Mario Ascoli 
(Department of Pharmacology, University of Iowa, College of Medicine, Iowa City).  Stock 
cells were grown in 150 mm tissue-culture dishes as described by Ascoli et al. [120] in 
complete medium (Waymouth’s MB 752/1 supplemented with 15% horse serum, 2% L-
glutamine, 20 mM HEPES, and 50 μg/mL Gentamicin).  For all cell culture experiments, 
dishes were coated with a 0.1% solution of gelatin for 30 min before plating cells.  All 
incubations were performed at 37oC in a humidity-controlled atmosphere of 5% CO2-air.   
 
Progesterone and Testosterone Inhibition   
Cells were plated in 24-well plates at a density of 1 x 105 cells/well in 0.5 mL 
complete medium and allowed to incubate for 24 hrs.   The medium was then removed and 
replaced with serum-free medium (SFM) containing 0 (0.1% DMSO), 1, 3, 10, 30, 100, 300, 
1000 μM MEHP.  After 24 hrs, the medium was replaced with SFM containing the same 
inhibitor concentration supplemented with a maximum stimulating concentration of LH (100 
ng/mL).  The medium was collected after 6 hrs and stored at -20oC.  PG and testosterone in 
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the medium were measured using ELISA assays (Neogen Corporation, Lexington, KY) 
according to the manufacturer’s directions.  
 
Protein Content and Viability Analysis  
Cells were collected from each well and combined for each dose.  Each well was 
treated with 100 μL of lysis buffer (0.1 M Tris-HCl (pH= 8.0), 0.05 M EDTA, 0.1 M NaCl, 
1% sodium dodecyl sulfate, 1% sarcosyl) supplemented with HALT Protease Inhibitor 
Cocktail (10 μL/1 mL buffer) (Thermo Fisher Scientific Inc., Rockford, IL) and the cells 
were dislodged using a cell scraper.  The resulting lysate was homogenized and stored at -
80oC prior to analysis. Total protein content was measured using a bicinchoninic acid (BCA) 
assay (Sigma-Aldrich) according to the manufacturer’s directions.   Cell viability was also 
tested in triplicate using the ATPlite luminescence assay (Perkin Elmer, Boston, MA) 
according to manufacturer’s instructions. 
 
Quantitative RT-PCR  
MA-10 cells were plated at a density of 3x106 cells/well in 100 mm cell culture dishes 
(CellStar) in 20 mL complete medium.  24 hrs after plating, medium was replaced with 20 
mL SFM containing 0 (DMSO) or 100 μM MEHP.  Cells were incubated for 24 hrs and 
medium was replaced with SFM containing the same inhibitor concentration supplemented 
with PBS (no treatment control) or a maximum stimulating concentration of LH (100 
ng/mL).  After 6 hrs, medium was aspirated from the plate, cells were washed with 
Ca++/Mg++-free PBS and removed from the plate using a disposable cell scraper.  Total RNA 
was isolated from the cells of each cell culture dish using an RNeasy Mini Kit (Qiagen, 
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Valencia, CA). cDNA was prepared for each sample using the High Capacity cDNA kit 
(Applied Biosystems, Foster City, CA) according to the manufacturer’s protocol.  Reverse 
transcription (RT) reactions were performed on the Taqman 7900HT system (Applied 
Biosystems, Foster City, CA).  Taqman gene expression assays for mouse Cyp17A1, 
GAPDH, P450scc, SR-B1, and StAR were purchased from Applied Biosystems (Foster City, 
CA).  Samples were run in triplicate and the change in expression of target genes were 
normalized to GAPDH.   The fold change for each gene normalized to GAPDH and relative 
to expression in no treatment control (NTC) samples was determined by the 2-ΔΔCt method 
[121].   
 
Examination of Pharmacodynamic Differences among Phthalates 
The ability of five additional phthalates to inhibit testosterone synthesis in the MA-10 
cell was examined using the method described for MEHP above.  MBP (TCI America), MEP 
(Accustandard), and MNOP, MBeP, and MMP (Sigma-Aldrich) were dissolved separately in 
DMSO to obtain stock solutions (1 M) for each of the phthalates. Cells were pre-treated with 
0, 1, 3, 10, 30, or 100 μM of an individual phthalate for 24 hrs in SFM.  Cells were then 
stimulated with 100 ng/mL LH in the presence of the inhibitor (or DMSO) and medium was 
collected for hormone analysis.  Cell protein content was assayed for all tested compounds at 
each dose.  Cell viability assays were also run for each treatment in triplicate using the 
ATPlite luminescence assay (Perkin Elmer, Boston, MA).  
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D.  RESULTS 
Examination of Pharmacokinetic Differences among Phthalates.   
Despite the number of in vivo effect studies, little information is available regarding 
phthalate disposition during gestation.  In fact,  active metabolite (MBP) concentrations in 
the target tissue (fetal testes) have only been published for DBP (Chapter 2).  Thus, the first 
question in interpreting the effect studies is whether the fetus is exposed to the active 
metabolites.  Testes were collected from fetuses of dams exposed to 500 mg/kg/day DMP, 
DEP, BBP, DBP, or DEHP from gestation day (GD) 12- 19, and their free monoester 
metabolites, MMP, MEP, MBP or MBeP, MBP and MEHP, respectively, were measured 
using HPLC/MS-MS (Figure 4.1).   
All of the monoesters were found in the fetal testes after maternal exposure to the 
dialkyl esters.  MMP and MEP, the monoesters derived from the two “inactive” phthalates 
were present at the highest concentrations, with mean concentrations of 396 and 409 μM, 
respectively.  Mean testes concentrations of MBP (189 μM) indicate that it is also efficiently 
transported into the fetus.  MEHP, on the other hand, was present at much lower 
concentrations (12 μM) than MBP (189 μM), despite the fact that both DBP and DEHP are 
potent inhibitors of fetal development at this administered dose (500 mg/kg/day).  In rats 
exposed to BBP, MBP was the major metabolite found in the testes: the mean concentration 
(124 μM) was 5-fold greater than MBeP (21 μM).     
   
Validation of an in vitro assay for phthalate inhibition of steroidogenesis   
The PD effect of interest for the phthalates is delayed sexual development of the fetal 
rat [33, 80].  Inhibition of testosterone production in the Leydig cell of the fetal testes has 
 121
been shown to precede the more overt physiological effects, such as nipple retention and 
hypospadias [46, 72, 113] and may be a useful early marker of sexual development 
disruption.  To test whether the phthalates have different potencies for steroid inhibition, an 
assay was needed that allows direct exposure of the Leydig cell and a measurable biomarker.  
To this end, an assay in the murine Leydig tumor (MA-10) cell line was developed based on 
the method of Dees et al. [122], who reported inhibition of progesterone production after 
stimulation with human chorionic gonadotropin.   MA-10 cells are known to produce 
progesterone (PG; the testosterone precursor) in response to stimulation by luteinizing 
hormone.  The MA-10 cell has been widely used as a model for studying the steroidogenic 
pathway in the Leydig cell, measuring alterations in PG in a variety of conditions [55].  
 Based on previous reports that PG was the terminal point in MA-10 steroid synthesis, 
initial assay development focused on the ability of MEHP, a known inhibitor of steroid 
production, to inhibit LH-stimulated PG production.  Treatment of MA-10 cells was found to 
inhibit PG production at doses concentrations > 1 μM (Figure 4.2).  Cell viability assessed 
via intracellular ATP and total protein content were > 90% of control values at doses up to 
100 μM.  At 300 and 1000 μM, reduced viability ( < 90% of control) was observed.   
Gene array studies performed on whole testes samples obtained from the fetal rat 
after gestational phthalate exposure [46, 80, 123] revealed consistent down-regulation of 
genes associated with steroidogenesis in the Leydig cell, including genes that encode proteins 
at multiple points in the biosynthesis pathway for testosterone.  Some of the key genes 
identified in these studies include scavenger receptor class B family 1 (SR-B1), steroid acute 
regulatory protein (StAR), cytochrome P450 17a1 (Cyp17a1), and P450 side chain cleavage 
(P450scc) (Figure 4.3).  SR-B1 and StAR encode proteins responsible for the transport of 
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cholesterol into the cell and across the mitochondrial membrane, respectively.  P450scc is 
required for the conversion of cholesterol to pregnenolone, which is then metabolized by 
Cyp17a1 over several steps to form androstenedione, the immediate precursor to 
testosterone.   
Expression of SR-B1, StAR, Cyp17a1 and P450scc were evaluated in MA-10 cells by 
quantitative RT-PCR. All four genes were significantly up-regulated within 6 hrs of LH 
stimulation compared to controls (Figure 4.4A).  When pre-treated with 100 μM MEHP, 
Cyp17a1, P450scc, SR-B1 and StAR were decreased relative to LH stimulated cells (Figure 
4.4B).  
Cyp17a1 changes were particularly interesting due to the fact that the enzyme is 
responsible for metabolism of PG, indicating that the enzymes necessary for synthesis of the 
subsequent steroids, androstenedione and testosterone, are present in the MA-10 cell.  In 
response to these observations, medium from control and LH-stimulated MA-10 cells was 
analyzed for testosterone by ELISA assay.  The ELISA assay has less than 1% cross 
reactivity with the precursor steroids, including progesterone, pregnenolone, 17-
hydroxyprogesterone, and androstenedione.  The MA-10 cells were found to produce 
testosterone in response to LH-stimulation.  At 100 ng/mL LH, testosterone concentration in 
the medium was 0.27 + 0.3 ng/mL (vs. <0.01 ng/mL in no treatment controls).  When the 
cells were pre-treated with MEHP, testosterone production was reduced in a dose-dependent 
manner.  MEHP concentrations as low as 1 μM resulted statistically significant (p<0.05) 
testosterone inhibition (Figure 4.5) 
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Examination of pharmacodynamic differences among phthalates.   
MEHP induced inhibition of testosterone and steroidogenic gene expression in the 
MA-10 cell is consistent with in vivo phthalate effects, indicating that this assay may provide 
a reasonable model for the action of phthalate monoesters on Leydig cell function.  Because 
the in vitro assay eliminates PK differences inherent in in vivo studies, the MA-10 in vitro 
assay was used to compare the PD behavior of different phthalates (Figure 4.6).  The dose-
response curve for MBP, another endocrine active phthalate, was remarkably similar to that 
of MEHP, with significant inhibition at 3 μM.  In contrast, neither MMP nor MEP inhibited 
testosterone synthesis significantly at concentrations up to 100 μM.   
 
Predictive use of the MA-10 inhibition assay. 
A reliable in vitro assay for phthalate-induced inhibition of steroidogenesis would  
improve our ability to identify endocrine active phthalates while reducing the need for in life 
animal testing.  The proposed MA-10 assay was used to predict the anti-androgenic activity 
of mono-n-octyl phthalate (MnOP) and monobenzyl phthalate (MBeP), two esters with 
unknown activity in vivo (Figure 4.7). Neither DnOP nor MnOP have been tested in rat 
developmental studies and MBeP has only been tested in a mixture with MBP (BBP 
administration). MnOP treatment of MA-10 cells caused similar inhibition of testosterone to 
MEHP and MBP.  MBeP, on the other hand, did not show appreciable inhibition of 
testosterone at any of the measured concentrations (< 100 μΜ). 
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E.  DISCUSSION 
Comparative in vivo studies in pregnant rats have identified several phthalates, 
including DBP, DEHP, and BBP, that induce developmental responses in male offspring.  
These active phthalates have similar effects on male reproductive tract development, 
testosterone production and gene expression in the fetal testes.  Other phthalates, however, 
including DMP and DEP do not have the same effects in vivo.  The data presented here for 
monoester phthalate concentrations in the fetal testes demonstrates for the first time that 
these differences in phthalate potency are not a result of varying kinetic properties (i.e., lack 
of fetal exposure).  MEP and MMP are efficiently transferred to the fetus.  Thus, their 
inability to disrupt sexual development indicates that MMP and MEP do not share the same 
mode of action as the endocrine active phthalates (i.e., MBP).   
Use of an in vitro Leydig cell assay allows this hypothesis to be tested quantitatively, 
through examination of the steroidogenic effects of phthalates directly in the cell.  Several 
important differences exist between the MA-10 cell line and the cell of interest in vivo.  The 
MA-10 is a tumor derived cell line obtained from the adult male mouse.  The most striking in 
vivo effects, however, occur in the fetal rat.  The fetal mouse does not exhibit the same T 
dependent effects in vivo that are seen in the rat, despite receiving a similar fetal dose [35].  
Nonetheless, phthalates have been shown to cause similar [122] steroidogenic and 
morphological effects in the MA-10 [122] and primary rat Leydig cell [119].  Treatment with 
endocrine active phthalates (MEHP, MBP) caused reductions in LH-stimulated 
steroidogenesis, mitochondrial swelling and vesiculation of the golgi apparatus in both the 
MA-10 and the primary rat Leydig cell.   Gene expression data from the current study were 
also consistent with the fetal rat in vivo data, showing down-regulation of steroidogenic 
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genes involved in both cholesterol transport (SR-B1, StAR) and metabolism (Cyp17a1, 
P450scc).  The similarities in cellular response to phthalate exposure indicates that the MA-
10 cell should be a reasonable model of phthalate effects on the Leydig cell itself despite 
species and age-related differences observed in whole animal studies.   
Concentrations required to inhibit testosterone synthesis in the MA-10 cell were 
similar to those expected in the fetus.  Dose-response studies with DBP have shown that 
external doses between 50 and 500 mg/kg/day significantly reduced fetal testes testosterone 
levels [46] (Chapter 2).  Based on recent PK studies and physiologically based PK (PBPK) 
modeling (Chapters 2-3), fetal MBP concentrations associated with reduced testosterone 
have been estimated to be in the low micromolar range (2-9 μM).  Likewise, the current 
study equates testes concentrations of 12 μM MEHP with the external doses of 500 mg 
DEHP/kg/day, which cause > 50% reduction in fetal testes testosterone content [113].  The in 
vitro assay also accurately identified phthalates that are without effects on androgen synthesis 
– neither MMP nor MEP was able to repress testosterone synthesis in vitro.  This observation 
is in agreement with data from isolated rat Leydig cells [119] and in vivo studies where DEP 
and DMP did not cause the reproductive [33] or gene expression changes [80], despite 
significant exposure of the fetus to the monoester metabolites verified in this study.    
Application of this in vitro assay to other phthalates enables the classification of 
various phthalate metabolites according to their ability to inhibit steroid production, 
supporting a more informed assessment of human risk.  MnOP has not been tested in the fetal 
rat.  It reduced testosterone synthesis in the MA-10 cell, indicating that it likely shares the 
same mechanism of action as MBP and MEHP.  This conclusion is consistent with studies in 
the adult rat, showing similar effects of DEHP and DnOP administration in the Leydig cells 
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of adult rats in vivo, as well as reduced testosterone production in cultured rat Leydig cells 
(Jones et al., 1993).   Interestingly, MBeP did not inhibit steroidogenesis in vitro, despite the 
fact that BBP has been shown to be a potent anti-androgen in fetal rats [33, 46].  The lack of 
effect in vitro, together with the testes metabolite data showing minimal transfer of MBeP to 
the fetus, indicates that the observed fetal effects after administration of BBP are due to the 
preferential hydrolysis of BBP to MBP in the rat [124]. 
The use of this MA-10 assay to evaluate mixed exposures would be particularly 
useful in the effort to predict cumulative human risk, since human exposure occurs as a 
mixture of both endocrine active and inactive compounds.  In vivo efforts to evaluate mixed 
exposures are limited by the expense incurred for the many sets of exposures required and 
the challenges in accounting for differences in pharmacokinetics when rats are dosed with 
multiple compounds at high doses that produce dose-dependent changes in kinetics (Chapter 
3).  A reliable in vitro test would also allow examination of relative potencies and the 
combined effect of oxidative metabolites in addition to the intact monoesters.  MEHP, for 
example, is only a minor metabolite of DEHP in the blood of the rat [12].  In the human, 
blood concentrations of potentially endocrine active oxidative metabolites such as mono(2-
ethyl-5-oxohexyl) phthalate and mono(2-ethyl-5-hydroxyhexyl) phthalate are similar to 
MEHP [81].  A better understanding of the relative potency of the monoester derivatives and 
their combined effect on the Leydig cell would be valuable in predicting human risk and in 
determining the most informative measure of human exposure for biomonitoring data 
collection.    
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F.  CONCLUSION 
Together, our studies provide insight on both the PK and PD factors responsible for 
the phthalate-induced inhibition of steroidogenesis observed in animal studies, and indicate 
how these animal studies may be used to estimate human risk.  For example, because MBP 
and MEHP are commonly found in human urine, and have anti-androgenic activity in the 
fetal rat and in vitro, both would need to be included in a cumulative phthalate risk 
assessment.  Despite the lack of information on DnOP fetal development, it would also be 
advisable to account for its potential exposure in a cumulative risk assessment, as its primary 
metabolite reduces Leydig cell steroid production.  Limited studies indicate that tissue and 
plasma kinetics of MnOP are similar to MEHP [125].  MEP and MMP, on the other hand, 
should be excluded from calculations of total phthalate exposure in relation to fetal testes 
effects as they do not share the same mode of action. BBP is an interesting case, in that 
despite the adverse effects seen in rat developmental studies, it might still be excluded from a 
cumulative risk assessment in the human.  The observed effects in the rat are clearly driven 
by MBP concentrations.  The human, however, preferentially hydrolyzes BBP to MBeP 
[110], which does not exhibit anti-androgenic activity in vitro.  In this case, species PK 
differences indicate that the human would be less susceptible than the rat to developmental 
toxicity from BBP exposure.   
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Figure 4.1.  Measured monoester concentrations in the fetal testes from dams given 
daily oral doses of DMP, DEP, DBP, DEHP, or BBP from GD 12-19.   
Testes were collected 2 hrs after the final dose. Bars represent mean + SD from 3 fetuses of 
2-3 dams.  
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Figure 4.2. Progesterone concentration in the medium of MA-10 cells treated with 100 
ng/mL LH and varying concentrations of MEHP.   
Bars represent mean + SE from 3 separate experiments performed in triplicate.  *p<0.05 
analyzed by 1-Way ANOVA with Dunnett’s post-test.  300 and 1000 μM concentrations 
caused cell loss.  1 – 100 mM MEHP did not cause cellular toxicity as assessed by total 
protein and ATP content (>90% of control). 
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Figure 4.3.  Genes encoding proteins in the Leydig cell steroidogenic pathway. 
Broken lines represent transport proteins, solid arrows represent enzymatic proteins.   
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Figure 4.4.  Expression of selected steroidogenic genes in MA-10 cells. 
Bars represent mean + SE (n=6) of the values measured via RT-PCR. *p< 0.005, 
**p=0.0005, ***p<0.0001 Student’s t-test for comparison of (A) no treatment (NT) vs. LH 
control or (B) LH control vs. MEHP (100 μM) treated groups. 
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Figure 4.5. Testosterone concentration in the medium of MA-10 cells treated with 100 
ng/mL LH and varying concentrations of MEHP.   
Bars represent mean + SE from 3 separate experiments performed in triplicate.  *p<0.05 
analyzed by 1-Way ANOVA with Dunnett’s post-test.  300 and 1000 μM concentrations 
caused cell loss.  1 – 100 μM MEHP did not cause cellular toxicity as assessed by total 
protein and ATP content (>90%). 
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Figure 4.6.  Monobutyl, monoethyl, and monomethyl phthalate inhibition of LH-
stimulated testosterone synthesis in MA-10 Leydig cells.   
Bars represent mean + SE from 3 separate experiments performed in triplicate.  *p<0.05 
analyzed by 1-Way ANOVA with Dunnett’s post-test.   Cell viability was > 90% based on 
total protein and ATP content. 
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Figure 4.7.  Mono-n-octyl and monobenzyl phthalate inhibition of LH-stimulated 
testosterone synthesis in MA-10 Leydig cells.   
Bars represent mean + SE from 3 separate experiments performed in triplicate.  *p<0.05 
analyzed by 1-Way ANOVA with Dunnett’s post-test.  Cell viability was > 90% based on 
total protein and ATP content. 
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CHAPTER 5 
 
 
 
 
 
 
 
 
 
Evaluation of Cytosolic Phospholipase A2 as a Potential Target of 
Steroid Inhibiting Phthalates 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is expected to be submitted for publication in Biology of Reproduction or a 
similar peer-reviewed journal in June 2009. 
A.  ABSTRACT 
Phthalate monoesters disrupt sexual development in the male rat fetus, at least in part, 
through the inhibition of testosterone synthesis in the Leydig cell.  Several of the phthalates, 
including monoethylhexyl phthalate, inhibit testosterone synthesis in vivo and in vitro.  The 
mechanism of this inhibition, however, remains unknown.  The purpose of this study was to 
attempt to identify molecular targets for MEHP in the Leydig cell.  Studies in mouse MA-10 
Leydig cell line showed similar effects on steroidogenic gene expression and testosterone 
production when pretreated with MEHP or chloroquine (CQ), a known inhibitor of 
arachidonic acid (AA) release.   LH-stimulated release of AA from MA-10 cells was also 
inhibited to a similar extent by MEHP and CQ, indicating that MEHP also interferes with the 
arachidonic pathway, which is a co-regulator of steroid synthesis.  HEK 293 cells 
overexpressing EGFP-cPLA2 were used to determine the effect of MEHP treatment on 
cPLA2 activation by calcium.  Both MEHP and CQ interfered with translocation of the 
activated cPLA2 to the nuclear membrane and endoplasmic reticulum.  These studies support 
the conclusion that MEHP may disrupt steroid signaling in the Leydig cell by inhibiting 
arachidonic acid release by cPLA2 and induction of steroid hormone production by AA.   
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B.  INTRODUCTION 
Phthalate esters are widely used as plasticizers, and are ubiquitous drinking water 
contaminants.  Epidemiological studies have shown evidence of phthalate exposure in the 
urine from samples from every subset of the US population [4, 5, 82].  Some of the longer 
chain alkyl phthalates, such as di-(2,4-ethylhexyl)phthalate (DEHP), have been identified as 
potential reproductive toxicants in rats [32, 33, 68].  Effects of gestational exposure to DEHP 
are similar to those induced by androgen receptor (AR) inhibitors:  nipple retention, 
hypospadias, delayed testes descent, and vaginal pouch development in the male rat pup.  
Rather than interacting with the AR, however, the phthalates appear to exert their anti-
androgenic effect through inhibition of testosterone synthesis in the Leydig cell [33, 46, 84, 
113, 126].  The mechanism of this inhibition, however, is unknown.  
Luteinizing hormone (LH) stimulates testosterone synthesis through binding and 
activation of a specific G-coupled protein receptor on the surface of the Leydig cell.  In the 
adult Leydig cell (ALC), the primary regulatory pathway for steroidogenesis is regulated by 
the LH-stimulated release of cyclic AMP (c-AMP), which activates protein kinase A (PKA) 
and up-regulates transcription of certain steroidogenic genes, such as those encoding steroid 
acute regulatory (StAR) protein, and the cytochrome P450 enzymes side chain cleavage 
(P450scc) and 17a1 (Cyp17a1).  LH also stimulates a secondary signaling cascade, which 
uses arachidonic acid (AA) as a second messenger.  This pathway has similar down-stream 
effects to the better known c-AMP/PKA cascade, yet appears to be independent (or at least 
downstream) of c-AMP.  AA release up-regulates StAR transcription and steroid production 
without altering c-AMP levels [55-57].  Figure 5.1 illustrates this two-pathway model for 
testosterone regulation. 
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Several in vitro studies have examined the effect of MBP on the LH regulatory 
pathway and found that disruption occurs prior to StAR gene transcription up-regulation [46, 
127].  Yet, phthalate treatment does not affect intracellular c-AMP levels [55], indicating that 
the monoesters act either independently or downstream of c-AMP.  In the classic literature, 
MEHP was shown to inhibit AA release in activated platelets [60].  This observation , 
together with histological studies showing decreased lipid metabolism in MA-10 cells with 
MEHP treatment [122], indicates that the phthalates may target the AA pathway rather than 
the more dominant c-AMP cascade.  The purpose of this project was to determine the site of 
interaction between the monophthalate esters and this signaling cascade, focusing on the 
release of AA by LH regulation of cytosolic phospholipase A2 (cPLA2).   
 
 
 
 
 
 139
C. METHODS 
Inhibition of Testosterone in MA-10 Cells 
MA-10 cells were obtained from Dr. Mario Ascoli (Department of Pharmacology, 
University of Iowa, College of Medicine, Iowa City).  For all cell culture experiments, dishes 
were coated with a 0.1% solution of gelatin for 30 min before plating cells.  All incubations 
were performed at 37oC in a humidity-controlled atmosphere of 5% CO2-air.  Cells were 
plated in 24-well plates at a density of 1 x 105 cells/well in 0.5 mL complete medium 
(Waymouth’s MB 752/1 supplemented with 15% horse serum, 2% L-glutamine, 20 mM 
HEPES, and 50 μg/mL Gentamicin) and allowed to incubate for 24 hrs.   The medium was 
then removed and replaced with serum-free medium (SFM) containing 0 (DMSO), MEHP, or 
the PLA2 inhibitor CQ.  After 24 hrs, the medium was replaced with SFM containing the 
same inhibitor concentration supplemented with a maximum stimulating concentration of LH 
(100 ng/mL).  The medium was collected after 6 hrs and stored at -20oC.  Testosterone was 
measured using an ELISA assays (Neogen Corporation, Lexington, KY) according to the 
manufacturer’s directions.  
 
Protein Assay 
Cells from each well were treated with 100 μL of lysis buffer (0.1 M Tris-HCl (pH= 
8.0), 0.05 M EDTA, 0.1 M NaCl, 1% sodium dodecyl sulfate, 1% sarcosyl) supplemented 
with HALT Protease Inhibitor Cocktail (10 μL/1 mL buffer) (Thermo Fisher Scientific Inc., 
Rockford, IL) and the cells were dislodged using a cell scraper.  The resulting lysate was 
homogenized and stored at -80oC prior to analysis. Total protein content was measured using 
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a bicinchoninic acid (BCA) assay (Sigma-Aldrich) according to the manufacturer’s 
directions.    
 
Quantitative RT-PCR  
MA-10 cells were plated at a density of 3x106 cells/well in 100 mm cell culture 
dishes (CellStar) in 20 mL complete medium.  24 hrs after plating, medium was replaced 
with 20 mL SFM containing 0 (DMSO), 100 μM MEHP or 10 μM CQ.  Cells were 
incubated for 24 hrs and medium was replaced with SFM containing the same inhibitor 
concentration supplemented with PBS (no treatment control) or a maximum stimulating 
concentration of LH (100 ng/mL).  After 6 hrs, medium was aspirated from the plate, cells 
were washed with Ca++/Mg++-free PBS and removed from the plate using a disposable cell 
scraper.  Total RNA was isolated from the cells of each cell culture dish using an RNeasy 
Mini Kit (Qiagen, Valencia, CA). cDNA was prepared for each sample using the High 
Capacity cDNA kit (Applied Biosystems, Foster City, CA) according to the manufacturer’s 
protocol.  Reverse transcription (RT) reactions were performed on the Taqman 7900HT 
system (Applied Biosystems, Foster City, CA).  Taqman gene expression assays for mouse 
Cyp17A1, GAPDH, P450scc, SR-B1, and StAR were purchased from Applied Biosystems 
(Foster City, CA).  Samples were run in triplicate and changes in expression of target genes 
were normalized to GAPDH.   The fold change for each gene normalized to GAPDH and 
relative to expression in no treatment control (NTC) samples was determined by the 2-ΔΔCt 
method [121].  
 
 141
Inhibition of AA Release in MA-10 Cells 
PLA2 activity was evaluated by measuring the cellular release of radiolabeled AA 
[128].  MA-10 cells were plated in 24-well plates at a density of 1 x 105 cells/well in 0.5 mL 
complete medium.  After 24 hrs, the medium was replaced with SFM containing 0.3 μCi/mL 
radiolabeled arachidonic acid (5,6,8,9,11,12,14,15-3H) (Perkin Elmer, Inc.) for 18 hrs.  Cells 
were washed once with 0.1% fatty acid-free BSA/PBS and twice with Ca++-free PBS.  SFM 
containing 0, 1, 3, 10, or 30 μM MEHP or CQ in DMSO was then added to the cells.  30 min 
after application of the inhibitor, LH (100 ng/mL) was added to all wells other than the no 
treatment (NT) controls.  1 min after addition of LH, the medium was transferred to 
scintillation vials.  Cells were removed from the plate using 0.25% trypsin/EDTA and 
transferred to separate scintillation vials.  Total radioactivity in the medium and cell lysate 
was determined by scintillation counting.   
 
Calcium Stimulated EGFP-cPLA2 Translocation 
 HEK 293 cells, stably transfected with pEGFP-cPLA2 (human), were generously 
provided by Dr. Joseph O’Flaherty (Wake Forest University Health Sciences, Winston-
Salem, NC).  HEK cells were cultured at 37°C with 5% CO2 in DMEM containing penicillin, 
streptomycin, L-glutamine, and 10% FBS (Invitrogen, Carlsbad, CA).  Cells were plated at 
3.0 x 105 cells/well in two-chamber Nunc Lab-Tek II chambered cover glasses (Thermo 
Fisher Scientific, Rochester, NY) in DMEM  with 10% FBS.  After 18 hr, the medium was 
replaced with SFM plus DMSO, 100 μM MEHP or 30 μM CQ.  Cells were visualized using 
confocal microscopy 60 min after changing to SFM.  After an initial scan, cells were treated 
with 20 μM calcium ionophore A23187 (Fisher Scientific, Pittsburg, PA).   
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 Confocal Microscopy 
 Fluorescence was detected with a Zeiss LSM 510 META laser scanning microscope 
(Carl Zeiss, International, Oberkochen, Germany) equipped with a 40x oil corrected lens, 
heated stage and incubation chamber.  During microscopy, cells were maintained at 37oC and 
5% CO2 with a Zeiss CTI-Controller 3700 and Tempcontrol 37-2.  EGFP was visualized 
using an Argon laser with a 488-nm laser line for excitation and a 520-nm band pass filter for 
emission.  OFP was visualized using a He-Ne laser with a 552-nm laser line for excitation 
and a 570-nm band pass filter for emission. 
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D.  RESULTS AND DISCUSSION 
MEHP and CQ Have Similar Effects on Testosterone Production and Steroidogenic 
Gene Expression in MA-10 Cells  
 Unlike the phthalates, which showed no indication of cellular toxicity in vitro at 
concentrations up to 300 μM (see Chapter 4), CQ induced toxicity at concentrations > 60 
μM, as evidenced by reduced total protein (< 80% of control).  Nonetheless, CQ was found 
to be a highly effective inhibitor of steroidogenesis at non-toxic doses, with significant 
testosterone reduction at the lowest tested concentration - 1 μM (Figure 5.2A).  In fact, CQ 
was more potent testosterone inhibitor than MEHP.  CQ was able to induce 67% inhibition at 
10 μM.  MEHP required a 10-fold higher concentration to cause the same level of inhibition 
(Figure 5.2B).   
 At concentrations sufficient to cause ~65% inhibition of testosterone, CQ and MEHP 
induced similar changes in the expression of genes required for steroidogenesis (Figure 5.3).  
Steroid acute regulatory protein (StAR) promotes the transport of intracellular cholesterol 
into the mitochondria, where the first step in its conversion to the active steroids takes place.  
P450scc and Cyp17a1 encode enzymes responsible for the conversion of cholesterol to 
progesterone and testosterone.  All three genes were up-regulated in the MA-10 cell upon 
stimulation with LH (see Chapter 4).  LH stimulated expression of these genes was inhibited 
by pretreatment with 10 μM CQ or 100 μM MEHP.  Down-regulation of P450scc by this 
concentration of CQ was not statistically significant, but the trend was consistent with 
MEHP, which caused only a 20% decrease (Figure 5.3). 
 The ability of CQ and MEHP to inhibit steroid production and steroidogenic gene 
expression is consistent with in vivo studies in the fetal rat.  CQ and DEHP have been shown 
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to inhibit fetal testes testosterone production at maternal doses as low as 10 and 30 
mg/kg/day, respectively.  Significant down-regulation of several steroidogenic genes, 
including StAR, P450scc and Cyp17a1, is also associated with CQ and DEHP administration 
during gestation (Chapter 6) [80].   The similar effects on the steroidogenic pathway in vivo 
and in the MA-10 indicate that CQ and MEHP are likely to have a common target in the 
Leydig cell.   
 
MEHP and CQ Inhibit LH-stimulated AA Release in MA-10 Cells 
 CQ is known inhibitor of PLA2 activity and AA release.  MEHP has also been shown 
to prevent AA release from platelets in vitro [60].  In the Leydig cell, AA acts as a second 
messenger for LH, leading to increased transcription of steroidogenic genes, such as StAR, 
and increased steroid production.  To test whether MEHP and CQ affect LH activation of the 
AA pathway, the release of membrane-incorporated 3H-AA was measured in MA-10 cells.  
Treatment with LH (100 ng/mL) caused a rapid release of AA from MA-10 cells.  At 1 
minute, total radioactivity in the medium from LH stimulated cells was approximately 150% 
that of untreated cells (Figure 5.4).  MEHP and CQ caused similar dose-related decreases in 
AA release after LH-stimulation (Figure 5.5) and abolished the burst of AA at doses in the 
low micromolar range (~10 μM).   
The rapid response to inhibitor treatment indicates that MEHP and CQ disrupt AA 
signaling via interaction with PLA2 protein, rather than at the transcriptional level.  The PLA2 
enzymes consist of a broad group of proteins that catalyze the release of fatty acids from the 
membrane phospholipids sn-2 position [129].   cPLA2, specifically, is the essential 
component in the release of intracellular AA.   Activation of this PLA2 is regulated through 
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calcium (Ca++) binding and phosphorylation (Figure 5.6) [130].  The C2 domain located on 
the C-terminus of cPLA2 binds to Ca++ ions, targeting the enzyme to phospholipid 
membranes of the endoplasmic reticulum (ER), golgi body and nuclear membrane.  The 
cPLA2 C2 domain binds the head group of phosphatidylcholine (PC), and through 
nucleophilic attack, the catalytic portion of the enzyme cleaves the phospholipid, releasing 
AA into the cell.  Inhibition of AA release could be accomplished through inhibition of the 
initial binding of Ca++, which is required for activation of the cytosolic protein, or through 
interference with the interaction between the activated protein and membrane phospholipids. 
 
MEHP and CQ Interfere with Calcium Stimulated Translocation of EGFP-cPLA2 to 
the Perinuclear Region 
 The effect of MEHP and CQ on cPLA2 activation and translocation was studied using 
HEK 293 cells stably transfected with EGFP-cPLA2.  In the absence of inhibitor, 
translocation of the cytosolic protein to the perinuclear region was observed in cells over-
expressing EGFP-cPLA2 within 30 minutes of stimulation by the calcium ionophore A23187 
(Figure 5.7A - C).  In order to verify the location of the activated EGFP-cPLA2, HEK cells 
expressing EGFP-cPLA2 were transiently transduced with a commercial ER marker 
containing the ER signal sequence of calreticulin coupled to orange fluorescent protein 
(OFP-ER) (Organelle Lights, Invitrogen, Carlsbad, CA) (Figure 5.7D - F).  Prior to 
stimulation with the calcium ionophore, EGFP-cPLA2 is not concentrated at the ER, but is 
dispersed throughout the cytoplasm.  After activation with the calcium ionophore, 
colocalization of the EGF-cPLA2 and OFP-ER marker is clearly observed (Figure 5.7G - I).  
EGFP-cPLA2 becomes highly concentrated around the nucleus. 
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 Pre-treatment with 100 μM MEHP for 1 hr prior to stimulation with A23187 caused 
notable inhibition of cPLA2 translocation to the perinuclear region (Figure 5.8).  
Interestingly, it appears that cPLA2 is still activated in the presence of MEHP.  However, 
rather than concentrating at the ER, small clusters of the EGFP-tagged protein are scattered 
throughout the cell.   This speckled appearance is remarkably similar to the behavior reported 
in cells stimulated with arachidonic acid rather than calcium ionophore [168].  Wooten and 
coauthors reported that these sites of cPLA2 concentration corresponded to organelles that 
were discrete from the golgi body and largely composed of lipids.  CQ caused the same 
punctate behavior as MEHP in A23187 stimulated cells (Figure 5.8).   Neither MEHP nor 
CQ affected distribution of EGFP-cPLA2 in the absence of calcium ionophore (not shown).  
The fact that the cPLA2 protein attempts to respond to calcium stimulation, but does not 
appear to bind the nuclear membrane indicates that the interaction between these inhibitors 
and cPLA2 occurs after binding of Ca++ to the C2 domain, but prior to binding to the 
phospholipid membrane.     
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D. CONCLUSIONS 
From the literature, it is apparent that the release of AA by PLA2 is a regulatory step 
in testosterone production [55, 131, 132] and that MEHP can inhibit PLA2 activity [60, 73].  
Our studies show that MEHP and CQ, a known PLA2 inhibitor, have similar effects on 
steroid synthesis, steroidogenic gene expression and LH-stimulated AA release in Leydig 
cells.  Based on these studies, together with the ability of MEHP to inhibit translocation, but 
not activation, of cPLA2, we propose the following mechanism of action for MEHP in the 
Leydig cell.  The longer chain alkyl phthalates  mimic the shape of the phospholipid head 
group of phosphatidylcholine, bind Ca++ activated C2 domain and preventing binding to the 
nuclear/ER membrane. Reduced AA may be responsible for diminished gene transcription 
and subsequent steroid synthesis, particularly in the fetal Leydig cell, where LH feedback is 
not fully established.  Examination of the 2-dimensional chemical structures for the known 
PLA2 inhibitors, CQ and quinacrine, and the testosterone inhibitor, MEHP, show striking 
similarity to the portion of PC that is thought to bind to the C2 domain of cPLA2 (Figure 5.7).  
Additional studies are underway to better define the nature of the interaction between 
endocrine active phthalates like MEHP and cPLA2.  
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Figure 5.1.  Two-pathway model for Co-Regulation of Testosterone in the 
Leydig Cell.   
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Figure 5.2.  Effect of MEHP and CQ on LH-stimulated testosterone synthesis in MA-10 
cells.    
Cells pre-treated with DMSO or various concentrations of (A) MEHP or (B) CQ for 24 hr in 
SFM prior to stimulation with 100 ng/mL LH.  Each data point represents the mean + SE 
from 3 separate experiments performed in triplicate.  *p < 0.05, 1-Way ANOVA, Dunnetts 
post-test. 
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 Figure 5.3.  Effect of MEHP and CQ on steroidogenic gene expression in MA-10 cells. 
Cells were pretreated with DMSO, 100 μM MEHP, or 10 μM CQ for 24 hr prior to 
stimulation with 100 ng/mL LH.  Bars represent mean + SE (n=6) of the values measured via 
RT-PCR. *p< 0.005, **p=0.0005, ***p<0.0001 Student’s t-test for treatment vs. LH control 
groups. 
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Figure 5.4.  LH Stimulation of Arachidonic Acid Release from MA-10 Cells.   
Cells were incubated with 0.3 μCi/mL 3H-AA in serum free medium for 18 hrs, rinsed with 
Ca++-free PBS, and incubated in SFM for 30 min.  1 min after stimulation with 100 ng/mL 
LH, medium was removed and analyzed for total radioactivity with a liquid scintillation 
counter.  Data points represent mean + SE from 3 independent trials with treatments 
performed in triplicate.  ***p < 0.0001, student’s t-test. 
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Figure 5.5. Effect of MEHP and CQ on arachidonic acid release in MA-10 cells.   
Cells were incubated with 0.3 uCi/mL AA in serum free medium for 18 hrs.  After washing 
with Ca++ free PBS, cells were treated with inhibitor or DMSO in SFM for 30 min, followed 
by stimulation with 100 ng/mL LH.  1 min after LH, medium was removed and analyzed 
with a scintillation counter.  Data points represent mean + SE of 3 independent trials with 
treatments performed in triplicate.  *p < 0.05, 1-Way ANOVA, Dunnett’s post-test. 
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Figure 5.6.  Activation, translocation and phospholipase activity of cPLA2. 
 
Ca++ ions bind the free C2 domain of resting cPLA2, resulting in a conformational change 
that allows the C2 domain to bind phospholipid head groups, particularly 
phosphatidylcholine (PC).  Once bound, the catalytic region penetrates the phospholipid 
membrane and cleaves PC at the sn-2 position, releasing AA into the cell.  Phosphorylation 
of membrane-bound cPLA2 at serine-505 is not necessary for phospholipase activity, but acts 
to retain cPLA2 at the membrane and increase AA release [133]. 
 
 
P
MAPKs
cytosolic PLA2-α
(ser505)
Ca++
C2
arachidonic acid
 
 
 154
Figure 5.7. Calcium stimulated translocation of EGFP-cPLA2 in control cells. 
HEK 293 cells stably transfected with pEGFP-cPLA2 and transiently transduced with an 
orange fluorescent protein-tagged endoplasmic reticulum (ER) marker.  Cells were treated 
with vehicle for 1 hr and scanned just before (A, D, G), 14 minutes (B, E, H) or 30 minutes 
after (C, F, I) stimulation with 20 μM A23187.  Panels A-C illustrate response of EGFP-
cPLA2 to calcium ionophore.  Panels D-F show ER marker at 0, 14, and 30 minutes.  Panels 
G-I show areas of overlap of the EGFP-CPLA2 and OFP-ER marker in yellow. 
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 Figure 5.8. Inhibition of EGFP-cPLA2 translocation by MEHP and CQ.  
Control cells were treated with vehicle for 1 hr and scanned just before (A, C) or 30 minutes 
after (B, D) stimulation with A23187.  MEHP treated cells were incubated in 100 μM MEHP 
for 1 hr and scanned just before (E, G) or 30 min after (F, H) stimulation with A23187.  CQ 
treated cells were incubated with 30 μM CQ for 1 hr and scanned just before (I, K) or 30 min 
after (J, L) stimulation with A23187. 
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 Figure 5.9.  Two-dimensional structures of the natural ligand for cPLA2, 
phosphatidylcholine, and potential inhibitors CQ and MEHP.   
Dotted lines indicate areas of structural similarities that may mediate binding of substrate, 
CQ, and MEHP to the C2 domain.   The phospholipid is shown, without charges on the 
phosphate group or the quaternary nitrogen, esterified with aliphatic fatty acids.  cPLA2 
catalyzes the release of arachidonic acid from the sn-2 position of the phospholipid. 
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CHAPTER 6 
 
 
 
 
 
 
 
 
 
In Utero Exposure to Chloroquine Alters Sexual Development in the Male Fetal Rat 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was submitted for publication in Toxicology and Applied Pharmacology in 
March 2009. 
A.  ABSTRACT 
Chloroquine (CQ), a drug that has been used extensively for the prevention and 
treatment of malaria, is currently considered safe for use during pregnancy.   However, CQ 
has been shown to disrupt steroid homeostasis in adult rats and similar compounds, such as 
quinacrine, inhibit steroid production in the Leydig cell in vitro.  To explore the effect of in 
utero CQ exposure on fetal male sexual development, pregnant Sprague-Dawley rats were 
given a daily dose of either 0 or 100 mg CQ/kg/day from GD 16-18 by oral gavage.  Three 
days of CQ treatment resulted in reduced maternal and fetal weight on GD 19 and increased 
necrosis and steatosis in the maternal liver.  Fetal livers also displayed mild lipid 
accumulation.  Maternal serum progesterone was increased after CQ administration.  Fetal 
testes testosterone, however, was significantly decreased.  Examination of the fetal testes 
revealed significant alterations in vascularization and seminiferous tubule development after 
short-term CQ treatment.  Anogenital distance was not altered.  Microarray and RT-PCR 
showed down-regulation of several genes associated with cholesterol transport and steroid 
synthesis in the fetal testes.  This study indicates that CQ inhibits testosterone synthesis and 
normal testis development in the rat fetus at human relevant doses.   
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B.  INTRODUCTION 
Chloroquine (CQ) is a commonly prescribed drug in the treatment and prevention of 
malaria and several connective tissue disorders, including rheumatoid arthritis and lupus.  For 
the treatment of malaria [134], CQ is typically administered in three doses over a period of 
three weeks (25 mg/kg/dose).  Connective tissue disorders usually require lower doses (~ 5 
mg/kg/day) that can continue for many years [135].  Negative side-effects associated with 
long-term CQ treatment range from rashes and gastrointestinal discomfort to retinopathy, a 
degenerative condition resulting from CQ accumulation in the eye [136].  In rare cases, CQ 
treatment can have more serious health effects, such as neuropathy, myopathy, and 
cardiomyopathy [135, 136].  
CQ is generally considered safe for use in pregnant women based on lack of evidence 
of increased miscarriage or overt birth defects in offspring of exposed mothers [137].  Yet, 
despite its widespread use, few reproductive toxicity studies are available for CQ, 
particularly at doses that are relevant to human exposures.  At doses as low as 10 - 40 
mg/kg/day the offspring of rats treated during gestation and lactation have reduced body and 
organ weights and delayed lung development [138, 139].  Much higher doses (700 mg/kg 
once during gestation) produce liver toxicity in the offspring, whether CQ was administered 
in early or late gestation [140].  This same CQ dose administered for fifteen days in gestation 
caused severe structural defects, reduced weight and liquification of visceral organs in the 
fetus [141].   
 Many of the adverse effects of CQ exposure (e.g., lipidosis) are associated with its 
ability to interfere with lipid metabolism [142, 143]. One molecular target of CQ is 
phospholipase A2 (PLA2) [144].  CQ inhibits phospholipid metabolism by PLA2, leading to 
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reduced intracellular arachidonic acid (AA) – a second messenger involved in numerous 
signaling pathways.  AA release is a necessary component of the Leydig cell’s steroidogenic 
pathway [55, 61].  Thus, the ability of CQ to inhibit AA signaling may have downstream 
effects on steroid production.  In vivo, CQ disrupts steroid homeostasis in both the adult male 
and female rat [145-147] and adversely affects fertility [148] as well as the structural 
integrity of the adult male testes at relatively low doses (> 0.57 mg/kg/day) [146, 148, 149].  
Since CQ is efficiently transferred to the fetus [150, 151], it may also interfere with 
steroidogenesis during fetal development, a time in which testosterone production is critical 
for normal sexual development.  The effect of CQ on testosterone-dependent sexual 
development has not been reported.  The purpose of the current study was to determine 
whether CQ affects testosterone production in the fetal rat and normal sexual development in 
male pups.  Indicators of overt reproductive tract toxicity (reduced anogenital distance, testis 
morphology) and early markers of perturbation of steroidogenesis (testosterone production, 
steroidogenic gene changes) were examined in the fetal rat. 
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C.  METHODS 
Animals 
 Pregnant Sprague-Dawley (Crl:CD(SD)) rats (sperm plug positive GD 0) were 
obtained from Charles River Laboratories (Raleigh, NC) and housed in the Animal Care 
Facility of the The Hamner Institutes for Health Sciences, which is accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care International. Rats 
were acclimated in a temperature- and humidity-controlled, HEPA-filtered environment on a 
12 hr light-dark cycle.  NIH rodent diet (NIH-07, Zeigler Bros., Gardner, PA) and reverse-
osmosis water were provided ad libitum. This study was approved by The Hamner Institute’s 
Animal Care and Use Committee.  
 
Dosing Solutions    
The stock solution was prepared by mixing chloroquine diphosphate salt (CQP) 
(CAS# 50-63-5; Sigma-Aldrich, St. Louis, MO) and reverse osmosis water to reach a 
nominal CQ (adjusted by molar ratio) concentration of 200 mg/mL.  The dosing solution was 
prepared with a 1:2 dilution of the 200 mg CQ/mL stock solution in reverse osmosis water, 
for a nominal concentration of 100 mg CQ/mL.  After adjusting for the molar ratio, CQ 
concentrations in the stock and dosing solutions were determined to be 203.5 and 98.7 mg 
CQ/mL using high performance liquid chromatography (HPLC) and UV-Vis detection [152].   
No CQ was detected in the water used for control animals. 
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Treatment 
 Pregnant rats (n = 6 per dose) were dosed once daily by oral gavage on gestation days 
(GD) 16-18 with reverse osmosis water or CQ.  On GD 16, the dams in the treatment group 
were given a loading dose (1mL/kg) of 200 mg/kg CQ.  This dose was followed by 
maintenance doses of 100 mg CQ/kg on GD 17 and 18.  Maternal body weights were 
recorded daily at the time of dosing.  All dams were euthanized by CO2 asphyxiation and 
exsanguination on GD 19 (24 hrs after the final dose).  Sacrifice times were randomized 
between the control and treatment group to minimize influence of time-dependent differences 
in hormone production on dose-response data.  Maternal blood was collected via cardiac 
puncture.  Serum was obtained from maternal blood by allowing the samples to sit at room 
temperature for 1.5 hrs, followed by centrifugation at 2500 rpm for 15 min (4oC).  Serum 
samples were kept at 4oC until clinical chemistry was performed (< 2 hrs).  Maternal liver 
was removed and two sections of the left lobe were processed for histopathology by either 
snap-freezing in liquid nitrogen or fixing in 10% formalin. 
 Fetuses were delivered by cesarean section, weighed and AGD was assessed using a 
dissecting microscope and micrometer lens (accuracy 0.05 mm).  All fetuses were euthanized 
by decapitation, sexed by internal inspection of the reproductive organs, and testes were 
collected from the male fetuses.  The testes pair of one male fetus from 5 control and 5 
treated dams were processed for frozen sections.  The trunk of 1 male fetus of each litter was 
fixed in modified Davidson’s fixative after sexing, but before removal of the testes.  The 
remaining fetal testes pairs were placed in separate cryogenic vials, snap-frozen in liquid 
nitrogen, and stored at -80oC.  The liver of one male fetus per litter was collected and 
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processed for histopathology: one half was prepared for frozen section and the other half was 
fixed in 10% formalin, stained with hematoxylin and eosin and evaluated histologically. 
 
CQ Analysis in Dosing Solutions 
Stock CQP solution was prepared by dissolving 10 mg CQP (Sigma-Aldrich, St. 
Louis, MO) in reverse osmosis water.  Standard solutions (0 – 600 μg/mL) and quality 
control standards were prepared by diluting the stock solution with the appropriate amount of 
reverse osmosis water.  CQP dosing solutions were diluted with water until they were within 
the linear range of the calibration curve (100 – 500 μg/mL).  Diluted dose solutions and 
extracted tissue samples were analyzed on an Agilent 1100 HPLC with a spectrophotometric 
detector (Agilent, Palo Alto, CA).  HPLC analysis used a reverse phase C-18 column (5 μm, 
4.6 x 250 mm), and a solvent flow rate of 1.5 mL/min.  Column temperature was maintained 
at 40oC.  Separation was achieved using a 2 solvent (A: 0.1%formic acid in water, B: 
0.1%formic acid in acetonitrile) gradient.  The solvent was maintained at a 95/5%  A/B for 1 
min and then increased to 100%  solvent B at 5 min.  100% Solvent B was maintained for 2.5 
min, and then decreased over 0.5 min to reach the initial solvent mixture of  95% solvent A, 
5% solvent B.  Injection volume was 20 μL.  Detector absorbance was set to 254 nm, with a 
20 mm bandwith. Peak area counts were calculated by subtracting background (determined 
from blank samples) and comparing to calibration standards, both averaged by analysis date.   
 
CQ Analysis in Serum Samples 
Analysis of CQ in rat serum was performed using a published method (Lejuene et al., 
2007) with some modifications.  Serum (100 μL) was thawed, transferred to a polypropylene 
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tube with 200 μL acetonitrile and vortexed to precipitate serum proteins. Samples were then 
acidified with 700 μL 0.1% trifluoroacetic acid, vortexed, and cooled at 4oC for 15 min.  
Supernatant was collected after centrifugation (10,000 rpm for 4 min) and analyzed via 
LC/MS/MS (Applied Biosystems, Foster City, CA). The liquid chromatograph (Perkin Elmer 
Series 200, Norwalk, CT) was equipped with two MicroPumps, autosampler, and on-line 
Vacuum Degasser. Chromatography was performed on a Luna® phenyl-hexyl column (50 
mm x 2 mm x 3 µm). The mobile phase consisted of 0.1% formic acid in HPLC-grade water 
and acetonitrile. The acetonitrile content was increased from 25 to 100% over 7 min, with a 3 
min post-run equilibration time. Column effluent was diverted to waste during pre-run and 
post-run equilibration using a Valco (Houston, TX) Model C2 6-port switching valve. 
Methanol-water (50:50, v:v) solvent was delivered using a make-up pump (Spectroflow 400, 
Kratos Analytical, Ramsey, NJ) when column effluent was diverted to waste. 
MS analysis (Applied Biosystems API 3000) was conducted in positive ion mode 
with a turbo ionspray interface. Curtain, nebulizing, and collision gases were set in the PE 
Sciex Analyst 1.1 software at 10 (nitrogen), 7 (air), and 4 (nitrogen), respectively. 
Turbospray gas was nitrogen at 7 L/min at 375oC. The nebulizing potential, declustering 
potential, and focusing potential were 4600 V, 61 V and 200 V, respectively. Quantitation 
was performed using selected reaction monitoring of precursor-product ion transitions at m/z 
320.4 to 246.9. Collision energy was optimized to 25 eV.  Data acquisition and initial 
analysis used PE Sciex Analyst 1.1 software on a Dell Precision 360 computer (Austin, TX). 
Integration data were manually corrected, if necessary, and then transferred to Excel™ 
(Microsoft®, Redmond, WA) for analysis.  
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Maternal Serum Hormone Analysis 
Maternal serum progesterone (PG) and estradiol (E2) levels were determined from 
individual dams using commercially available ELISA assay kits (Neogen Corporation, 
Lexington, KY) according to the manufacturer’s directions.  PG and E2 were extracted from 
50 μL of serum in 1000 μL of diethyl ether (Sigma-Aldrich, St. Louis, MO).  The organic 
layer was removed, dried under nitrogen and resuspended in 200 – 500 μL steroid diluent 
provided with the ELISA kits.  Samples were assayed in duplicate. 
  
Fetal Testosterone Analysis 
Fetal testes testosterone concentration was determined from all fetuses remaining 
after samples were taken for histopathology and gene expression analysis.  Testes from 
individual fetuses were assayed according to the method of Shultz et al. [123].  Each testes 
pair was homogenized in 100 mL of PBS-Gelatin buffer. The homogenate was then extracted 
three times with a total of 1 mL of a fresh mixture of ethyl acetate and chloroform (4:1). 
Extracts were dried under nitrogen and resuspended in 100 μL steroid diluent (MP 
Biomedicals, Solon, OH).  An aliquot (25 or 50 μL) of each testes sample was analyzed 
using a Testosterone Double Antibody RAI kit (MP Biomedicals).  Samples from different 
fetuses were not pooled. 
 
Bicinchoninic Acid (BCA) Protein Assay 
Protein concentration in fetal testes homogenate (5 µL) was quantified using a 
commercially available bicinchoninic acid (BCA) method (Sigma-Aldrich, St. Louis, MO). 
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 Histopathology   
One pair of GD19 fetal testes per litter from control rats (n=6) and rats treated with 
100mg/kg CQ (n=6) were immersion-fixed in modified Davidson’s fixative for 24 hr and 
then embedded in paraffin.  A section of the left lobe of the maternal liver and one half of the 
liver from one fetus per dam (n=5/dose) were fixed in 10% neutral buffered formalin and 
embedded in paraffin.  Paraffin embedded sections (5 μm) of livers and testes were prepared 
and stained with hematoxylin and eosin.  Maternal and fetal liver morphology was evaluated 
subjectively for lesions.  Centrilobular degeneration was graded on a scale of 1 to 4, where 1 
indicated minimal degeneration and 4 indicated marked degeneration.  Fetal testes 
seminiferous tubule diameter was evaluated quantitatively using Image Pro Plus software 
(version 4.5; Media Cybernetics, Carlsbad, CA).   
The remaining portions of the maternal and fetal livers were frozen, sectioned with a 
microtome and placed on slides.  One pair of fetal testes per litter from control (n=5) and CQ 
treated rats (n=5) were frozen as before, cut and placed on slides.  Oil Red O staining of 
maternal liver, fetal liver and fetal testes frozen sections was performed as previously 
described [153].  Lipid staining was evaluated subjectively using a scale of 1 to 4, with a 
score of 1 indicating minimal and 4 indicating marked lipid staining.   
 
Clinical Chemistry 
Serum samples were analyzed for alkaline phosphatase (ALP), alanine 
aminotransferase (ALT) and creatinine (Cre) using commercially available assay kits 
 167
according to the manufacturer’s instructions (Pointe Scientific, Canton, MI).  Samples were 
analyzed on a COBAS Fara II (Roche Diagnostics, Switzerland).   
 
Microarray Hybridization 
RNA was isolated from the testes of one individual fetus from each dam.  Testes were 
homogenized in RNA Stat-60 reagent (Tel-Test, Friendswood, TX) and processed using the 
RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol.  RNA 
concentration was determined spectrophotometrically and integrity was assessed using the 
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Double stranded DNA was 
synthesized from 2.5 μg of total RNA using a one-cycle cDNA synthesis kit (Affymetrix, 
Santa Clara, CA).  Biotin-labeled cRNA was transcribed from the cDNA using the Gene 
Chip IVT labeling kit (Affymetrix, Santa Clara, CA).  Labeled cRNA (15 μl) was fragmented 
and hybridized to the Affymetrix Rat Genome 230 2.0 microarray, which allows for 
measurement of over 28,000 genes representing the entire rat genome.  Each RNA sample 
was hybridized to a single microarray giving a total of 12 microarrays.  
 
Microarray Analyses 
A robust singular value decomposition algorithm was used to summarize the 
expression levels based on the probe level data. After normalization, the first robust principal 
component of the perfect match was extracted and the mean of the fitted value was used as 
the signal intensity. A log2 transformation was performed to stabilize the variance. A 
Student’s t –test was performed to compare gene expression between the CQ treated and 
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control animals. Probability values were adjusted for multiple comparisons using a false 
discovery rate of 5% (FDR = 0.05). 
 
Quantitative RT-PCR  
Total RNA was isolated from the testes of one fetus per litter from five control dams and 
five dams from the CQ treated group using RNA STAT-60 reagent (Tel-Test, Friendswood, 
TX) and the RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was prepared for each sample 
using the High Capacity cDNA kit (Applied Biosystems, Foster City, CA) according to the 
manufacturer’s protocol.  Polymerase chain reactions (PCR) were performed on the Taqman 
7900HT system (Applied Biosystems, Foster City, CA).  Taqman gene expression assays for 
rat Cyp17A1 (RN00562601), GAPDH (4352338E), Nppc (RN00587070), P450scc 
(RN00568733), SR-B1 (RN00580588), StAR (RN00580695) and Tm7sf2 (RN01479184) 
were purchased from Applied Biosystems (Foster City, CA).  Samples were run in triplicate 
and the change in expression of target genes was normalized to GAPDH.   The fold change 
for each gene normalized to GAPDH and relative to expression in control testes was 
determined by the 2-ΔΔCt method [121].   
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D.  RESULTS 
Analytical Chemistry 
 Though CQ kinetics are not well defined, the relatively long half-life (~7 hrs) [167] 
indicated that CQ would be present in detectable levels in the serum of the rats 24 hrs after 
the final dose.  CQ concentrations were therefore measured in maternal serum taken at the 
time of sacrifice in an attempt gain some understanding of internal dose associated with 
observed effects.  Maternal serum CQ levels were 1.6 + 0.4 mg/L (mean + SE) in the 100 
mg/kg/day dose group at 24 hrs post-dosing.  CQ was not detected in the serum of control 
animals. 
 
Body weight changes and liver toxicity 
Maternal body weight was significantly reduced after three days of CQ treatment 
(Table 6.1). The maternal liver weight was also reduced.  However, the body weight adjusted 
liver weight (g liver/g BW) was not different between the treated and control groups.  Fetal 
body and absolute liver weight also showed a small, but statistically significant (p< 0.001) 
reduction in weight after CQ treatment (Table 6.1).  Again, the fractional liver weight was 
not significantly different between the two groups.  Some fetuses in the 100 mg/kg/day dose 
group displayed significant edema. 
After three doses of 100 mg CQ/kg, the clinical chemistry did not indicate kidney or 
liver toxicity.  Maternal serum ALT, ALP, and creatinine levels in exposed dams were not 
significantly different from controls (Table 6.1).  Treatment effects were noted, however, 
upon histological examination of the maternal livers (Table 6.1).  Three of the CQ treated 
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dams exhibited centrilobular degeneration that was not present in the control group (Figure 
6.1A-B).   Oil Red O staining revealed mild to moderate steatosis in 5 out of the 6 dams 
given CQ (Figure 6.2A-B).   Examination of the fetal livers did not show evidence of 
necrosis after staining with hematoxylin and eosin (Figure 6.1C-D).  Three of the six fetuses 
in the CQ treated group had increased liver lipid content (grade 1-2) when stained with Oil 
Red O (Figure 6.2C-D).    
 
Effect of CQ on Hormone Homeostasis and Male Fetus Sexual Development 
Maternal and Fetal Hormone Measurement.  To determine whether CQ affected 
hormone levels in the pregnant rat, maternal serum samples from control and CQ treated 
dams collected at the time of sacrifice (24 hrs after the final dose) were analyzed for estradiol 
(E2) and progesterone (PG).  Serum E2 was reduced by 33% in CQ treated dams, though the 
difference was not statistically significant (p = 0.13, Student’s t test).  Interestingly, serum 
PG was significantly increased (p = 0.003) in CQ treated dams (Figure 6.3).   Testosterone 
was also measured in the testes of the male fetuses taken at the time of sacrifice.   Testes 
testosterone was significantly reduced after CQ exposure (Figure 6.4).     
Male Fetal Reproductive Tract Morphology and Testis Histopathology.  Reduced 
anogenital distance (AGD) is a commonly used marker of feminization in male rats.  In the 
current study, AGD was evaluated in both male and female pups (Figure 6.5).  CQ treatment 
had no effect on AGD measured at GD 19 in either the male or female fetuses.   Visual 
inspection of the gonads at the time of sacrifice revealed some changes in the testes 
vasculature after CQ exposure.  Typically, by GD 19 the fetal rat testis has a visible, well-
developed unbranched testicular artery displaying characteristic convolutions (Figure 6.6A).  
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In the CQ treated group, however, the testicular arteries were less organized.  The coiling of 
the main artery was reduced and looping was less uniform (Figure 6.6B).    
Cross sections from the testes of one male fetus of each litter were stained with 
hematoxylin and eosin and evaluated for CQ related changes in morphology.  Three days of 
CQ treatment did not significantly affect the organization of the fetal testes.  However, when 
the widths of the seminiferous tubules were measured, treatment effects were noted.  
Seminiferous tubules in the CQ treated testes were significantly larger in diameter than those 
of the control group (66 + 1 vs. 62 + 1 μm, mean + SE) (p < 0.005, Students’s t). 
Fetal Testes Gene Expression.  Relative gene expression was examined in the fetal 
testes of the 0 and 100 mg CQ/kg/day groups using genome-wide Affymetrix microarrays.  
Of 28,000 genes on the array, only 6 genes were statistically different from controls (FDR 
adjusted p<0.05) (Table 6.2).  Of the significantly altered genes in the 100 mg/kg/day group, 
5 have been characterized, all of which were down-regulated.  Argininosuccinate synthetase 
(Ass), saccharopine dehydrogenase (Sccpdh), coenzyme Q homologue (CoQ), and aldehyde 
dehydrogenase 1 family, member B1 (Aldh1b1) are associated with regulation of molecular 
oxygen.  Serine/threonine kinase receptor associate protein (Strap) is a negative regulator of 
TGFβ signaling. 
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When the stringency of the tests for significance were relaxed to include all gene 
changes > 1.5-fold, trends were also seen in genes associated with cytoskeleton organization, 
extracellular matrix proteins, intracellular calcium binding/regulation, oxygen and nitric 
oxide regulation, and fatty acid, cholesterol and steroid synthesis (Table 6.3).  Five genes 
associated with cholesterol and steroidogenesis were down-regulated with at least 1.5-fold 
change from control.     
Transmembrane 7 superfamily member 2 (Tm7sf2) and steroid acute regulatory 
(StAR) protein are involved in steroid synthesis.  Tm7sf2 encodes 3β-hydroxysterol-Δ14-
reductase (3βHSR), an enzyme required for the conversion of lanosterol to cholesterol [154].   
StAR protein regulates the transport of cholesterol into the mitochondria where it is 
metabolized to pregnenolone [155].   
Natriuretic peptide precursor type C (Nppc) and the prolactin receptor (PRL) are 
associated with external signaling of steroidogenesis.  Nppc encodes C-type natriuretic 
peptide (CNP), which has been shown to stimulate fetal rat testosterone production in vitro 
[156].  In the testes, this peptide is localized in the Leydig cell [157].  Peptides such as CNP 
may be responsible for regulation of fetal testosterone production prior to pituitary secretion 
of luteinizing hormone [156].  The role of the pituitary hormone prolactin and its receptor in 
steroidogenesis is not well defined.  However, secretion of prolactin has been shown to be 
regulated by estrogen levels, and administration of prolactin is associated with altered 
testosterone levels in the rat.  In cultured fetal rat Leydig cells, prolactin induces testosterone 
production [158].  Other genes that showed at least 1.5-fold difference between fetal testes 
from the CQ treated and control groups, such as stanniocalcin 2 (Stc2), visinin-like 1 (Vsnl1), 
and pregnancy induced growth inhibitor (Okl38), have not been definitively linked to 
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steroidogenesis.  However, the changes in expression of these genes in this study were 
consistent with studies of other steroid synthesis inhibitors (e.g., phthalate esters;[131]).   
RT-PCR was performed on fetal testes samples from 5 control and CQ treated 
animals to confirm the trend in steroidogenic genes indicated by the current microarray 
study.  Confirmation with RT-PCR revealed statistically significant decreases in StAR, 
Tm7sf2 and Nppc with CQ treatment (Figure 6.7A), which were consistent with the fold-
changes from the microarray study (Table 6.3).   
The expression of three additional steroidogenic genes (SR-B1, Cyp17A1, and 
P450scc) were evaluated using RT-PCR in an effort to obtain more targeted information 
about the effect of prenatal CQ treatment on steroidogenesis in the fetal testes (Figure 6.7B).   
These genes are typically induced in the testosterone-producing cell and are consistently 
down-regulated in the testes of fetal rats after exposure to known inhibitors of steroid 
synthesis, such as the phthalate esters [46, 80, 123].   Scavenger receptor class B type 1 (SR-
B1) regulates uptake of cholesterol into the Leydig cell [159], while Cyp17A1 and P450scc 
are required for the conversion of cholesterol to testosterone.  All three genes were 
significantly down-regulated (p< 0.05) in the CQ exposed fetal testes when evaluated by RT-
PCR. These gene changes were consistent with the microarray results: relative expression 
values for SR-B1, P450scc and Cyp17a1 in CQ treated animals were 0.73, 0.87, and 0.71 
when compared to controls.   
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E.  DISCUSSION 
CQ was administered to late-term pregnant rats at doses that are comparable to those 
recommended for the pregnant human. After three days of exposure, maternal rats exhibited 
signs of general toxicity, including reduced weight gain and general lethargy.  CQ treatment 
at 100 mg/kg/day) was associated with morphological liver changes in the maternal rat, as 
evidenced by increased incidence of centrilobular degeneration and steatosis.  Fetal rats in 
the CQ treated group also had reduced body weight when compared to controls, and mild 
lipidosis was noted in the histopathology of the fetal livers.    
 Clinical signs of toxicity were consistent with those presented in the literature.  CQ is 
known to cause liver toxicity in rats when given at high doses or for long periods of time (>1 
week) [160, 161]. Lipidosis, in particular, is a common result of CQ administration in the rat 
[142, 143].  While little work has been done to characterize CQ toxicity in utero, a recent 
study found that newborn rats exposed to CQ during gestation and lactation (10 mg/kg/day) 
had decreased liver weights, potentially indicating hepatotoxicity [140].  Our study confirms 
the CQ-induced reduction in liver weight.  However, when adjusted for body weight, the 
relative liver weight was the same in control and treated rats.  This, together with the lack of 
change in the morphology, indicates that the fetal liver is not a major target of CQ toxicity.  
Nonetheless, staining with Oil Red O does indicate some potential for development of fatty 
liver in the fetus. 
 The more significant finding in our study was the CQ-induced alteration in steroid 
hormone homeostasis in the both the dam and the male fetus after three days of treatment.  In 
the maternal rat, the decrease in serum estradiol, while not statistically significant, is 
consistent with previous reports of reduced estrogen levels in female rats after four weeks of 
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treatment [147].  The effect of CQ on progesterone has not been evaluated previously.  
However, since this hormone is vital to maintenance of normal pregnancy, it was measured 
in the current study and was significantly increased after three days of CQ treatment.  Fetal 
hormones were also affected by CQ treatment; fetal testes testosterone was significantly 
decreased 24 hrs after the last dose.  Testosterone is synthesized in the male fetal testes 
independent of maternal regulation.  Thus, the reduction in testosterone indicates a direct 
effect of CQ on the fetal testes. 
 AGD, a marker of disruption of male sexual development, was not reduced in the 
male fetuses of CQ treated animals.  Inhibition of testosterone signaling by chemicals such as 
flutamide and di-n-butyl phthalate (DBP) from GD 12 - 19 has consistently been shown to 
result in reduced AGD in male rats [68, 162].  This decrease was not seen in the current 
study, despite the significant reduction in testes testosterone.  It is possible that our dosing 
regimen was not optimal for detecting a difference in this parameter; dosing was started in 
late gestation and sacrifice performed on GD 19 rather than post-natal day 1 as is more 
typical [34, 162, 163].  Mychreest et al. [34] noted ~30% decrease in the AGD of post-natal 
day 1 male rats from DBP doses that caused > 90% reduction in fetal testosterone (500 
mg/kg/day; Lehmann et al., 2004).  A similar phthalate, di-isobutyl phthalate, caused only a 
14% reduction in AGD on GD 19 with a comparable dose (600 mg/kg/day) [164].  
Alterations in AGD are expected to be more noticeable if measured post-natally. 
 Despite the lack of change in AGD, early markers of sexual development were altered 
in the CQ treated fetus.  Clear changes were seen in the testes vasculature after CQ treatment 
upon gross examination of the testes.  Furthermore, the cord diameter was increased in the 
CQ treated testes.  These changes indicate an effect of CQ treatment on normal development 
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of the testes.  These alterations may represent some general effects on development.  
However, when coupled with the concurrent reduction in testosterone and the expression of 
genes associated with structural and vascular regulation in the testis, these alterations are 
more likely to represent a direct action of CQ on testes development.   
Our gene array studies, while limited in statistical power, indicated potential 
alterations in genes that are associated with steroid regulation in the testes, both at the level 
of cholesterol synthesis and in its conversion to testosterone.  The trends in gene changes 
observed in this study were consistent with those seen with DBP, which is also an anti-
androgenic chemical, indicating that CQ is able to reduce the production of testosterone in 
the fetal testes.  More targeted analysis of testes samples with RT-PCR confirmed CQ-related 
decrease in 6 genes associated with steroidogenesis, including StAR, SR-B1, P450scc, Cyp17, 
Tm7sf2, and Nppc.  These genes are also down-regulated with gestational phthalate treatment 
[80, 123], supporting the conclusion that CQ is able to interfere with fetal testosterone 
homeostasis through disruption of steroid synthesis.    
 This study demonstrated that the anti-malarial drug CQ disrupts sexual development 
in the male fetal rat at doses that are similar to those recommended for pregnant women.  At 
doses just 4-fold higher than those used in the human, structural differences were present in 
the testes of the male fetus (increased tubule diameter) and significant reductions were found 
in testosterone content and mRNA of genes associated with cholesterol transport and steroid 
synthesis.  On the basis of this study, further research is warranted on the effect of pre-natal 
CQ exposure on male sexual development and fertility.   
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F.  ADDITIONAL RESEARCH 
Dose-Response Evaluation of  Chloroquine Effects on Testosterone and Steroidogenic 
Gene Expression in the Fetal Rat Testes 
 
Chloroquine Administration to Pregnant Animals and Tissue Collection 
 Pregnant rats (n=3 per dose/study) were dosed once daily by oral gavage from 
gestational day (GD) 16-18 with reverse osmosis water or CQ.  On GD 16, the dams were 
given a loading dose (1mL/kg) of 20, 100 or 200 mg/kg CQ.  These doses were followed by 
maintenance doses of 10, 50, and 100 mg CQ/kg, respectively, on GD 17 and 18.  This study 
was performed twice (for a total of 6 dams/dose group), in an effort to verify original 
observations in the first study (Group I),  retain statistical power, and minimize variability 
due to the time of day at which animals were sacrificed and hormones measured.  Rats in the 
second study (Group II) were mated, dosed and euthanized 1 day after those in Group I.  
Maternal body weights were recorded daily at the time of dosing.  All dams were euthanized 
by CO2 asphyxiation and exsanguination on GD 19 (24 hrs after the final dose).  Sacrifice 
times were randomized across dose groups to minimize influence of time-dependent 
differences in hormone production on dose-response data.  Maternal blood was collected via 
cardiac puncture.  Fetuses were delivered by cesarean section, weighed and AGD was 
assessed using a dissecting microscope and a micrometer lens (accuracy 0.05mm).  All 
fetuses were euthanized by decapitation, sexed by internal inspection of the reproductive 
organs, and testes were collected from the male fetuses.  Each fetal testes pair was placed in a 
separate cryogenic vial, snap-frozen in liquid nitrogen, and stored at -80oC.   
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Analysis of Fetal Testes Testosterone and Steroidogenic Gene Expression 
Fetal testes testosterone concentration was determined from 3 individual fetuses from 
each litter in Group I and II following with the previously described method (Figure 6.8).   
Testosterone showed a dose-dependent decrease with CQ treatment. A 2-way ANOVA 
indicated that CQ treatment and study group were significant factors (p < 0.001 and p < 
0.003, respectively). Group I showed a greater reduction in testosterone than Group II.  
However both groups clearly had a negative dose-response.  Testosterone was significantly 
reduced (p < 0.05) in all treatment groups (> 10 mg/kg/day) when compared to controls. 
RT-PCR was performed on fetal testes samples from one testes pair from each litter 
in the control, 10, 50, and 100 mg/kg/day groups (n=6) using the probes for genes indicated 
from the single dose CQ study and from published gene expression studies with the DBP and 
DEHP [46, 80].    In addition to the genes described above, 7-dehydrocholesterol reductase 
(Dhcr7) and emopamil binding protein (EBP) expression were examined.  Dhcr7 and EBP 
are required for de novo cholesterol synthesis, and are consistently down-regulated with 
steroid inhibitors [46, 80].   With the exception of P450scc, all of the examined genes (Figure 
6.9) showed a dose-dependent decrease in expression following CQ exposure (p< 0.05, 2-
way ANOVA with LS means student’s t post-test).  Dhcr, StAR, Tm7sf2, Cyp17A1, P450scc, 
and Nppc were significantly down-regulated at CQ doses of 50 and 100 mg/kg/day.  The 
genes encoding EBP and the cholesterol transporter SR-B1, also showed decreasing trends 
with dose.  However, only the 100 mg/kg/day group was significantly different from 
controls.   
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Conclusions on Chloroquine In Vivo Studies 
 In addition to showing that CQ is able to disrupt fetal testosterone at doses that are 
within the range of those recommended for pregnant women (10 mg/kg/day), the second in 
vivo study demonstrated a clear dose-response for testosterone inhibition.  The concurrent 
dose-related decrease in the expression of genes responsible for regulation of steroidogenesis 
indicates that CQ interferes with testosterone regulation through inhibition of synthesis.  The 
ability of CQ, a known inhibitor of arachidonic acid release by PLA2s, to inhibit fetal 
testosterone synthesis in vivo supports our hypothesis that this enzyme is necessary for fetal 
rat steroidogenesis and may play a role in phthalate induced inhibition.   
 CQ treatment did not recapitulate all of the responses seen in rats exposed to DBP 
and DEHP during gestation.  In particular, the diameter of the seminiferous tubules was 
increased after exposure to DBP and decreased after CQ.  DBP and DEHP also caused 
significant changes in the expression of a larger number of gene transcripts than CQ when 
evaluated by microarray.  Liu et al. [80]  reported statistically significant alterations in 391 
genes after exposure to the endocrine active phthalates BBP, DBP, DEHP, and dipentyl 
phthalate (500 mg/kg/day).   In addition to those regulating testosterone, categories of altered 
genes included pathways involved in insulin signaling, transcription regulation and oxidative 
stress.  Many of the genes altered in the fetal testes after phthalate treatment are associated 
with seminiferous tubule structure and Sertoli cells.  Phthalates have been shown to have 
adverse effects on fetal sexual development not related to testosterone, such as 
cryptorchidism, induction of multinucleated gonocytes, and germ cell detachment in primary 
cell cultures [35, 165].  These effects on the Sertoli and germ cells were not recapitulated by 
CQ.   
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The ability to detect differences in gene expression from the CQ microarray studies 
was limited by the size of these studies and by the existence of batch effects.  For each of the 
CQ studies, six animals were used for each dose.  In the study by Liu et al. [80], where 391 
genes were significantly altered, the authors were able to combine results for inactive and 
active phthalates, giving an effective n of 16 and improving sensitivity.  Furthermore, the CQ 
studies demonstrated a much greater level of toxicity than the phthalates, with significant 
reductions in maternal and fetal body weight at relatively low doses (50 and 100 mg/kg/day, 
respectively), which limited the doses at which testes effects could be examined.  
Nonetheless, the similarity in their effect on the steroidogenic pathway indicates that CQ and 
the endocrine active phthalates may have a common target in the Leydig cell. 
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Table 6.1.  Body Weights and Markers of Liver Toxicity   
 
 Dam Fetus 
Dose (mg/kg/day) 0 100 0 100 
Body Weight (g)a 327.4 (7.1) 281.9 (7.1)** 2.32 (0.17) 2.18 (0.25)* 
Liver Weight (g) 14.9 (1.7) 12.3 (1.2)** 0.21 (0.02) 0.173 (0.04)* 
Fractional 
Liver Weightb 
0.045 
(0.004) 0.044 (0.005) 0.088 (0.005) 0.082 (0.005) 
Liver 
Centrilobular 
Degeneration 
(incidence)c 
Not present 
= 6 
Not present  
= 3  
Grade 2 = 3 
Not present  
= 5 
Not present  
= 5 
Liver Lipid 
Accumulation 
(incidence)c 
Not present 
= 6 
Grade 1 = 1 
Grade 2 = 2 
Grade 3 = 2 
Not present 
= 5 
Not present  
= 2 
Grade 1 = 3 
Serum ALT (U/L) 170.3 (22.2) 148.0 (23.5) --- --- 
Serum ALP (U/L) 44.5 (2.5) 43.0 (2.6) --- --- 
Serum Creatinine 
(mg/dL) 0.55 (0.02) 0.55 (0.02) --- --- 
Values shown for mean (SE) from dams (n = 6) and their litters.   
aMean fetal body weight was calculated from all fetuses for each dose group.   
bFetal fractional liver calculated from 1 fetus/litter (liver weight divided by weight of 
corresponding fetus).  
cCentrilobular degeneration and lipid accumulation in the maternal (n = 6/dose) and fetal 
liver (n = 5-6/dose) were evaluated after staining of sections with hematoxylin and eosin or 
Oil Red O, respectively.  Changes in histopathology were evaluated on the following scale: 
Grade 1 = minimal, Grade 2 = mild, Grade 3 = moderate, and Grade 4 = marked 
occurrence.     *p<0.05, **p<0.01, Student’s t-test.   
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Table 6.2.  Significantly altered genes in the testes of GD 19 male rat after CQ exposure 
(adjusted p < 0.05).   
 
Affymetrix 
ID 
Gene 
Symbol 
Gene Name Fold-
change
Functional Category 
1370964_at Ass argininosuccinate 
synthetase 
-1.56 NO regulation 
1372078_at Strap serine/threonine kinase 
receptor associated protein 
-1.08 Regulation of TGFβ 
signaling 
1372741_at Sccpdh saccharopine 
dehydrogenase (putative) 
-1.08 Oxidoreductase activity 
1372774_at Coq6 Coenzyme Q6 homolog 
(yeast) 
-1.67 Oxidoreductase activity 
1383472_at Aldh1b1 aldehyde dehydrogenase 1 
family, member B1 
-1.93 Oxidoreductase activity 
1381684_at --- Transcribed locus 1.08 Uncharacterized 
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Table 6.3.  Characterized genes with changes in fetal testis expression of at least a 1.5 
fold after maternal CQ treatment.   
 
Affymetrix 
ID 
Gene 
Symbol 
Fold-
Change 
Raw     
P Value 
Adjusted 
P Value 
Putative Function 
 
1368406_at Star -1.94 5.1e-5 0.1 Steroid synthesis 
1368453_at Fads2 -1.53 2.0e-4 0.1 Long chain fatty acid 
synthesis 
1368854_at Vsnl1 -2.18 0.006 0.3 Calcium 
regulation/signaling 
1369579_at Stc2 -1.54 9.2E-5 0.1 Calcium regulation  
1369951_at Ctrb -2.34 0.009 0.4 Apoptosis signaling 
1370336_at Okl38 -1.54 0.001 0.2 Inhibit cell growth 
1370355_at Scd1 -1.59 0.003 0.3 Long chain fatty acid 
synthesis 
1370384_a_
at 
Prlr -1.57 0.003 0.3 Steroid regulation 
1370964_at Ass -1.56 5.0e-6 0.0 NO regulation 
1373386_at Gjb2 -1.66 0.182 0.7 Gap junction  
1374787_at kcnf1 -1.63 0.007 0.3 Putative K+ channel 
1376944_at Prlr -1.54 0.002 0.3 Steroid regulation 
1387174_a_
at 
Star -1.79 0.185 0.2 Steroid regulation 
1387744_at Nppc -2.35 0.001 0.2 Steroid regulation, 
angiogenesis 
1388269_at Hbg1 -1.69 0.001 0.7 heme binding, oxygen 
transport 
1389725_at Tm7sf2 -1.81 0.191 0.2 Cholesterol synthesis 
1382431_at ABCA1 -1.66 0.001 0.7 Lipid efflux from Sertoli 
cells 
1391519_at RGD13063
49_pred 
-1.68 0.030 0.5 Cytoskeleton organization 
1392664_at Admr -1.52 0.001 0.2 Vasodilation, NO 
response 
1396877_at LAMC1 -1.69 0.139 0.7 Extracellular matrix 
protein, oxidative stress 
response 
1368187_at Gpnmb 1.71 2.0e-4 0.1 Melanoprotein 
1368290_at Cyr61 1.77 0.184 0.7 Angiogenesis, cell 
proliferation/adhesion 
1370428_x_
at 
RT1-A2 /// 
RT1-A3 /// 
RT1-Aw2 
1.74 0.260 0.8 Antigen presentation to 
immune system 
1373130_at Myom2 1.73 0.012 0.4 Cytoskeleton structure 
1387011_at Lcn2 1.51 0.428 0.9 Reactive oxygen species 
response, apoptosis 
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Figure 6.1.  Sections of (A-B) maternal or (C-D) fetal liver after exposure to 0 or 100 
mg/kg/day CQ.   
(A) Maternal liver from control animal.  (B) Maternal liver from CQ treated animal.  (C) 
Fetal liver from control group.  (D) Fetal liver from CQ treated group.  Livers were fixed 
10% formalin, embedded in paraffin, sectioned at 5 μm and stained with hematoxylin and 
eosin.      
 
A B 
 
C D 
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Figure 6.2.  Lipid accumulation in the (A-B) maternal or (C-D) fetal liver after exposure 
to 0 or 100 mg/kg/day CQ.   
(A) Maternal liver from control animal.  (B) Maternal liver from CQ treated animal.  (C) 
Fetal liver from control group.  (D) Fetal liver from CQ treated group.  Livers were frozen, 
sectioned at 5 μm and stained with Oil Red O.  Arrow indicates small lipid droplets in fetal 
liver. 
 
A 
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Figure 6.3.  Maternal serum estradiol and progesterone levels on GD 19 after maternal 
CQ exposure to 0 or 100 mg/kg/day from GD 16 – 18.    
Bars represent mean + SE of the measured data.  *p< 0.05, Student’s t-test for comparison of 
treatment vs. control groups. Black bars indicate control hormone levels.  Gray bars indicate 
hormone levels in CQ treated dams. 
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Figure 6.4.  Fetal testes testosterone levels on GD 19 after maternal CQ exposure to 0 or 
100 mg/kg/day from GD 16 – 18. 
Bars represent mean + SE of the measured data.  *p< 0.05, Student’s t-test for comparison of 
treatment vs. control groups. 
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Figure 6.5.  Effect of CQ treatment on fetal anogenital distance (AGD) after maternal 
exposure to 0 or 100 mg/kg/day from GD 16-18. 
Bars represent mean + SE of the measured values for male (black) or female (gray) fetal rats. 
*p< 0.05, Student’s t-test for comparison of treatment vs. control groups. 
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Figure 6.6.  Testicular artery after maternal CQ administration at 0 or 100 mg/kg/day 
from GD 16-18. 
(A) Testicular artery in control fetus shows several regular loops.  (B) Testicular artery in 
high dose fetus has fewer convolutions and irregular loops.  White arrows indicate the 
testicular artery. 
 
A 
 
B 
 
 190
Figure 6.7.  Effect of CQ treatment on expression of selected steroidogenic genes in fetal 
testes testosterone after maternal administration of 0 or 100 mg/kg/day from GD 16-18. 
Bars represent mean + SE of the values measured via RT-PCR. *p< 0.05, Student’s t-test for 
comparison of treatment vs. control groups. 
 
CQ Dose (mg/kg/day)
0 100
R
el
at
iv
e 
E
xp
re
ss
io
n
0.0
0.5
1.0
1.5 Nppc
*
 CQ Dose (mg/kg/day)
0 100
R
el
at
iv
e 
E
xp
re
ss
io
n
0.0
0.5
1.0
1.5 Cyp17A1
***
 
CQ Dose (mg/kg/day)
0 100
R
el
at
iv
e 
E
xp
re
ss
io
n
0.0
0.5
1.0
1.5 Tm7sf2
***
 CQ Dose (mg/kg/day)
0 100
R
el
at
iv
e 
E
xp
re
ss
io
n
0.0
0.5
1.0
1.5 P450scc
*
 
CQ Dose (mg/kg/day)
0 100
R
el
at
iv
e 
E
xp
re
ss
io
n
0.0
0.5
1.0
1.5 StAR
**
 CQ Dose (mg/kg/day)
0 100
R
el
at
iv
e 
E
xp
re
ss
io
n
0.0
0.5
1.0
1.5 SR-B1
***
 
 
 191
Figure 6.8.  Testosterone in fetal testes after maternal CQ administration at 0, 10, 50, or 
100 mg/kg/day from GD 16-18.  Open circles represent Group I.  Triangles represent Group 
II.  *p< 0.05, 2-way ANOVA for dose and treatment group with Tukey’s post-test. 
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Figure 6.9.  Expression of selected steroidogenic genes in fetal testes after maternal CQ 
administration at 0, 10, 50, or 100 mg/kg/day from GD 16-18.  *p< 0.05, 2-way ANOVA 
for dose and treatment group with Tukey’s post-test. 
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CHAPTER 7 
 
 
 
 
 
 
 
 
 
GENERAL DISCUSSION 
 
 
A.  Summary of Experiments 
 The purpose of this project was to provide data and quantitative tools that could be 
used to improve risk assessments for phthalates.  To that end, a series of in vivo, in vitro and 
in silico experiments were performed to evaluate the pharmacokinetic and pharmacodynamic 
factors controlling the phthalates’ anti-androgenic effects.  Chapters 2 and 3 focused on 
better defining phthalate distribution during gestation, using DBP as the representative 
endocrine active phthalate.  The kinetic studies in Chapter 2 served two purposes.  First, the 
dose-response study was the first in which phthalate and testosterone concentrations were 
simultaneously measured in the fetus.  The publication of the plasma and tissue metabolite 
levels following repeated DBP exposure allowed the observed adverse effect (testosterone 
reduction) to be directly related to the concentration of the active metabolite in the target 
tissue (fetal plasma, testes).   
 The second purpose of the time-course data collected across doses was to provide the 
data needed to develop a PBPK model for DBP in the pregnant and fetal rat, which could 
later be extended to other phthalates of interest (e.g., DEHP).   Chapter 3 describes the 
development and validation of a PBPK model for DBP and its metabolites MBP and MBP-
glucuronide in the adult male, pregnant female and fetal rat.  The model, which was tested 
against a wide variety of data collected in different rat strains and life-stages, and across 
different doses and exposure routes, is able to accurately predict maternal and fetal plasma 
levels of the active metabolite (MBP) with both acute and repeated dosing.  Thus, the model 
allows fetal dose to be calculated for studies in which kinetic data were not collected.  
Furthermore, incorporation of the various metabolic pathways into the model allowed 
identification of the important determinants of the non-linear kinetics observed in vivo.  
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Importantly, glucuronidation, a major clearance pathway for MBP, is saturated at very high 
DBP doses (500 mg/kg/day), which may account for the large number of developmental 
effects seen at this dose.  Successful extrapolation of the DBP model to DEHP allowed fetal 
concentrations of the active metabolites, MBP and MEHP, to be calculated based on toxicity 
studies and compared.  While DBP appears to induce developmental effects at lower 
administered doses than DEHP [46, 113], comparison of the fetal metabolite concentrations 
demonstrates that these two monoesters are equally potent. 
Chapter 4 evaluated the pharmacokinetic and pharmacodynamic factors affecting the 
different potency across phthalates.  Measured monoester concentrations in the fetal testes 
after repeated doses of BBP, DEP, DBP, DEHP, and DMP revealed that all of the 
corresponding monoesters were transferred to the fetus.  When considered together with the 
results of testosterone inhibition in MA-10 Leydig cells, it became clear that the difference in 
the ability of the monoesters to cause developmental toxicity resides in pharmacodynamics, 
i.e., similar target tissue concentrations have significantly different outcomes in the 
developing testes.  The in vitro assay developed in Chapter 4 also provided a model for 
subsequent investigations into the mechanism of phthalate disruption of testosterone 
signaling in the Leydig cell. 
Few studies have attempted to identify the molecular target for the phthalates in the 
Leydig cell, despite numerous studies indicating their effect on steroid synthesis and 
steroidogenic gene expression [33, 46, 55, 72, 80, 122].  Based on the available data with 
chloroquine (CQ), regarding its action on steroidogenesis, and a fairly simple comparison of 
the two-dimensional  chemical structures of phthalate monoesters, CQ and the natural ligand 
of cPLA2 (Figure 5.9), we hypothesized that the phthalates disrupted steroid signaling 
 196
through inhibition of AA release by cPLA2.  Chapter 5 examined the ability of the PLA2 
inhibitor CQ and MEHP to inhibit testosterone production, steroidogenic gene expression 
and AA release in the LH-stimulated Leydig cell.  Like MEHP, CQ was able to inhibit 
testosterone production in vitro, and CQ and MEHP caused similar changes in LH-stimulated 
gene expression and AA release. The ability of CQ and MEHP to interfere with cPLA2 
translocation after activation by calcium stimulation was also confirmed.   
In Chapter 6, the in vivo effects of AA inhibition by CQ were evaluated in the fetal 
rat.  While the liver effects were vastly different from those seen with phthalate 
administration (phthalates are hypolipidemic; CQ causes steatosis), the effects on 
steroidogenesis were similar.  CQ reduced fetal testes testosterone levels in a dose-dependent 
manner.   CQ treatment also led to down-regulation of steroidogenic genes that were also 
down-regulated in studies with the active phthalates [80].  The similarity in steroidogenic 
response to phthalate and CQ treatment further supports the possible role of cPLA2 in 
phthalate-induced inhibition of testosterone production. 
Improved understanding of the molecular target(s) for phthalates in the testes is 
vitally important to future risk assessment efforts, as these assessments are likely to be 
focused on the developmental effects of phthalate exposure.  Together, the studies described 
in this thesis provide the initial evidence that cPLA2 is a key target of these phthalates 
leading to decreased arachidonic acid release and decreased testosterone production.  Overall 
the results of our work can be used to support a more quantitative evaluation of the potential 
molecular targets for the phthalates using the dose-response data collected in the previous 
chapters.
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B. Using Dose-response Modeling to Evaluate Potential Molecular Targets of the 
Phthalate Monoesters in the Leydig Cell 
 The previous studies confirm the ability of MEHP to interfere with the arachidonic 
acid release and cPLA2 translocation.  Together with the published data showing that 
arachidonic acid pathways are necessary for testosterone signaling in the Leydig cell, these 
studies suggest that the phthalate monoesters reduce the production of testosterone by 
inhibiting cPLA2 activity.  However, cPLA2 is clearly not the only possible molecular target 
within the Leydig cell.  MEHP binds to and activates PPARα, a nuclear receptor that induces 
expression of enzymes that regulate lipid homeostasis and is present in the Leydig cell.   In 
order to evaluate the feasibility of these proposed molecular targets, a series of quantitative 
models were applied to the various in vivo and in vitro data collected in the previous studies.  
Using several pharmacokinetic models, ranging from simple one-compartment structures to 
more complex physiological (PBPK) models, we compared the potency of the phthalates of 
interest for different endpoints in the steroidogenic pathway (Table 7.1).  The purpose of this 
analysis was to help pin-point the molecular target of the phthalates, based on the premise 
that the phthalates should have a potency for the terminal and precursor effects similar to that 
for interaction with the molecular target. 
Maternal DEHP and DBP exposure causes decreased testosterone production in the 
testes of male fetal rats, which results in a variety of developmental effects.  However, for the 
purpose of this work, decreased testosterone production was considered the key terminal 
effect.  Dose-response data for inhibition of fetal testosterone by both DEHP and DBP have 
been published [46, 55, 72].  The external dose required to yield 50% inhibition (ED50) was 
calculated to be 35 and 63 mg/kg-day for DBP and DEHP, respectively.  Because the fetal 
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monophthalate concentrations were not measured in these experiments, the PBPK models 
were used to convert the ED50 values to the corresponding values for the monophthalate 
concentrations in fetal plasma (as described in Chapter 3). The resulting plasma IC50 values 
for the two phthalates were 1.9 and 1.4 μM for MBP and MEHP, respectively.  These values 
served as points of comparison for the various precursor effects.  Phthalate concentrations 
required for inhibition of testosterone synthesis in MA-10 cells were similar to the IC50s 
estimated from the in vivo diester exposure data.  The IC50s for MBP and MEHP inhibition of 
testosterone production in vitro were 4.4 and 5.1 μM, respectively.  
It has been suggested that the PPAR family of nuclear receptors may mediate the anti-
steroidogenic effects associated with phthalates [58, 166].  MEHP is a well-known activator 
of the PPAR family, particularly PPARα, which leads to induction of a variety of lipid 
metabolizing enzymes.   While the role of PPAR activation in phthalate-induced testicular 
effects was not within the scope of the current work, the pharmacokinetic tools that were 
developed for evaluating target tissue dose can be used to evaluate the published PPAR data.  
Information on the dose-response for PPAR activation by the phthalates in the testes is not 
available in the published literature.  Activation of PPARα in the liver, however, has been 
studied extensively and dose-response data are available for both DEHP and DBP 
administration in vivo.  The relationship between external phthalate dose and induction of the 
peroxisomal enzyme carnitine acetyltransferase (CAT) in the liver of exposed adult rats [25] 
was modeled with a rectangular hyperbola increasing from a basal level to a fully induced 
response.  The external dose required to cause half-maximal induction (ED50) was 
determined for DEHP and DBP (Table 7.1).  The PBPK models for DEHP and DBP in the 
adult rat were then used to convert the ED50s to plasma monoester concentrations as 
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described previously for in vivo testosterone inhibition (Chapter 3).  The resulting IC50s for 
CAT induction by MEHP and MBP were 36 and 323 μM, respectively.   
 In contrast to the trend seen in testosterone inhibition, CAT induction was not similar 
between the two phthalates.  DBP is a much weaker peroxisome proliferator in vivo, even 
after accounting for differences in monoester kinetics.  Activation of both mouse PPARα and 
PPARγ by MEHP and MBP in transfected COS-1 cells [59] showed a similar trend to that 
seen in the  in vivo study in the rat.  MEHP was a potent activator of mouse PPARα and γ 
(IC50 = 0.6 - 10 μM), but MBP showed no significant activation at concentrations up to 300 
μM.  The ability of MBP to inhibit testosterone at similar concentrations to MEHP, despite 
its lack of effect on PPAR, indicates that the nuclear receptor is not likely to be the primary 
mediator of the anti-androgenic effects of phthalates. This is not to say that PPAR activation 
does not have any effect on steroid homeostasis.  In fact, up-regulation of PPAR dependent 
testosterone metabolizing enzymes has been measured in liver microsomes after 13 weeks of 
PP exposure [166]. Nonetheless, when all of the dose-response information is taken into 
consideration, direct activation of the nuclear receptor through phthalate/PPAR binding does 
not appear to be the driving force behind phthalate inhibition of steroid synthesis in the 
testes. 
We have hypothesized that cPLA2 may be the molecular target for the phthalates 
within the testes.  Our studies on the phthalate-induced inhibition of AA release and cPLA2 
translocation, and those comparing the effects of CQ and MEHP (Chapter 5 and 6), indicate 
that inhibition of this enzyme’s activity is likely to be responsible for the reduced 
testosterone observed with phthalate exposure in vivo and in vitro.  The measured dose-
response for AA inhibition in Leydig cells with monoester phthalate treatment is given in 
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Chapter 5.  In order to quantitatively compare this dose-response data to testosterone 
inhibition data, the AA inhibition data were modeled using one-site inhibition curves.  As is 
the case with testosterone inhibition, MEHP and MBP have a similar ability to inhibit AA 
release.  Average measured IC50 values were 4.7 and 5.2 μM for MBP and MEHP, 
respectively.   These IC50s were also remarkably similar to those calculated for testosterone 
inhibition (Table 7.1).  The similarity in AA and testosterone response in the Leydig cell to 
phthalate administration strongly supports our hypothesis that the anti-androgenic activity of 
the phthalates is mediated through cPLA2.      
While additional studies are needed to confirm cPLA2 as the molecular target for the 
phthalates in the testes, this hypothesis is in agreement with a data large body of research.  
Specifically, the inhibition of steroidogenesis through inactivation of cPLA2 and subsequent 
stimulation of steroidogenic gene expression is consistent with the following information.  1) 
Both MEHP and MBP reduce testosterone production in the fetal testes in vivo and in the 
isolated Leydig cell in vitro.  2) IC50s based on dose-response modeling are similar for 
MEHP and MBP inhibition of steroid synthesis and AA release from Leydig cells, but not for 
effects of these monoesters on hepatic PPAR induction.  3)  Inhibition of AA by known 
PLA2 inhibitors decreases steroidogenesis in vivo and in cells in vitro through disruption of 
LH-induced gene transcription of steroid regulatory proteins that are also down-regulated by 
the phthalates.  4) Phthalate perturbation of LH signaling in the Leydig cell occurs 
independently, or at least down-stream, of c-AMP [55].     
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C.  Implications for Phthalate Risk Assessment 
The studies performed during the completion of this dissertation were ultimately 
intended to aid in the development of a more accurate risk assessment for the phthalates 
based on their ability to adversely affect sexual development in the male fetus.  Prior to the 
onset of this work, three key areas were identified where information required for an 
informed risk assessment was lacking: 1) data relating target tissue concentrations and 
observed effects, 2) understanding of the relative potency and combined effects of phthalates 
other than DEHP and DBP, and 3) knowledge of the mechanism of action of the phthalates 
within the Leydig cell.  The studies described here, which range from in vivo kinetic 
evaluations and PBPK model development to the examination of potential mechanisms of 
action, provide important new data and novel quantitative tools for increasing our 
understanding of these issues and improving the current state of the phthalate risk 
assessment.   
 
Relating target tissue doses and observed effects 
 The kinetic studies in Chapter 2 served two purposes.  First, the dose-response study 
was the first in which phthalate and testosterone concentrations were simultaneously 
measured in the fetus.   The publication of the plasma and tissue metabolite levels following 
repeated DBP exposure allowed the observed adverse effect (testosterone reduction) to be 
directly related to the concentration of the active metabolite in the target tissue (fetal plasma, 
testes).  This data is itself important to risk assessment, in that it allows a direct comparison 
of human blood concentrations to those concentrations associated with adverse effects in 
animals.  The second purpose of the time-course data collected across doses was to enable 
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the development of a PBPK model for DBP, and eventually DEHP, in the pregnant and fetal 
rat (Chapter 3).   
 PBPK models incorporate information on physiology, chemical specific kinetics and 
biochemical interactions obtained from experiments.  When the structures of these models 
reflect the important determinants of the chemical kinetics, they can be used to predict the 
qualitative and quantitative behavior of a chemical in vivo.  In particular, a properly validated 
PBPK model can be used to perform the high-to-low dose, dose-route, and interspecies 
extrapolations necessary for estimating human risk on the basis of animal toxicology studies.  
In recent years, the use of PBPK modeling with environmental chemicals and drugs and their 
incorporation in chemical risk assessment efforts has increased dramatically (Reddy et al., 
2005).  The phthalate models developed in Chapter 3 provide a means for calculating the 
target tissue dose for exposures where kinetic data has not been measured – a particularly 
useful tool in comparing potency across endpoints and chemicals as done in Table 7-1.  
Furthermore, the validated model can also serve as a basis for extrapolation across species, 
life-stages, and exposure scenarios (acute v. repeated dosing) to provide quantitative 
measures of target tissue dosimetry in the population of interest.  Work is already underway 
to apply the models developed in Chapter 3 for the rat to the human adult and fetus (J. 
Campbell, personal communication).  By accounting for species differences in physiology 
and metabolism, these validated PBPK models can predict target tissue dose in the human 
population and increase the accuracy of predictions of human risk from environmental 
exposure.  
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Determining relative potency of the phthalates 
 While the majority of animal toxicity studies and the previous risk assessment efforts 
have focused on individual phthalates, human exposure actually occurs as mixture of a 
variety of parent diester phthalates, as well as their monoester metabolites.  The Centers for 
Disease Control currently monitors the general population for exposure to several of the 
more highly used phthalates, including BBP, DBP, DEP, DBP, DEHP and DOP through 
detection of their monoester metabolites in urine [6].   Several phthalates (BBP, DBP, DEHP, 
dipentyl phthalate, diiosbutylphthalate) have similar effects on the male reproductive tract in 
the rat when administered to the pregnant rat from GD 12-19 (500 mg/kg/day) and share a 
common mechanism.  Other phthalates (DEP, DMP), however, do not affect male rat 
reproductive tract development [33, 80].   Because human exposure occurs as a mixture of 
active and inactive phthalates, one of the more important considerations in a comprehensive 
risk assessment is accounting for the differences in potency among phthalates, as well as the 
potential additivity of response.   
 The experiments in Chapter 4 were designed to address these issues specifically, by 
testing whether differences in potency were a result of PK or PD differences and by 
providing a possible model for testing relative potency in vitro.  The fetal testes data showing 
that the inactive phthalates (MEP, MMP) are transferred efficiently to the fetal testes confirm 
that they have much reduced potency for causing inhibition of steroid synthesis than do the 
endocrine active phthalates.  Ideally, the cumulative risk assessment for a family of 
chemicals such as the phthalates would attempt to account for the combined exposure to only 
those chemicals with the same molecular targets and to account for differing potencies.   
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 The in vitro testosterone assay in MA-10 cell should be particularly useful to risk 
assessment efforts, in that it provides a method for determining the anti-androgenic activity 
of the different phthalates without the necessity of conducting expensive, time-consuming in 
life developmental studies.   Identification of active and inactive phthalates in vitro 
eliminates confounding PK factors inherent in in vivo toxicity studies and simplifies 
decisions regarding which phthalates to include in a cumulative risk assessment.  The in vitro 
model would also be useful for testing the effect of combined exposures on testosterone 
production and assumptions of additivity. 
 
Improving understanding of the phthalates’ mechanism of action in the testes 
 Without knowledge of the mechanism of action for a chemical, it is impossible to 
know whether animal toxicity studies are applicable to the human.  This is particularly true 
when, as in the case of the phthalates, the human epidemiological data is not straight-
forward. While phthalate inhibition of steroid synthesis in the fetal testes has been 
demonstrated to be the likely cause of the androgen-dependent effects in rat sexual 
development, the mechanism by which testosterone is inhibited is not known.   The studies 
performed in Chapters 5 and 6 were designed to specifically test the hypothesis that the 
phthalates may work through cPLA2 to inhibit testosterone synthesis in the Leydig cell.  The 
similarity in effects between MEHP and the PLA2 inhibitor CQ on gene expression, 
testosterone production and arachidonic release support this hypothesis.  Quantitative 
comparison of these endpoints, as well as activation of PPAR by different phthalates, 
indicates that cPLA2 is the more likely mediator of testosterone inhibition.   With a better 
understanding of the molecular mode of action for these compounds, targeted experiments 
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can be performed to determine whether the phthalates are likely to have similar effects in the 
human.   
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D. Study Limitations and Future Directions 
 The studies in this dissertation indicate that the testosterone dependent developmental 
effects in rats exposed to phthalates involve inhibition of steroidogenesis through the 
arachidonic acid signaling pathway.  However, several important data gaps still exist that 
limit the use of this information in risk assessment applications.  Of particular import to risk 
assessment efforts is the uncertainty in the human relevance of this particular pathway.  
Currently, the role of arachidonic acid in the human steroidogenic process has not been 
defined.  Therefore, simply defining the mechanism of testosterone inhibition in the rodent is 
not sufficient.  Studies are needed that examine the signaling pathways responsible for 
steroid signaling in the human.  The successful use of the mouse tumor cell line in predicting 
testosterone inhibition in the rat indicate that immortal human steroidogenic cell lines may be 
useful for predicting in vivo sensitivity.   Currently, no human Leydig cell lines have been 
created, although steroid producing immortalized adrenal cells are available.  The utility of 
this model for Leydig cell effects is not known, however.  Development of a primary or 
immortalized cell assay will be crucial for defining whether or not the mode of action in 
rodents applies to humans.  Nonetheless, risk assessments would go forward with the 
assumption that humans are as responsive as rodents to altered testosterone synthesis and 
consequences of altered testosterone during development. 
 The database for in vivo phthalate effects indicates greater susceptibility in the fetal 
rat than the adult male rat, though the reason for this difference has not been identified.  We 
were able to use the MA-10 cell line to examine relative phthalate potency in vivo.  However, 
this model has three important drawbacks: 1) the cell line is derived from the mouse, which 
does not exhibit similar anti-androgenic effects as those seen in the rat.  2) The MA-10 cell is 
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derived from the adult Leydig cell, which is morphologically distinct from the fetal Leydig 
cell.  3) Stimulation of testosterone was accomplished using luteinizing hormone, which does 
not regulate fetal steroidogenesis.  In order to better understand age-dependent differences in 
susceptibility, models are needed which allow testing directly in the Fetal Leydig cell. 
Studies employing fetal testes explants to examine testosterone inhibition have been 
inconsistent and isolation of Fetal Leydig cells has had little success due their small numbers 
in fetal rat testes.  Development of an immortalized fetal Leydig cell line would be 
particularly valuable for continued study of fetal steroidogenesis.   Use of a more biologically 
relevant stimulating factor than LH is also needed; the factor that initiates fetal 
steroidogenesis is not known.  Fetal sensitivity may be the result of stimulation of only a 
portion of the entire steroid pathway or stimulation of a different pathway than the one 
regulated by LH.  In order to test this, however, the mechanisms surrounding fetal 
testosterone production must first be better defined. 
 Finally, while we have shown that the anti-androgenic activity of the phthalates 
appears to involve arachidonic acid release by cPLA2, the nature of the interaction between 
the phthalate monoesters and the cPLA2 protein remains uncharacterized.  The translocation 
assay was performed in a previously available stably transfected human cell line that is not 
steroidogenic.  Thus activation of cPLA2 was accomplished by increasing intracellular 
calcium concentrations with an ionophore.  In order to test how LH-stimulation of cPLA2 
activation would be affected, it would be necessary to examine inhibition of translocation in 
transfected testosterone producing cells, such as the MA-10.   Binding assays using purified 
cPLA2 are also needed to better define the interaction between the phthalates and cPLA2.  By 
identifying the site of interaction for the phthalates and comparing the relative activity across 
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species, we will better predict species susceptibility to phthalate endocrine effects.  Despite 
the very real opportunity for extending the results from the studies in this thesis by future 
experimentation, our studies are an important step in reaching the goal of understanding the 
mechanisms of action of phthalates on steroidogenesis and in describing the dose-response 
behavior of several developmentally active phthalate monoesters.. 
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 Table 7.1.  Estimated Potency of Phthalates: Comparison Across Biological Endpoints. 
 Average IC50 values given were calculated using Prism 4.0 (GraphPad Software, Inc., 
LaJolla, CA) from experiments described in Chapters 2 – 6 or were available in published 
literature.  Values in parentheses represent the 95% confidence interval of calculated values.   
 
Biological Response 
 
Model 
 
Study 
Type 
IC50 (μM)a 
MEHP 
IC50 (μM)a 
MBP 
Testosterone Inhibitionb Rat Testes - Fetus In vivo 1.4 (0.1-25) 1.9 (1-5) 
Testosterone Inhibition Mouse Leydig Cell In vitro 4.4 (2-10) 3.5 (1-8) 
AA (cPLA2) Inhibition 
Mouse Leydig 
Cell In vitro 4.7 (1-19) 5.2 (1-20) 
CAT (PPAR) Inductionc Rat – Adult Male In vivo 36 323 
PPARα Activationd Mouse Gene Overexpression In vitro 0.6 > 300 
PPARγ Activationd Mouse Gene Overexpression In vitro 10 > 300 
a Fetal or adult rat plasma concentrations calculated from ED50 values using the PBPK 
models as described in Chapter 3. 
b Inhibition of fetal testes testosterone after 4 days administration of DEHP (Borch et al. 
20004; Parks et  al., 2000) or DBP (Chapter 2; Lehmann et al., 2004). 
c Carnitine acetyltransferase induction after 14 days DBP or DEHP administration (Seo et al., 
2004). 
d
 Mouse PPARα and γ overexpressed in COS-1 cells and measured by luciferase assay 
(Hurst and Waxman, 2003).  Cells were treated with MEHP or MBP. 
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